Methods and compositions for modulating beta-chain-mediated immunity

Abstract

To provide a novel antibody with antitumor activity. [Solution] An anti-Vβ17 antibody or its antigen-binding fragment is described. Also described are a nucleic acid encoding the antibody, a composition containing the antibody, a method for producing the antibody, and a method for using the antibody to treat or prevent a disease.

Description

[Technical Field]

[0001] (Cross-reference of related applications) This application is U.S. Patent Application No. 63 / 077,314, filed on September 11, 2020. U.S. Patent Application No. 63 / 077,397, filed on September 11, 2020. U.S. Patent Application No. 63 / 077,387, filed on September 11, 2020, granted on October 2, 2020. U.S. Patent Application No. 63 / 104,220, filed on October 2, 2020 The U.S. Patent Application No. 63 / 104,247 was filed on October 22, 2020. U.S. Patent Application No. 63 / 104,265, filed on January 28, 2021. U.S. Patent Application No. 63 / 142,930, filed on January 28, 2021. U.S. Patent Application No. 63 / 142,940, filed on January 28, 2021. No. 44, U.S. Patent Application No. 63 / 165,053, filed on March 23, 2021, 2 U.S. Patent Application No. 63 / 176,112, filed on April 16, 2021, and 2021 Claiming the benefits of U.S. Patent Application No. 63 / 237,972, filed on August 27, [year]. Each of these disclosures is incorporated herein by reference in its entirety.

[0002] (Field) The present invention particularly relates to an anti-Vβ17 molecule containing an anti-Vβ17 antibody, a bispecific antibody, and the antibody Encoding nucleic acids and expression vectors, recombinant cells containing the vector, and the antibody This relates to compositions containing the above antibodies, and methods for producing the above antibodies, and for modulating the immune response. A method using the antibody is also provided.

[0003] (Reference to electronically submitted sequence listings) This application was submitted electronically via EFS-Web as an ASCII-formatted sequence listing. The file name is "14620-406-228_SL.txt" and was created on September 5, 2021. Created and containing a sequence listing with a size of 889,896 bytes. Via EFS-Web The submitted sequence listings are part of this specification and are incorporated in their entirety by reference. Born.

[0004] (overview) In one embodiment, T cell receptor beta variant 17, V Antibodies that bind to β17) are provided herein.

[0005] In one embodiment, an antibody that binds to Vβ17 is provided, wherein the antibody (i) each of the sequences VH CDR1, VH CDR2, and VH C have amino acid sequence number 21. VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequence of DR3. (ii) VH containing (ii) VL having the amino acid sequence of SEQ ID NO: 677 VL CDR has the amino acid sequences of CDR1, VL CDR2, and VL CDR3. 1. Includes VLs including VL CDR2 and VL CDR3. In another embodiment, Vβ17 An antibody that binds to is provided, and the above antibody (i) each of the amino acid sequences of SEQ ID NO: 77 is provided. The amino acid sequences of VH CDR1, VH CDR2, and VH CDR3 of VH are (ii) VH including VH CDR1, VH CDR2, and VH CDR3 VL CDR1 and VL CDR2, respectively, have the amino acid sequence of SEQ ID NO: 78. , and VL CDR1, VL CDR2, and which have the amino acid sequence of VL CDR3. The VL comprises VL containing VL CDR3. In another embodiment, an antibody that binds to Vβ17 is provided. The above antibodies are (i) VH CD of VH having the amino acid sequence of SEQ ID NO: 79. VH CDR1, which has the amino acid sequences of R1, VH CDR2, and VH CDR3, VH including VH CDR2 and VH CDR3, and (ii) the respective sequence numbers of 80 VL CDR1, VL CDR2, and VL CDR3 have amino acid sequences VL containing VL CDR1, VL CDR2, and VL CDR3 having a mino acid sequence This includes. In another embodiment, an antibody that binds to Vβ17 is provided, wherein the antibody (i) is These are VH CDR1, VH CDR2, and VH, which have the amino acid sequence of SEQ ID NO: 81. VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequence of VH CDR3. (ii) VH containing CDR3, and (ii) VL having the amino acid sequence of SEQ ID NO: 82, respectively. VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequences of VL Includes VLs including CDR1, VL CDR2, and VL CDR3. In another embodiment, An antibody that binds to Vβ17 is provided, and the above antibody is (i) each of the amines of SEQ ID NO: 83. The amino acids of VH CDR1, VH CDR2, and VH CDR3, which have an anoic acid sequence. VH having an acid sequence, including VH CDR1, VH CDR2, and VH CDR3, (ii) VL CDR1 and VL, respectively, having the amino acid sequence of SEQ ID NO: 84 VL CDR1, VL CDR3, which have the amino acid sequences of CDR2 and VL CDR3. 2, and VL containing VL CDR3. In another embodiment, an antibody that binds to Vβ17 Provided, the above antibodies (i) each have the amino acid sequence of SEQ ID NO: 85 of VH VH CDR1, VH CDR2, and VH CDR3 have amino acid sequences. VH including DR1, VH CDR2, and VH CDR3, and (ii) sequence number VL CDR1, VL CDR2, and VL CD have amino acid sequence number 86. VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence R3. Includes VL. In another embodiment, an antibody that binds to Vβ17 is provided, the antibody is ( i) VH CDR1 and VH CD, respectively, which have the amino acid sequence of SEQ ID NO: 87. VH CDR1, VH CDR2, which have the amino acid sequences of R2 and VH CDR3, (ii) VH containing VH CDR3, and (ii) each having the amino acid sequence of SEQ ID NO: 88 The VL has the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3. VL includes VL CDR1, VL CDR2, and VL CDR3. The product provides an antibody that binds to Vβ17, and the above antibody is (i) Sequence ID No. 1 VH CDR1, VH CDR2, and VH CD have the amino acid sequence 000. VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequence R3. (ii) VH containing VL having the amino acid sequence of SEQ ID NO: 1001 VL CDR has the amino acid sequences of CDR1, VL CDR2, and VL CDR3. 1. Includes VLs including VL CDR2 and VL CDR3. In another embodiment, Vβ17 An antibody that binds to is provided, and the above antibody is (i) each of the amino acids of SEQ ID NO: 1032 The amino acid sequences of VH CDR1, VH CDR2, and VH CDR3 of VH VH having columns, including VH CDR1, VH CDR2, and VH CDR3, and (i i) VL CDR1 and VL, each having the amino acid sequence of SEQ ID NO: 1033. VL CDR1, VL CDR3, which have the amino acid sequences of CDR2 and VL CDR3. 2, and VL containing VL CDR3. In another embodiment, an antibody that binds to Vβ17 Provided, the above antibodies (i) each have the amino acid sequence of SEQ ID NO: 1064 VH CDR1, VH CDR2, and VH CDR3 have amino acid sequences, VH including CDR1, VH CDR2, and VH CDR3, and (ii) each of them VL CDR1, VL CDR2, and VL have the amino acid sequence of column number 1065. VL CDR1, VL CDR2, and VL C have the amino acid sequence of L CDR3. The VL includes DR3. In another embodiment, an antibody that binds to Vβ17 is provided, and the above antibody (i) Each of the VH CDR1 has the amino acid sequence of SEQ ID NO: 1096. VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. (ii) VH including CDR2 and VH CDR3, and (ii) the respective sequence numbers 1097 VL CDR1, VL CDR2, and VL CDR3 have amino acid sequences VL containing VL CDR1, VL CDR2, and VL CDR3 having a mino acid sequence This includes. In another embodiment, an antibody that binds to Vβ17 is provided, wherein the antibody (i) is These are VH CDR1 and VH CDR2, which have the amino acid sequence of SEQ ID NO: 1128. , and VH CDR1, VH CDR2, and which have the amino acid sequence of VH CDR3. VH containing VH CDR3, and (ii) each having the amino acid sequence of SEQ ID NO: 1129 The VL has the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3. It includes VLs including VL CDR1, VL CDR2, and VL CDR3. In that embodiment, VH CDR1, VH CDR2, VH CDR3, VL CDR1 The amino acid sequences of VL CDR2 and VL CDR3 follow the Kabat numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR3, VL The amino acid sequences of CDR1, VL CDR2, and VL CDR3 are assigned by Chothia numbering. Follow the stem. In some embodiments, VH CDR1, VH CDR2, VH CD The amino acid sequences of R3, VL CDR1, VL CDR2, and VL CDR3 are AbM-attached. It follows the numbering system. In some embodiments, VH CDR1, VH CDR2, VH The amino acid sequences of CDR3, VL CDR1, VL CDR2, and VL CDR3 are Co It follows the ntact numbering system. In some embodiments, VH CDR1, VH CD R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acids The sequence follows the IMGT numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 The mino acid sequence follows an exemplary numbering system.

[0006] In some embodiments of the Vβ17 antibody provided herein, the antibody is a humanized antibody. In some embodiments, the antibody is an IgG antibody. In some embodiments, The IgG antibody is an IgG1 antibody. In some embodiments, the IgG antibody is IgG It is a two-antibody. In some embodiments, the IgG antibody is an IgG3 antibody. In this embodiment, the IgG antibody is an IgG4 antibody. In some embodiments, the antibody is , containing kappa light chains. In some embodiments, the antibody contains lambda light chains. In this embodiment, the antibody is a monoclonal antibody.

[0007] In some embodiments of the various Vβ17 antibodies provided herein, the antibody is Vβ17 It binds to the antigen. In some embodiments, the antibody binds to the Vβ17 epitope. In some embodiments, the antibody specifically binds to Vβ17. are VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR 2. And VL CDR3 forms the binding site for the Vβ17 antigen. In terms of application type, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 form binding sites for the Vβ17 epitope. In some embodiments, Vβ17 is located on the surface of T cells.

[0008] In some embodiments of the Vβ17 antibodies provided herein, the antibodies are polyvalent. In some embodiments, the antibody can bind to at least three antigens. In one embodiment, the antibody can bind to at least four antigens. In embodiments, the antibody can bind to at least five antigens. Provided herein In some embodiments of the Vβ17 antibody, the antibody is a multispecific antibody.

[0009] In another embodiment, a multispecific Vβ17 antibody is provided, and the multispecific Vβ17 antibody is, (a) A first binding domain that binds to Vβ17, wherein the first binding domain is (b) The first binding domain, which includes the Vβ17 antibody provided in the specification, and (b) Vβ17 It includes a second binding domain that binds to a second target, which is not present.

[0010] In some embodiments of the multispecific Vβ17 antibodies provided herein, the antibody is two It is a bispecific antibody. In some embodiments, the antibody is a trispecific antibody. In that embodiment, the antibody is a quadruple-specific antibody.

[0011] In some embodiments of the multispecific Vβ17 antibodies provided herein, a second binding The domain binds to the antigen of the second target. In some embodiments, the second binding domain The molecule binds to the epitope of a second target. In some embodiments, the second binding domain The second binding domain specifically binds to the second target. In some embodiments, the second binding domain VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, And VL CDR3 forms a binding site for the second target antigen. Several implementations Morphologically, the second binding domains are VH CDR1, VH CDR2, VH CDR3, V L CDR1, VL CDR2, and VL CDR3 target the epitope of the second target. It forms a binding site. In some embodiments, the second target is located on the surface of the target cell. It exists. In some embodiments, the second binding domain that binds to the second target is polyvalent. In some embodiments, the second binding domain binds to at least three antigens. This is possible. In some embodiments, the second binding domain has at least four antibodies. It can bind to the original. In some embodiments, the second binding domain is at least It can also bind to five antigens.

[0012] In some embodiments of the multispecific Vβ17 antibodies provided herein, the second target This is CD123. In some embodiments, a second coupling arm is coupled to CD123. (i) VH CDR1 and V, respectively, have the amino acid sequence of SEQ ID NO: 40. VH CDR1, VH CDR1, VH CDR3 have amino acid sequences H CDR2 and VH CDR3. (ii) VH containing DR2 and VH CDR3, and the amino acids of SEQ ID NO: 41, respectively. The amino acid composition of VL CDR1, VL CDR2, and VL CDR3 of VL having the sequence Includes VLs that have columns, including VL CDR1, VL CDR2, and VL CDR3. In another embodiment, a multispecific antibody that binds to Vβ17 is provided, and the multispecific antibody The body is (a) a first binding domain that binds to Vβ17, and the first binding domain (i) VH CDR1 and VH, respectively, which have the amino acid sequence of SEQ ID NO: 25. VH CDR1, VH CD, which have the amino acid sequences of CDR2 and VH CDR3. (ii) VH containing R2 and VH CDR3, and the amino acid combination of SEQ ID NO: 26 Amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of VL having columns A VL having VL CDR1, VL CDR2, and VL CDR3, (b) a first binding domain and a second domain which is BCMA, DLL3, PSMA, or KLK2. It includes a second binding domain that binds to the target of Vβ17. In another embodiment, it includes a polybinding domain that binds to Vβ17. A heavily specific antibody is provided, and the above heavily specific antibody is (a)(i) respectively of SEQ ID NO: 7 VH CDR1, VH CDR2, and VH CDR3 have amino acid sequences VH CDR1, VH CDR2, and VH CDR3, which have a mino acid sequence. (ii) VL CDR1 and VL, respectively, having the amino acid sequence of SEQ ID NO: 8 VL CDR1, VL CD, which have the amino acid sequences of CDR2 and VL CDR3, respectively. (b) VL including R2 and VL CDR3, and (b) BCMA, DLL3, PSMA, or K It includes a second binding domain that binds to a second target, which is LK2. In another embodiment, Vβ A multispecific antibody that binds to 17 is provided, and the above multispecific antibody is (a)(i) each Therefore, VH CDR1, VH CDR2, and VH have the amino acid sequence of SEQ ID NO: 9. VH CDR1, VH CDR2, and VH C have the amino acid sequence H CDR3. (ii) VH containing DR3 and VL having the amino acid sequence of SEQ ID NO: 10. VL CDR1, VL CDR2, and VL CDR3 have amino acid sequences. VL including DR1, VL CDR2, and VL CDR3, and (b) BCMA, DLL3 It includes a second binding domain that binds to a second target, which is PSMA or KLK2. In another embodiment, a multispecific antibody that binds to Vβ17 is provided, and the multispecific antibody (a) and (i) respectively are VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 19. VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. VH including CDR2 and VH CDR3, and (ii) each of the ami with sequence number 22. amino acids of VL CDR1, VL CDR2, and VL CDR3, which have an anoic acid sequence. VL containing VL CDR1, VL CDR2, and VL CDR3 having an acid sequence, (b) A second target which binds to a second target which is BCMA, DLL3, PSMA, or KLK2 A binding domain is provided. In another embodiment, a multispecific antibody that binds to Vβ17 is provided. The above multispecific antibodies (a) and (i) each have the amino acid sequence of SEQ ID NO: 19. The amino acid sequences of VH are VH CDR1, VH CDR2, and VH CDR3. VH including VH CDR1, VH CDR2, and VH CDR3, and (ii) each VL CDR1, VL CDR2, and VL have the amino acid sequence of SEQ ID NO: 23. VL CDR1, VL CDR2, and VL C have the amino acid sequence of L CDR3. (b) a VL including DR3 and a second which is BCMA, DLL3, PSMA, or KLK2 It includes a second binding domain that binds to a target. In another embodiment, it includes multiple binding domains that bind to Vβ17. A specific antibody is provided, and the above multispecific antibody is (a)(i) respectively of Sequence ID No. 19 VH CDR1, VH CDR2, and VH CDR3 have amino acid sequences VH CDR1, VH CDR2, and VH CDR3, which have a mino acid sequence. (ii) VL CDR1 and VL, respectively, having the amino acid sequence of SEQ ID NO: 24. VL CDR1, VL CDR3, which have the amino acid sequences of L CDR2 and VL CDR3. (b) BCMA, DLL3, PSMA, or It includes a second binding domain that binds to a second target, which is KLK2. In another embodiment, A multispecific antibody that binds to Vβ17 is provided, and the above multispecific antibody is (a)(i) VH CDR1 and VH CDR2, respectively, have the amino acid sequence of SEQ ID NO: 20. , and VH CDR1, VH CDR2, and which have the amino acid sequence of VH CDR3. VH containing VH CDR3, and (ii) each having the amino acid sequence of SEQ ID NO: 22 The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 are present in VL. VL including VL CDR1, VL CDR2, and VL CDR3, and (b) BCMA, A second binding domain that binds to a second target which is DLL3, PSMA, or KLK2, Includes. In another embodiment, a multispecific antibody that binds to Vβ17 is provided, and the multispecific The isoantibodies are (a) and (i), respectively, VH of VH having the amino acid sequence of SEQ ID NO: 20. VH CDR has the amino acid sequences of CDR1, VH CDR2, and VH CDR3. 1. VH containing VH CDR2 and VH CDR3, and (ii) Sequence ID 2, respectively VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence 3. VL CDR1, VL CDR2, and VL CDR3 have the following amino acid sequence (b) The VL binds to a second target which is BCMA, DLL3, PSMA, or KLK2. It includes a second binding domain. In another embodiment, a multispecific anti-Vβ17 binding The body is provided, and the above multispecific antibody is (a)(i) respectively the amino acid of SEQ ID NO: 20 The amino acid sequences of VH CDR1, VH CDR2, and VH CDR3 of VH VH having columns, including VH CDR1, VH CDR2, and VH CDR3, and (i i) VL CDR1 and VL CD, respectively, which have the amino acid sequence of SEQ ID NO: 24. VL CDR1, VL CDR2, having the amino acid sequences of R2 and VL CDR3, and VL including VL CDR3, and (b) BCMA, DLL3, PSMA, or KLK2 It includes a second binding domain that binds to a second target, which is Vβ1 A multispecific antibody that binds to 7 is provided, and the above multispecific antibody is (a)(i) respectively VH CDR1, VH CDR2, and VH have the amino acid sequence of SEQ ID NO: 21. VH CDR1, VH CDR2, and VH C have the amino acid sequence H CDR3. (ii) VH containing DR3 and VL having the amino acid sequence of SEQ ID NO: 22. VL CDR1, VL CDR2, and VL CDR3 have amino acid sequences. VL including DR1, VL CDR2, and VL CDR3, and (b) BCMA, DLL3 It includes a second binding domain that binds to a second target, which is PSMA or KLK2. In another embodiment, a multispecific antibody that binds to Vβ17 is provided, and the multispecific antibody (a) and (i) respectively are VH CDR1 of VH having the amino acid sequence of SEQ ID NO: 21. VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. VH including CDR2 and VH CDR3, and (ii) each of the ami with sequence number 23. amino acids of VL CDR1, VL CDR2, and VL CDR3, which have an anoic acid sequence. VL containing VL CDR1, VL CDR2, and VL CDR3 having an acid sequence, (b) A second target which binds to a second target which is BCMA, DLL3, PSMA, or KLK2 A binding domain is provided. In another embodiment, a multispecific antibody that binds to Vβ17 is provided. The above multispecific antibodies (a) and (i) each have the amino acid sequence of SEQ ID NO: 21. It has the amino acid sequences of VH CDR1, VH CDR2, and VH CDR3. (ii) VH including VH CDR1, VH CDR2, and VH CDR3, and These are VL CDR1, VL CDR2, and VL CDR1, which have the amino acid sequence of SEQ ID NO: 24. VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence of VL CDR3. (b) a VL containing CDR3 and (b) a BCMA, DLL3, PSMA, or KLK2. It includes a second binding domain that binds to target 2. In another embodiment, it binds to Vβ17. A multispecific antibody is provided, and the above multispecific antibody is (a)(i) respectively, sequence number VH CDR1, VH CDR2, and VH CD have amino acid sequence number 46. VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequence R3. (ii) VL CD containing VH and VL having the amino acid sequence of SEQ ID NO: 49. VL CDR1, which has the amino acid sequences of R1, VL CDR2, and VL CDR3, VL including VL CDR2 and VL CDR3, and (b) BCMA, DLL3, PSM It includes a second binding domain that binds to a second target, which is A or KLK2. In this embodiment, the first coupling arm has VH CDR1, VH CDR2, VH CDR3 The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 are from Kabat. The numbering system is followed. In some embodiments, the first coupling arm VH CDR1, V H CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 The amino acid sequence follows the Chothia numbering system. In some embodiments, the first The coupling arm of VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The amino acid sequences of L CDR2 and VL CDR3 follow the AbM numbering system. In one embodiment, the first coupling arm has VH CDR1, VH CDR2, VH CD The amino acid sequences of R3, VL CDR1, VL CDR2, and VL CDR3 are as follows: Con It follows the tact numbering system. In some embodiments, the VH CD of the first coupling arm R1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL The amino acid sequence of CDR3 follows the IMGT numbering system. In some embodiments, 1 coupling arm VH CDR1, VH CDR2, VH CDR3, VL CDR1, The amino acid sequences of VL CDR2 and VL CDR3 follow an exemplary numbering system.

[0013] In some embodiments of the multispecific Vβ17 antibodies provided herein, the second target This is BCMA. In some embodiments, a second coupling arm coupled to the BCMA is (i) VH CDR1 and VH, respectively, having the amino acid sequence of SEQ ID NO: 95 VH CDR1, VH CDR3, which have the amino acid sequences of CDR2 and VH CDR3. 2. VH containing VH CDR3, and (ii) the amino acid sequence of SEQ ID NO: 96, respectively. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of VL having It includes VLs, including VL CDR1, VL CDR2, and VL CDR3.

[0014] In some embodiments of the multispecific Vβ17 antibodies provided herein, the second target This is DLL3. In some embodiments, a second coupling arm coupled to DLL3 is (i) VH CDR1 and VH, respectively, having the amino acid sequence of SEQ ID NO: 694. VH CDR1, VH CD, which have the amino acid sequences of CDR2 and VH CDR3. (ii) R2 and VH containing VH CDR3, and the amino acids of SEQ ID NO: 695, respectively. The amino acid composition of VL CDR1, VL CDR2, and VL CDR3 of VL having the sequence Includes VLs that have columns, including VL CDR1, VL CDR2, and VL CDR3. .

[0015] In some embodiments of the multispecific Vβ17 antibodies provided herein, the second target This is a PSMA. In some embodiments, a second coupling arm coupled to the PSMA is (i) VH CDR1 and VH, respectively, having the amino acid sequence of SEQ ID NO: 730. VH CDR1, VH CD, which have the amino acid sequences of CDR2 and VH CDR3. (ii) R2 and VH containing VH CDR3, and the amino acids of SEQ ID NO: 731, respectively. The amino acid composition of VL CDR1, VL CDR2, and VL CDR3 of VL having the sequence Includes VLs that have columns, including VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the second coupling arm that couples to the PSMA is (i) each, VH CDR1, VH CDR2, and VH have the amino acid sequence of SEQ ID NO: 732. VH CDR1, VH CDR2, and VH C have the amino acid sequence H CDR3. (ii) VH containing DR3 and VL having the amino acid sequence of SEQ ID NO: 733 VL CDR1, VL CDR2, and VL CDR3 have amino acid sequences. Includes VLs including CDR1, VL CDR2, and VL CDR3. Several implementations In this configuration, the second coupling arm that connects to the PSMA is (i) the arm of sequence number 734. VH CDR1, VH CDR2, and VH CDR3 have a mino acid sequence. VH containing VH CDR1, VH CDR2, and VH CDR3, which have an acid sequence (ii) VL CDR1 and VL, respectively, having the amino acid sequence of SEQ ID NO: 735. VL CDR1, VL CDR3, which have the amino acid sequences of L CDR2 and VL CDR3. Includes DR2 and VL including VL CDR3. In one embodiment, it is coupled to PSMA. The second binding arm is (i) each of the VH having the amino acid sequence of SEQ ID NO: 736 VH CDR1, VH CDR2, and VH CDR3 have amino acid sequences. VH including DR1, VH CDR2, and VH CDR3, and (ii) sequence number VL CDR1, VL CDR2, and VL C have amino acid sequence 737. VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence of DR3. Includes a VL which includes a PSMA. In some embodiments, a second coupling arm which couples to the PSMA is (i) VH CDR1 and VH, respectively, having the amino acid sequence of SEQ ID NO: 899. VH CDR1, VH CD, which have the amino acid sequences of CDR2 and VH CDR3. (ii) R2 and VH containing VH CDR3, and the amino acids of SEQ ID NO: 900, respectively. The amino acid composition of VL CDR1, VL CDR2, and VL CDR3 of VL having the sequence Includes VLs that have columns, including VL CDR1, VL CDR2, and VL CDR3. .

[0016] In some embodiments of the multispecific Vβ17 antibodies provided herein, the second target This is KLK2. In some embodiments, the second coupling arm coupled to KLK2 is (i) VH CDR1 and VH, respectively, having the amino acid sequence of SEQ ID NO: 887 VH CDR1, VH CD, which have the amino acid sequences of CDR2 and VH CDR3. (ii) R2 and VH containing VH CDR3, and the amino acids of SEQ ID NO: 888, respectively. The amino acid composition of VL CDR1, VL CDR2, and VL CDR3 of VL having the sequence Includes VLs that have columns, including VL CDR1, VL CDR2, and VL CDR3. .

[0017] In some embodiments of the multispecific Vβ17 antibodies provided herein, a second binding Arm VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL C The amino acid sequences of DR2 and VL CDR3 follow the Kabat numbering system. In that embodiment, the second coupling arm has VH CDR1, VH CDR2, VH CDR 3. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 are Chot The HIA numbering system is followed. In some embodiments, the VH CDR of the second coupling arm 1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL C The amino acid sequence of DR3 follows the AbM numbering system. In some embodiments, the second Coupling arms: VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL The amino acid sequences of CDR2 and VL CDR3 follow the Contact numbering system. In some embodiments, the second coupling arm VH CDR1, VH CDR2, VH The amino acid sequences of CDR3, VL CDR1, VL CDR2, and VL CDR3 are: It follows the IMGT numbering system. In some embodiments, the VH CD of the second coupling arm R1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL The amino acid sequence of CDR3 follows an exemplary numbering system.

[0018] In another embodiment, a multispecific Vβ17 antibody is provided, and the multispecific Vβ17 antibody This is a first method that can bind Vβ17 on the surface of T cells, and a method that is not Vβ17. The invention includes a second means capable of binding a second target. In some embodiments, the The target of type 2 is located on the surface of the target cell.

[0019] In another embodiment, nucleic acids encoding the Vβ17 antibody provided herein are provided. In one embodiment, a vector comprising nucleic acid encoding the Vβ17 antibody provided herein is provided. In another embodiment, a vector comprising nucleic acid encoding the Vβ17 antibody provided herein Host cells containing the ter are provided.

[0020] In another embodiment, a vector comprising nucleic acid encoding the Vβ17 antibody provided herein is A kit containing the Vβ17 antibody provided herein and other A kit is provided, including the package. In another embodiment, V provided herein A pharmaceutical composition is provided comprising a β17 antibody and a pharmaceutically acceptable carrier. In another embodiment, This is a pharmaceutical composition comprising the Vβ17 antibody provided herein and a pharmaceutically acceptable carrier. A method for manufacturing a substance is provided, wherein the above method combines the above antibody with a pharmaceutically acceptable carrier. The process also includes the step of obtaining the above-mentioned pharmaceutical composition.

[0021] In another embodiment, a method for activating T cells expressing Vβ17 is provided, and the above method is The process includes contacting T cells with the Vβ17 antibody provided herein. Morphologically, the contact process compared CD69, C to control T cells expressing Vβ17. This results in increased D25 and / or granzyme B expression.

[0022] In another embodiment, a process is provided for producing antibodies that bind to two or more target molecules. Thus, the above process obtains a first binding domain that binds to Vβ17 present on T cells. The process for performing the function and the second binding domain that binds to a second target on the surface of the target cell The process for performing the function of obtaining Vβ17 present on T cells and on the surface of target cells The process includes a step to provide an antibody that binds to a second target. In this embodiment, the function is to obtain a second binding domain that binds to a second target on the surface of the target cell. The above process is repeated n times to accomplish this, targeting Vβ17 and n targets present on T cells. n steps to perform the function of providing a first binding domain that binds to a molecule, The process further includes a step in which n is at least 2.

[0023] In another embodiment, a method is provided for directing T cells expressing Vβ17 to target cells, The method described herein involves the step of contacting the target cells with the multispecific Vβ17 antibody described herein. The second target is present on the surface of the target cell, and the step of contacting the T cell is performed. The cells are directed towards the target cells.

[0024] In another embodiment, a method for inhibiting the growth of target cells is provided, and the above method is described herein. The multispecific Vβ17 antibody described above is applied to the surface of the target cells where the second target exists. The process includes bringing the target cells into contact with the T cells expressing Vβ17. In the presence of cells, the above contact process inhibits the growth of the target cells. In one embodiment, a method is provided for inhibiting the proliferation of target cells, and the above method is described herein in part The heavy-specific Vβ17 antibody is applied to the target cells on which the second target exists on the surface of the target cells. The process includes a step of bringing the cells into contact, and the above contact step involves the presence of T cells expressing Vβ17. The above contact process inhibits the proliferation of the target cells.

[0025] In another embodiment, a method for eliminating target cells in a subject is provided, and the above method is described in this specification. The multispecific Vβ17 antibody described in the document is applied to the surface of the target cells where the second target is present. The process includes bringing the above target cells into contact, and the above contact process involves bringing the above Vβ17 into contact. In the presence of T cells, the above contact process leads to the elimination of the target cells. In one embodiment, a method for treating a disease in a subject is provided, and the method is provided in an effective amount of the Spec. The process includes administering the multispecific Vβ17 antibody described above to the subject, and the disease is a targeted disease. This is caused, in whole or in part, by target cells in which the above-mentioned second target is present on the surface of the cell. In some embodiments, the subject is a human. In some embodiments, the subject is a human. This is the target group that requires this method.

[0026] In some embodiments, the second target is located on the surface of the target cell, and the target cell is cancer These are cells. In some embodiments, cancer cells are adrenal cancer, anal cancer, appendiceal cancer, bile duct cancer, bladder cancer, etc. Bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer, gestational trophoblastic disease, head and neck cancer Intestinal cancer, Hodgkin lymphoma, colon cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, multiple cancers Sexual myeloma, neuroendocrine tumors, non-Hodgkin lymphoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, Sinus cancer, skin cancer, soft tissue sarcoma, spinal cord cancer, stomach cancer, testicular cancer, pharyngeal cancer, thyroid cancer, uterine cancer, intrauterine cancer These are cells of membrane cancer, vaginal cancer, or vulvar cancer. In some embodiments, the second target is an Geopoietin, BCMA, CD19, CD20, CD22, CD25 (IL2-R), C D30, CD33, CD37, CD38, CD52, CD56, CD123(IL-3R ), cMET, DLL / Notch, EGFR, EpCAM, FGF, FGF-R, GD 2, HER2, Mesothelin, Nectin-4, PAP, PDGFRα, PSA, PSA3, PSMA, RANKL, SLAMF7, STEAP1, TARP, TROP2, VEGF , or VEGF-R. In some embodiments, the second target is CEA, undeveloped Mature laminin receptor, TAG-72, HPV E6, HPV E7, BING-4, Calcium Um-dependent chlorine channel 2, cyclin-B1, 9D7, EpCAM, EphA3, He r2 / neu, telomerase, mesothelin, SAP-1, surviving, BAGE family Lee antigen, CAGE family antigen, GAGE ​​family antigen, MAGE family antigen SAGE family antigen, XAGE family antigen, NY-ESO-1 / LAGE-1 , PRAME, SSX-2, Melan-A, MART-1, Gp100, pmel17 Tyrosinase, TRP-1, TRP-2, P. polypeptide, MC1R, prostate-specific antimicrobial agent It is either the progenitor, β-catenin, or BRCA1.

[0027] In some embodiments, the second target is CD123. In some embodiments, The second target is BCMA. In some embodiments, the second target is DLL3. In some embodiments, the second target is the PSMA. The second target is KLK2.

[0028] In some embodiments, (i) adrenal carcinoma is an adrenocortical carcinoma. (ii) the above anal cancer (m, ACC), adrenocortical carcinoma, pheochromocytoma, or neuroblastoma However, it is squamous cell carcinoma, cloacal carcinoma, adenocarcinoma, basal cell carcinoma, or melanoma. (iii) The above appendiceal cancer is a neuroendocrine tumor (NET), mucinous gland (iv) The above Bile duct cancer can be extrahepatic cholangiocarcinoma, adenocarcinoma, hilar cholangiocarcinoma, hilar region cholangiocarcinoma, distal cholangiocarcinoma, or (v) The above bladder cancer is a transitional cell carcinoma. a. TCC), papillary carcinoma, squamous carcinoma, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, or (vi) The above bone cancers are primary bone cancer, sarcoma, osteosarcoma, chondrosarcoma, sarcoma, fibrous Sarcoma, malignant fibrous histiocytoma, giant cell tumor of bone, chordoma, or metastatic bone cancer, (v ii) The above brain cancers include astrocytoma, brainstem glioma, glioblastoma, meningioma, ependymoma, oligodendroglia. Tumors, mixed gliomas, pituitary cancer, pituitary adenoma, craniopharyngioma, germ cell tumors, pineal gland tumors, medulla tumors (viii) The above breast cancer is a blastoma or primary CNS lymphoma, or is an invasive breast cancer. Breast cancer, non-invasive breast cancer, breast sarcoma, metaplastic carcinoma, adenofibular carcinoma, phyllodes tumor, angiosarcoma, HER2 (ix) The above cervical cancers, which are positive for breast cancer, triple-negative breast cancer, or inflammatory breast cancer. However, (x) the above colorectal cancer is a colorectal adenocarcinoma. Primary colorectal lymphoma, gastrointestinal stromal tumor, leiomyosarcoma, carcinoid tumor, mucinous gland (xi) The above (xii) The esophageal cancer is adenocarcinoma or squamous cell carcinoma, It is papillary adenocarcinoma, adenosquamous cell carcinoma, squamous cell carcinoma, small cell carcinoma, or sarcoma. (xiii) The above-mentioned gestational trophoblastic disease (GTD) , hydatidiform mole, gestational trophoblastic neoplasia (GTN), choriocarcinoma, placental-site trophoblast tumor (PSTT) ), or epithelioid trophoblastic tumor (ETT) (xiv) The head and neck cancer is laryngeal cancer, nasopharyngeal cancer, hypopharyngeal cancer, nasal cavity cancer, sinus cancer, (xv) Hodgkin lymphoma as described above is a salivary gland cancer, oral cancer, oropharyngeal cancer, or tonsil cancer. Classical Hodgkin lymphoma, nodular sclerosis type, mixed cell type, lymphocyte-rich type, lymphopenic type , or nodular lymphocyte-predominant Hodgkin lymphoma (H2N1). (xvi) The above intestinal cancer is small intestinal cancer (small intesti cancer). ne cancer), small bowel cancer, adenocarcinoma, sarcoma, gastrointestinal stromal tumor, cultivar (xvii) The above kidney cancer is a renal cell carcinoma (renal ce ll carcinoma, RCC), clear cell RCC, papillary RCC, chromophobe RCC, collecting duct RCC Unclassified RCC, transitional cell carcinoma, urothelial carcinoma, renal pelvis carcinoma, or renal sarcoma, (xvi ii) The above leukemia is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (chroni c lymphocytic leukemia (CLL), chronic myeloid leukemia (C Myelodysplastic syndrome (ML), hairy cell leukemia (HCL), or myelodysplastic syndrome (xix) The above liver cancer is a symptom of myelodysplastic syndrome (MDS), and is hepatocellular carcinoma. hepatocellular carcinoma (HCC), fibrolamellar HCC, cholangiocellular carcinoma, angiosarcoma (xx) The above lung cancer is small cell lung cancer, small cell carcinoma, or combined small cell lung cancer. Carcinoma, non-small cell lung cancer, lung adenocarcinoma, squamous cell lung cancer, large cell anaplastic carcinoma, lung nodules, metastasis Severe lung cancer, adenosquamous cell carcinoma, large cell neuroendocrine carcinoma, salivary gland type lung cancer, pulmonary carcinoid, (xxi) The above melanomas are skin tumors, sarcomatoid carcinomas of the lung, or malignant granular cell lung tumors. Superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, malignant melanoma, achromatic melanoma It is a chromoma, fibrous melanoma, ocular melanoma, or metastatic melanoma, (xxii) among the above The skin tumor is pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, or testicular mesothelioma, (xxii i) The above-mentioned multiple myeloma is active or smoldering multiple myeloma, (xxiv) The above neuroendocrine tumors include gastrointestinal neuroendocrine tumors, pancreatic neuroendocrine tumors, or pulmonary neuroendocrine tumors. The above non-Hodgkin lymphomas, which are tumors, are anaplastic large cell lymphomas and lymphoblastomas. Cystic lymphoma, peripheral T-cell lymphoma, follicular lymphoma, cutaneous T-cell lymphoma, lymphoid lymphoma Suppository lymphoma, marginal zone B-cell lymphoma, MALT lymphoma, small cell lymphocytic lymphoma Burkitt lymphoma, chronic lymphocytic leukemia (CL) L), small lymphocytic lymphoma (SLL), progenitor T lymphoblast Cytic leukemia / lymphoma, acute lymphocytic leukemia (ALL) , adult T cell lymphoma / leukemia (ATLL), hair loss B-cell leukemia, B-cell lymphoma, diffuse large B-cell lymphoma (Ill lymphoma, DLBCL), primary mediastinal B-cell lymphoma, primary central nervous system (central n) Lymphoma of the ervous system (CNS), mantle cell lymphoma (M CL), marginal zone lymphoma, mucosa-associated lymphoid tissue, MALT lymphoma, nodular marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, lymphoid type Suppository lymphoma, B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, natural Killer cell lymphoma, cutaneous T-cell lymphoma, Alibert-Bazin syndrome, Sézary syndrome , primary cutaneous anaplastic large cell lymphoma, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma angioimmunoblastic T cell lymphoma (AITL), anaplastic large cell lymphoma (anap lastic large-cell lymphoma (ALCL), systemic ALCL, enteropathic T-cell lymphoma (en Teropathy-type T cell lymphoma (EATL), or hepatosplenic gamma / delta T cell lymphoma (xxvi) The above oral cancers include squamous cell carcinoma, verrucous carcinoma, minor salivary gland carcinoma, and phosphorus carcinoma. Parkinson's disease, benign oral tumors, eosinophilic granulomas, fibromas, granular cell tumors, keratosacral cell tumors, leiomyomas Osteochondroma, lipoma, Schwann cell tumor, neurofibroma, papilloma, condyloma acuminata, verrucous type Xanthomas, pyogenic granulomas, rhabdomyomas, odontogenic tumors, leukoplakia, erythroplakia, squamous cell carcinoma of the lip, (xxvii) The above ovarian cancers are basal cell lip cancer, oral cancer, gingival cancer, or tongue cancer. Focal cell carcinoma, mucinous epithelial ovarian carcinoma, endometrial epithelial ovarian carcinoma, clear cell epithelial ovarian carcinoma, undifferentiated epithelial ovarian carcinoma Focal cancer, low-grade ovarian tumors, primary peritoneal cancer, fallopian tube cancer, germ cell tumors, teratomas, undifferentiated ovarian embryos Cellular carcinoma, endodermal sinus tumor, sex cord-stromal tumor, sex cord-gonadal stromal tumor, ovarian stromal tumor, granulosa cell tumor Surgery, granulosa follicular tumor, Sertoli-Leydig tumor, ovarian sarcoma, ovarian carcinosarcoma, ovarian glandular sarcoma It is a tumor, ovarian leiomyosarcoma, ovarian fibrosarcoma, Krukenberg tumor, or ovarian cyst, ( xxviii) The above pancreatic cancer is exocrine pancreatic carcinoma, endocrine pancreatic carcinoma, or pancreatic adenocarcinoma, or islet cell tumor. (xxix) The above prostate cancer is a ulcer or neuroendocrine tumor, prostate adenocarcinoma, prostate Adenosarcoma, transitional cell carcinoma, small cell carcinoma, or neuroendocrine tumor, (xxx) the above sinus Cancers include squamous cell carcinoma, mucosal cell carcinoma, adenoid cystic cell carcinoma, acinar cell carcinoma, and undifferentiated sinuses. It is carcinoma, nasal cavity cancer, paranasal sinus cancer, maxillary sinus cancer, ethmoid sinus cancer, or nasopharyngeal cancer, (xxxi ) The above skin cancers include basal cell carcinoma, squamous cell carcinoma, melanoma, Merkel cell carcinoma, and Kaposi's sarcoma. Kaposi sarcoma (KS), actinic keratosis, cutaneous lymphoma, or keratosacral cell tumor, ( xxxii) The above soft tissue cancers include angiosarcoma, dermatofibrosarcoma, epithelial sarcoma, and Ewing's sarcoma. Fibrosarcoma, gastrointestinal stromal tumor (GIST), Kaposi's sarcoma Tumor, leiomyosarcoma, liposarcoma, dedifferentiated liposarcoma (DL) , myxoid / round cell liposarcoma (MRCL), well-differentiated type Well-differentiated liposarcoma (WDL), malignant fibrous histiocytoma, nerve ridge It is visceral sarcoma, rhabdomyosarcoma (RMS), or synovial sarcoma, (xxx iii) The above spinal cord cancer is a metastatic tumor of the spinal cord, (xxxiv) The above gastric cancer is a gastric adenocarcinoma, Gastric lymphoma, gastrointestinal stromal tumor, carcinoid tumor, gastric carcinoid tumor, type I ECL cells Carcinoid, type II ECL cell carcinoid, or type III ECL cell carcinoid The above testicular cancers are seminoma, non-seminoma, embryonic carcinoma, and yolk sac carcinoma. tumor, choriocarcinoma, teratoma, gonadal stromal tumor, Leydig cell tumor, or Sertoli cell tumor (xxxiv) The above pharyngeal cancer may include squamous cell carcinoma, adenocarcinoma, sarcoma, laryngeal cancer, Head cancer, nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, laryngeal squamous cell carcinoma, laryngeal adenocarcinoma, phosphorus Paeonia, spindle cell carcinoma, verrucous carcinoma, undifferentiated carcinoma, or lymph node carcinoma, (xxxv ) The above thyroid cancers include papillary carcinoma, follicular carcinoma, Haasle cell carcinoma, medullary thyroid carcinoma, and if (xxxvi) The above uterine cancers are endometrial cancer, endometrial adenocarcinoma, etc. Endometrial carcinoma, serous adenocarcinoma, adenosquamous carcinoma, uterine carcinosarcoma, uterine sarcoma, uterine leiomyosarcoma , endometrial stromal sarcoma or undifferentiated sarcoma, (xxxvii) the above vaginal cancer, squamous It is a dermal cell carcinoma, adenocarcinoma, melanoma, or sarcoma, or (xxxviii) the above vulva The cancer is either squamous cell carcinoma or adenocarcinoma.

[0029] In some embodiments, the second target is located on the surface of the target cell, and the target cell is , B cells. In some embodiments, the second target is CD1a, CD1b, CD1 c, CD1d, CD2, CD5, CD6, CD9, CD11a, CD11b, CD11c , CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24 , CD25, CD26, CD27, CD29, CD30, CD31, CD32a, CD3 2b, CD35, CD37, CD38, CD39, CD40, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49 b, CD49c, CD49d, CD50, CD52, CD53, CD54, CD55, C D58, CD60a, CD62L, CD63, CD68, CD69, CD70, CD72 , CD73, CD74, CD75, CD75S, CD77, CD79a, CD79b, C D80, CD81, CD82, CD83, CD84, CD85E, CD85I, CD85 J, CD86, CD92, CD95, CD97, CD98, CD99, CD100, CD 102, CD108, CD119, CD120a, CD120b, CD121b, CD1 22, CD124, CD125, CD126, CD130, CD132, CD137, C D138, CD139, CD147, CD148, CD150, CD152, CD162 , CD164, CD166, CD167a, CD170, CD171, CD175, CD 175s, CD180, CD184, CD185, CD192, CD196, CD197 , CD200, CD205, CD201a, CDw210b, CD212, CD213a 1, CD213a2, CD215, CD217, CD218a, CD218b, CD22 0, CD221, CD222, CD224, CD225, CD226, CD227, CD 229, CD230, CD232, CD252, CD252, CD254, CD255, CD256, CD257 CD258, CD259, CD260, CD261, CD26 2, CD263, CD264, CD267-270, CD272, CD274, CD27 5, CD277, CD279, CD283, CD289, CD290, CD295, CD 298, CD300, CD300c, CD305, CD306, CD307a, CD30 7b, CD307c, CD307d, CD307e, CD314, CD215, CD31 6, CD317, CD319, CD321, CD327, CD328, CD329, CD 338, CD351, CD352, CD353, CD354, CD355, CD356, These are CD357, CD358, CD360, CD361, CD362, or CD363. In some embodiments, the second target is BCMA.

[0030] In another embodiment, an antibody that binds to Vα10.2 is provided, wherein the antibody (i) , VH CDR1, VH CDR2, and VH having the amino acid sequence of SEQ ID NO: 568 VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequence of VH CDR3. (ii) VH containing CDR3, and VL having the amino acid sequence of SEQ ID NO: 569, respectively. VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequences of VL Includes VLs including CDR1, VL CDR2, and VL CDR3. In another embodiment, An antibody that binds to Vα10.2 is provided, and the above antibody is (i) Sequence ID No. 570 VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequence of VH V containing amino acid sequences, including VH CDR1, VH CDR2, and VH CDR3 H and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 571, respectively. VL CDR1, VL CDR3, which have the amino acid sequences of VL CDR2 and VL CDR3. Includes VL including CDR2 and VL CDR3. In some embodiments, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and V The L CDR3 amino acid sequence follows the Kabat numbering system. In some embodiments, , VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 The amino acid sequences of the VL CDR3 follow the Chothia numbering system. In this embodiment, VH CDR1, VH CDR2, VH CDR3, VL CDR1, V The L CDR2 and VL CDR3 amino acid sequences follow the AbM numbering system. In that embodiment, VH CDR1, VH CDR2, VH CDR3, VL CDR1 The amino acid sequences of VL CDR2 and VL CDR3 are assigned to the Contact numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR3, V The amino acid sequences of L CDR1, VL CDR2, and VL CDR3 are assigned by the IMGT numbering system. Follow the system. In some embodiments, VH CDR1, VH CDR2, VH CDR 3. The amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 are exemplary. The system follows a specific numbering system. In some embodiments, the Vα10.2 antibody is a humanized antibody. In some embodiments, the Vα10.2 antibody is an IgG antibody. So, the antibody is either IgG1, IgG2, IgG3, or IgG4 isotype. In some embodiments, the IgG antibody contains a kappa light chain. The G antibody contains a lambda light chain. In some embodiments, the Vα10.2 antibody is mo It is a noclonal antibody. In some embodiments, the Vα10.2 antibody is Vα10 .2 Binds to the antigen. In some embodiments, the Vα10.2 antibody binds to the Vα10.2 antigen. It binds to the epitope. In some embodiments, the Vα10.2 antibody binds to Vα10.2. It binds specifically to VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are antiviral agents for Vα10.2. It forms a binding site to the source. In some embodiments, VH CDR1, VH CD R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are Vα It forms a binding site for the epitope 10.2. In some embodiments, Vα10 .2 is present on the surface of T cells. In some embodiments, the Vα10.2 antibody is poly It is a value. In some embodiments, the Vα10.2 antibody is a multispecific antibody. In some embodiments, the Vα10.2 antibody is a bispecific antibody. Then, the multispecific Vα10.2 antibody further binds to a second target, and the above second target is B I am a CMA.

[0031] In yet another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody is (i ) VH CDR1 having the amino acid sequence of SEQ ID NO: 48, and the amino acid sequence of SEQ ID NO: 49 It contains VH CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 50. , VH and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 51, SEQ ID NO: 52 VL CDR2 having the amino acid sequence of SEQ ID NO: 53, and VL The antibody contains CDR3 and VL. In some embodiments, the antibody is the same as in SEQ ID NO: 77. It contains VH having a mino acid sequence. In some embodiments, the antibody is the amino acid sequence of SEQ ID NO: 78 It contains a VL having an amino acid sequence. In some embodiments, the antibody is the amino acid sequence of SEQ ID NO 77. It contains VH having an acid sequence and VL having the amino acid sequence of SEQ ID NO: 78. In some embodiments, the antibody includes a humanized antibody. In some embodiments, the antibody is an IgG antibody. The body contains. In some embodiments, the antibody is IgG1, IgG2, IgG3, or Ig Contains a G4 antibody. In some embodiments, the antibody binds to the Vβ17 antigen. In one embodiment, the antibody binds to the Vβ17 epitope. In some embodiments, The above antibodies VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 form the binding sites for the Vβ17 antigen. In one embodiment, the above antibodies VH CDR1, VH CDR2, VH CDR3, V L CDR1, VL CDR2, and VL CDR3 are related to the Vβ17 epitope. It forms a binding site. In some embodiments, the antibody is present on the surface of the Vβ cell. Includes 17. In certain embodiments, T cells are T cells. In some embodiments In some embodiments, the T cells are CD8+ T cells. These are cells. In some embodiments, T cells are cytotoxic T lymphocytes. These are mphocytes (CTLs). In some embodiments, the antibody is a polyvalent bispecific antibody. Includes. In some embodiments, the antibody can bind to at least three antigens. In some embodiments, the bispecific antibody is capable of binding to at least five antigens. Yes, it is possible. In some embodiments, the antibody is a multispecific antibody.

[0032] In one embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) sequence VH CDR1 has amino acid sequence number 48, and has amino acid sequence number 54. VH CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 55 are included. (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 56, and the amino acid sequence of SEQ ID NO: 57 VL CDR2 having an amino acid sequence, and VL CD having the amino acid sequence of SEQ ID NO 58. The antibody contains R3 and VL. In some embodiments, the antibody contains the amino acids of SEQ ID NO: 79 It contains VH having the sequence. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 80 It includes a VL having a column. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 79 It includes VH having and VL having the amino acid sequence of SEQ ID NO: 80. Several implementation forms In this embodiment, the antibody includes a humanized antibody. In some embodiments, the antibody includes an IgG antibody. In some embodiments, the antibody is IgG1, IgG2, IgG3, or IgG4 antibody. The body contains. In some embodiments, the antibody binds to the Vβ17 antigen. In the application form, the antibody binds to the Vβ17 epitope. In some embodiments, the above Antibodies VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD R2 and VL CDR3 form the binding sites for the Vβ17 antigen. In this embodiment, the above antibodies VH CDR1, VH CDR2, VH CDR3, VL C DR1, VL CDR2, and VL CDR3 are binding sites for the Vβ17 epitope. It forms a position. In some embodiments, the antibody targets Vβ17 present on the surface of T cells. Includes. In some embodiments, the antibody includes a polyvalent bispecific antibody. Several embodiments Morphologically, an antibody can bind to at least three antigens. Several embodiments So, a bispecific antibody can bind to at least five antigens. In terms of application, the antibody is a multispecific antibody.

[0033] In yet another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody is (i ) VH CDR1 having the amino acid sequence of SEQ ID NO: 59, and the amino acid sequence of SEQ ID NO: 49 It contains VH CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 60. , VH and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 61, SEQ ID NO: 62 VL CDR2 having the amino acid sequence of SEQ ID NO: 63, and VL The antibody contains CDR3 and VL. In some embodiments, the antibody is the same as in SEQ ID NO: 81. It contains VH having a mino acid sequence. In some embodiments, the antibody is the amino acid sequence of SEQ ID NO: 82 It contains a VL having an amino acid sequence. In some embodiments, the antibody is the amino acid sequence of SEQ ID NO 81. It contains VH having an acid sequence and VL having the amino acid sequence of SEQ ID NO: 82. In some embodiments, the antibody includes a humanized antibody. In some embodiments, the antibody is an IgG antibody. The body contains. In some embodiments, the antibody is IgG1, IgG2, IgG3, or Ig Contains a G4 antibody. In some embodiments, the antibody binds to the Vβ17 antigen. In one embodiment, the antibody binds to the Vβ17 epitope. In some embodiments, The above antibodies VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 form the binding sites for the Vβ17 antigen. In one embodiment, the above antibodies VH CDR1, VH CDR2, VH CDR3, V L CDR1, VL CDR2, and VL CDR3 are related to the Vβ17 epitope. It forms a binding site. In some embodiments, the antibody is present on the surface of the Vβ cell. Includes 17. In some embodiments, the antibody comprises a polyvalent bispecific antibody. In this embodiment, the antibody can bind to at least three antigens. In this application, bispecific antibodies can bind to at least five antigens. In that embodiment, the antibody is a multispecific antibody.

[0034] In yet another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody is (i ) VH CDR1 having the amino acid sequence of SEQ ID NO: 64, and the amino acid sequence of SEQ ID NO: 65 It contains VH CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 66. , VH and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 67, SEQ ID NO: 68 VL CDR2 having the amino acid sequence of SEQ ID NO: 69, and VL The antibody contains CDR3 and VL. In some embodiments, the antibody is SEQ ID NO: 83 It contains VH having a mino acid sequence. In some embodiments, the antibody is the amino acid sequence of SEQ ID NO: 84. It contains a VL having an amino acid sequence. In some embodiments, the antibody is the amino acid sequence of SEQ ID NO 83. It contains VH having an acid sequence and VL having the amino acid sequence of SEQ ID NO: 84. In some embodiments, the antibody includes a humanized antibody. In some embodiments, the antibody is an IgG antibody. The body contains. In some embodiments, the antibody is IgG1, IgG2, IgG3, or Ig Contains a G4 antibody. In some embodiments, the antibody binds to the Vβ17 antigen. In one embodiment, the antibody binds to the Vβ17 epitope. In some embodiments, The above antibodies VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 form the binding sites for the Vβ17 antigen. In one embodiment, the above antibodies VH CDR1, VH CDR2, VH CDR3, V L CDR1, VL CDR2, and VL CDR3 are related to the Vβ17 epitope. It forms a binding site. In some embodiments, the antibody is present on the surface of the Vβ cell. Includes 17. In some embodiments, the antibody comprises a polyvalent bispecific antibody. In this embodiment, the antibody can bind to at least three antigens. In this application, bispecific antibodies can bind to at least five antigens. In that embodiment, the antibody is a multispecific antibody.

[0035] In one embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) sequence VH CDR1 has amino acid sequence number 70, and has amino acid sequence number 49. VH CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 71 are included. (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 61, and the amino acid sequence of SEQ ID NO: 72 VL CDR2 has an amino acid sequence, and VL CD has the amino acid sequence of SEQ ID NO 73. The antibody contains R3 and VL. In some embodiments, the antibody contains the amino acids of SEQ ID NO: 85 It contains VH having the sequence. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 86 It includes a VL having a column. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 85 It includes VH having and VL having the amino acid sequence of SEQ ID NO: 86. Several implementation forms In this embodiment, the antibody includes a humanized antibody. In some embodiments, the antibody includes an IgG antibody. In some embodiments, the antibody is IgG1, IgG2, IgG3, or IgG4 antibody. The body contains. In some embodiments, the antibody binds to the Vβ17 antigen. In the application form, the antibody binds to the Vβ17 epitope. In some embodiments, the above Antibodies VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD R2 and VL CDR3 form the binding sites for the Vβ17 antigen. In this embodiment, the above antibodies VH CDR1, VH CDR2, VH CDR3, VL C DR1, VL CDR2, and VL CDR3 are binding sites for the Vβ17 epitope. It forms a position. In some embodiments, the antibody targets Vβ17 present on the surface of T cells. comprises. In some embodiments, the antibody comprises a multivalent bispecific antibody. In some embodiments, the antibody can bind to at least three antigens. In some embodiments the bispecific antibody can bind to at least five antigens. In some embodiments the antibody is a multispecific antibody.

[0036] In one aspect, an antibody that binds to Vβ17 is provided herein, and the above antibody comprises a VH comprising (i) a VH CDR1 having the amino acid sequence of SEQ ID NO: 48, a VH CDR2 having the amino acid sequence of SEQ ID NO: 74, and a VH CDR3 having the amino acid sequence of SEQ ID NO: 75, and (ii) a VL comprising a VL CDR1 having the amino acid sequence of SEQ ID NO: 56, a VL CDR2 having the amino acid sequence of SEQ ID NO: 57, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 76. In some embodiments, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: 87. In some embodiments, the antibody comprises a VL having the amino acid sequence of SEQ ID NO: 88. In some embodiments, the antibody comprises a VH having the amino acid sequence of SEQ ID NO: 87 and a VL having the amino acid sequence of SEQ ID NO: 88. In some embodiments, the antibody comprises a humanized antibody. In some embodiments, the antibody comprises an IgG antibody. In some embodiments, the antibody comprises an IgG1, IgG2, IgG3, or IgG4 antibody. In some embodiments, the antibody binds to the Vβ17 antigen. In some embodiments, the antibody binds to a Vβ17 epitope. In some embodiments, the In this embodiment, the above antibodies VH CDR1, VH CDR2, VH CDR3, VL C DR1, VL CDR2, and VL CDR3 are binding sites for the Vβ17 epitope. It forms a position. In some embodiments, the antibody targets Vβ17 present on the surface of T cells. Includes. In some embodiments, the antibody includes a polyvalent bispecific antibody. Several embodiments Morphologically, an antibody can bind to at least three antigens. Several embodiments So, a bispecific antibody can bind to at least five antigens. In terms of application, the antibody is a multispecific antibody.

[0037] In one embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) sequence VH CDR1 having amino acid sequence number 1, VH having amino acid sequence number 2 VH and ( containing VH CDR3 having the amino acid sequence of CDR2 and SEQ ID NO: 3, ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 664, and the amino acid sequence of SEQ ID NO: 5 VL CDR2 has a column, and VL CDR3 has the amino acid sequence of SEQ ID NO: 6. It includes VL. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 21 It contains VH. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 665 It includes VL. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 21. It comprises VH and VL having the amino acid sequence of SEQ ID NO: 665. In some embodiments, The antibody includes a humanized antibody. In some embodiments, the antibody includes an IgG antibody. In some embodiments, the antibody is an IgG1, IgG2, IgG3, or IgG4 antibody. Includes. In some embodiments, the antibody binds to the Vβ17 antigen. In this state, the antibody binds to the Vβ17 epitope. In some embodiments, the above antibody VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 , and VL CDR3 form the binding site for the Vβ17 antigen. Several implementations In terms of morphology, the above antibodies are VH CDR1, VH CDR2, VH CDR3, and VL CDR 1. VL CDR2 and VL CDR3 have binding sites to the epitope of Vβ17. Forms. In some embodiments, the antibody contains Vβ17 present on the surface of T cells. In some embodiments, the antibody comprises a polyvalent bispecific antibody. Therefore, the antibody can bind to at least three antigens. In some embodiments, Bispecific antibodies can bind to at least five antigens. Several implementations In this state, the antibody is a multispecific antibody.

[0038] In one embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) sequence VH CDR1 has amino acid sequence number 979, and has amino acid sequence number 980. Includes VH CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 981. , VH and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 994, SEQ ID NO: 9 VL CDR2 has a 95-amino acid sequence, and has the amino acid sequence of SEQ ID NO: 996. VL CDR3 is included, and VL is included. In some embodiments, the antibody is SEQ ID NO: 1 It contains VH having the amino acid sequence 000. In some embodiments, the antibody is SEQ ID NO It contains a VL having an amino acid sequence of 1001. In some embodiments, the antibody is sequence number VH having the amino acid sequence of No. 1000 and V having the amino acid sequence of SEQ ID NO: 1001 L. In some embodiments, the antibody includes a humanized antibody. In some embodiments the antibody includes an IgG antibody. In some embodiments, the antibody is IgG1, IgG 2, IgG3, or IgG4 antibody. In some embodiments, the antibody binds to the Vβ17 antigen. In some embodiments, the antibody binds to the Vβ17 epitope. In some embodiments, the VH CDR1, VH CDR2, VH CDR3 , VL CDR1, VL CDR2, and VL CDR3 of the above antibody form a binding site for the antigen of Vβ17 . In some embodiments, the VH CDR1, VH CDR 2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of the above antibody form a binding site for the epitope of Vβ1 7. In some embodiments, the antibody includes Vβ17 present on the surface of T cells . In some embodiments, the antibody includes a multivalent bispecific antibody. In some embodiments, the antibody can bind to at least three antigens . In some embodiments, the bispecific antibody can bind to at least five antigens . In some embodiments, the antibody is a multispecific antibody.

[0039] In one aspect, an antibody that binds to Vβ17 is provided herein, and the above antibody is (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 1011, the amino acid sequence of SEQ ID NO: 1012 VH CDR2 having and VH CDR3 having the amino acid sequence of SEQ ID NO: 1013 , VH including, (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 1026, arrangement VL CDR2 having the amino acid sequence of SEQ ID NO: 1027, and VL CDR3 having the amino acid sequence of SEQ ID NO: 1028, VL CDR2 having the amino acid sequence of sequence number 1027, and amino acid sequence number 1028 VL includes VL CDR3 having an acid sequence. In some embodiments, the antibody is , containing VH having the amino acid sequence of SEQ ID NO: 1032. In some embodiments, antibody It contains VL having the amino acid sequence of SEQ ID NO: 1033. In some embodiments, anti The body has VH with the amino acid sequence of SEQ ID NO: 1032 and the amino acid sequence of SEQ ID NO: 1033 It includes a VL having a column. In some embodiments, the antibody includes a humanized antibody. In one embodiment, the antibody comprises an IgG antibody. In some embodiments, the antibody is Ig It contains G1, IgG2, IgG3, or IgG4 antibodies. In some embodiments, it contains anti The body binds to the Vβ17 antigen. In some embodiments, the antibody binds to the Vβ17 epitope. It binds to the above antibodies VH CDR1, VH CDR2, V H CDR3, VL CDR1, VL CDR2, and VL CDR3 are antiviral agents for Vβ17. It forms a binding site to the progenitor. In some embodiments, the VH CDR1 of the above antibody, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR 3 forms a binding site for the Vβ17 epitope. In some embodiments, The body contains Vβ17 present on the surface of T cells. In some embodiments, the antibody is multi It contains a bispecific antibody of a specific titer. In some embodiments, the antibody is effective against at least three antigens. It can bind. In some embodiments, the bispecific antibody has at least five It can bind to the antigen. In some embodiments, the antibody is a multispecific antibody. .

[0040] In one embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) sequence VH CDR1 having amino acid sequence number 1043, amino acid sequence of sequence number 1044 VH CDR2 having the amino acid sequence of SEQ ID NO: 1045, and VH CDR3 having the amino acid sequence of SEQ ID NO: 1045. (ii) VH and VL CDR1 having the amino acid sequence of SEQ ID NO: 1058, VL CDR2 having the amino acid sequence of sequence number 1059, and the amino acid sequence of sequence number 1060 VL includes VL CDR3 having an acid sequence. In some embodiments, the antibody is , containing VH having the amino acid sequence of SEQ ID NO: 1064. In some embodiments, antibody It contains VL having the amino acid sequence of SEQ ID NO: 1065. In some embodiments, anti The body has VH with the amino acid sequence of SEQ ID NO: 1064 and the amino acid sequence of SEQ ID NO: 165 It includes VL having. In some embodiments, the antibody includes a humanized antibody. In some embodiments, the antibody comprises an IgG antibody. In some embodiments, the antibody is IgG 1. Contains IgG2, IgG3, or IgG4 antibody. In some embodiments, antibody It binds to the Vβ17 antigen. In some embodiments, the antibody binds to the Vβ17 epitope. They bind. In some embodiments, the above antibodies VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are antigens of Vβ17. It forms a binding site for the above antibody VH CDR1, V H CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 This forms a binding site for the Vβ17 epitope. In some embodiments, the antibody It contains Vβ17 present on the surface of T cells. In some embodiments, the antibody is polyvalent. It contains a bispecific antibody. In some embodiments, the antibody binds to at least three antigens. It can be combined. In some embodiments, the bispecific antibody contains at least five antibodies. It can bind to the source. In some embodiments, the antibody is a multispecific antibody.

[0041] In one embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) sequence VH CDR1 having amino acid sequence number 1075, amino acid sequence of sequence number 1076 VH CDR2 has the amino acid sequence of SEQ ID NO: 1077, and VH CDR3 has the amino acid sequence of SEQ ID NO: 1077. (ii) VH and VL CDR1 having the amino acid sequence of SEQ ID NO: 1090, VL CDR2 having the amino acid sequence of sequence number 1091, and amino acid sequence number 1092 VL includes VL CDR3 having an acid sequence. In some embodiments, the antibody is , containing VH having the amino acid sequence of SEQ ID NO: 1096. In some embodiments, antibody It contains VL having the amino acid sequence of SEQ ID NO: 1097. In some embodiments, anti The body has VH with the amino acid sequence of SEQ ID NO: 1096 and the amino acid sequence of SEQ ID NO: 197 It includes VL having. In some embodiments, the antibody includes a humanized antibody. In some embodiments, the antibody comprises an IgG antibody. In some embodiments, the antibody is IgG 1. Contains IgG2, IgG3, or IgG4 antibody. In some embodiments, antibody It binds to the Vβ17 antigen. In some embodiments, the antibody binds to the Vβ17 epitope. They bind. In some embodiments, the above antibodies VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are antigens of Vβ17. It forms a binding site for the above antibody VH CDR1, V H CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 This forms a binding site for the Vβ17 epitope. In some embodiments, the antibody It contains Vβ17 present on the surface of T cells. In some embodiments, the antibody is polyvalent. It contains a bispecific antibody. In some embodiments, the antibody binds to at least three antigens. It can be combined. In some embodiments, the bispecific antibody contains at least five antibodies. It can bind to the source. In some embodiments, the antibody is a multispecific antibody.

[0042] In one embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) sequence VH CDR1 having amino acid sequence number 1107, amino acid sequence of sequence number 1108 VH CDR2 has the amino acid sequence of SEQ ID NO: 1109, and VH CDR3 has the amino acid sequence of SEQ ID NO: 1109. (ii) VH and VL CDR1 having the amino acid sequence of SEQ ID NO: 1122, VL CDR2 having the amino acid sequence of sequence number 1123, and amino acid sequence number 1124 VL includes VL CDR3 having an acid sequence. In some embodiments, the antibody is , containing VH having the amino acid sequence of SEQ ID NO: 1128. In some embodiments, antibody It contains VL having the amino acid sequence of SEQ ID NO: 1129. In some embodiments, anti The body has VH with the amino acid sequence of SEQ ID NO: 1128 and the amino acid sequence of SEQ ID NO: 1129 It includes a VL having a column. In some embodiments, the antibody includes a humanized antibody. In one embodiment, the antibody comprises an IgG antibody. In some embodiments, the antibody is Ig It contains G1, IgG2, IgG3, or IgG4 antibodies. In some embodiments, it contains anti The body binds to the Vβ17 antigen. In some embodiments, the antibody binds to the Vβ17 epitope. It binds to the above antibodies VH CDR1, VH CDR2, V H CDR3, VL CDR1, VL CDR2, and VL CDR3 are antiviral agents for Vβ17. It forms a binding site to the progenitor. In some embodiments, the VH CDR1 of the above antibody, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR 3 forms a binding site for the Vβ17 epitope. In some embodiments, The body contains Vβ17 present on the surface of T cells. In some embodiments, the antibody is multi It contains a bispecific antibody of a specific titer. In some embodiments, the antibody is effective against at least three antigens. It can bind. In some embodiments, the bispecific antibody has at least five It can bind to the antigen. In some embodiments, the antibody is a multispecific antibody. .

[0043] In another embodiment, (a) a first binding domain that binds to Vβ17, and (b) at Vβ17 This specification presents a bispecific antibody containing a second binding domain that binds to a second target, which is not present in this specification. To be served.

[0044] In some embodiments, the first binding domain of the bispecific antibody is (i) Sequence ID No. 4 VH CDR1 has an amino acid sequence of 8, and VH has an amino acid sequence of SEQ ID NO: 49. VH containing CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 50, and (i i) VL CDR1 having the amino acid sequence of SEQ ID NO: 51, amino acid sequence of SEQ ID NO: 52 VL CDR2 has the amino acid sequence of SEQ ID NO: 53 and VL CDR3 has the amino acid sequence of SEQ ID NO: 53. It includes VL and. In some embodiments, the bispecific antibody is the amino acid of SEQ ID NO: 77. It contains VH having an acid sequence. In some embodiments, the bispecific antibody is SEQ ID NO: 78 It contains a VL having the amino acid sequence. In some embodiments, the bispecific antibody has the sequence VH has amino acid sequence number 77, and VL has amino acid sequence number 78. Includes. In some embodiments, the bispecific antibody Vβ17 is present on the surface of T cells. In some embodiments, the first binding domain of the bispecific antibody is humanized. The second binding domain is humanized, or the first binding domain and the second Both binding domains are humanized. In some embodiments, the bispecific antibody is , containing IgG antibodies. In some embodiments, the bispecific antibodies are IgG1, IgG2 It contains an IgG3 or IgG4 antibody. In some embodiments, the first bispecific antibody The binding domain binds to the Vβ17 antigen. In some embodiments, a bispecific antibody The first binding domain binds to the Vβ17 epitope. In some embodiments, two Heavily specific antibodies: VH CDR1, VH CDR2, VH CDR3, VL CDR1, V L CDR2 and VL CDR3 form the binding sites for the Vβ17 antigen. In some embodiments, the bispecific antibodies VH CDR1, VH CDR2, and VH CD R3, VL CDR1, VL CDR2, and VL CDR3 are epitopes of Vβ17. It forms a binding site for the second binding site of the bispecific antibody. In some embodiments, the second binding site of the bispecific antibody The main target is the antigen of the second target. In some embodiments, the second target of the bispecific antibody is the antigen of the second target. The binding domain 2 binds to the epitope of the second target. In some embodiments, two Heavily specific antibodies: VH CDR1, VH CDR2, VH CDR3, VL CDR1, V L CDR2 and VL CDR3 form binding sites for the second target antigen. In some embodiments, the bispecific antibodies VH CDR1, VH CDR2, and VH C DR3, VL CDR1, VL CDR2, and VL CDR3 are the epithet of the second target. It forms a binding site for the pepper. In some embodiments, the second pepper of the bispecific antibody The target is located on the surface of the second cell.

[0045] In some embodiments, the first binding domain of the bispecific antibody is (i) Sequence ID No. 4 VH CDR1 has an amino acid sequence of 8, and VH has an amino acid sequence of SEQ ID NO: 54. VH containing CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 55, and (i i) VL CDR1 having the amino acid sequence of SEQ ID NO: 56, and the amino acid sequence of SEQ ID NO: 57 VL CDR2 has the amino acid sequence of SEQ ID NO: 58 and VL CDR3 has the amino acid sequence of SEQ ID NO: 58. It includes VL and. In some embodiments, the bispecific antibody is the amino acid of SEQ ID NO: 79. It contains VH having an acid sequence. In some embodiments, the bispecific antibody is SEQ ID NO: 80 It contains a VL having the amino acid sequence. In some embodiments, the bispecific antibody has the sequence VH has amino acid sequence number 79, and VL has amino acid sequence number 80. Includes. In some embodiments, the bispecific antibody Vβ17 is present on the surface of T cells. In some embodiments, the first binding domain of the bispecific antibody is humanized. The second binding domain is humanized, or the first binding domain and the second Both binding domains are humanized. In some embodiments, the bispecific antibody is , containing IgG antibodies. In some embodiments, the bispecific antibodies are IgG1, IgG2 It contains an IgG3 or IgG4 antibody. In some embodiments, the first bispecific antibody The binding domain binds to the Vβ17 antigen. In some embodiments, a bispecific antibody The first binding domain binds to the Vβ17 epitope. In some embodiments, two Heavily specific antibodies: VH CDR1, VH CDR2, VH CDR3, VL CDR1, V L CDR2 and VL CDR3 form the binding sites for the Vβ17 antigen. In some embodiments, the bispecific antibodies VH CDR1, VH CDR2, and VH CD R3, VL CDR1, VL CDR2, and VL CDR3 are epitopes of Vβ17. It forms a binding site for the second binding site of the bispecific antibody. In some embodiments, the second binding site of the bispecific antibody The main target is the antigen of the second target. In some embodiments, the second target of the bispecific antibody is the antigen of the second target. The binding domain 2 binds to the epitope of the second target. In some embodiments, two Heavily specific antibodies: VH CDR1, VH CDR2, VH CDR3, VL CDR1, V L CDR2 and VL CDR3 form binding sites for the second target antigen. In some embodiments, the bispecific antibodies VH CDR1, VH CDR2, and VH C DR3, VL CDR1, VL CDR2, and VL CDR3 are the epithet of the second target. It forms a binding site for the pepper. In some embodiments, the second pepper of the bispecific antibody The target is located on the surface of the second cell.

[0046] In some embodiments, the first binding domain of the bispecific antibody is (i) Sequence ID No. 5 VH CDR1 has an amino acid sequence of 9, and VH has an amino acid sequence of SEQ ID NO: 49. VH containing CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 60, and (i i) VL CDR1 having the amino acid sequence of SEQ ID NO: 61, amino acid sequence of SEQ ID NO: 62 VL CDR2 has the amino acid sequence of SEQ ID NO: 63 and VL CDR3 has the amino acid sequence of SEQ ID NO: 63. It includes VL. In some embodiments, the bispecific antibody is the amino acid of SEQ ID NO: 81. It contains VH having an acid sequence. In some embodiments, the bispecific antibody is SEQ ID NO: 82 It contains a VL having the amino acid sequence. In some embodiments, the bispecific antibody has the sequence VH having amino acid sequence number 81 and VL having amino acid sequence number 82 Includes. In some embodiments, the bispecific antibody Vβ17 is present on the surface of T cells. In some embodiments, the first binding domain of the bispecific antibody is humanized. The second binding domain is humanized, or the first binding domain and the second Both binding domains are humanized. In some embodiments, the bispecific antibody is , containing IgG antibodies. In some embodiments, the bispecific antibodies are IgG1, IgG2 It contains an IgG3 or IgG4 antibody. In some embodiments, the first bispecific antibody The binding domain binds to the Vβ17 antigen. In some embodiments, a bispecific antibody The first binding domain binds to the Vβ17 epitope. In some embodiments, two Heavily specific antibodies: VH CDR1, VH CDR2, VH CDR3, VL CDR1, V L CDR2 and VL CDR3 form the binding sites for the Vβ17 antigen. In some embodiments, the bispecific antibodies VH CDR1, VH CDR2, and VH CD R3, VL CDR1, VL CDR2, and VL CDR3 are epitopes of Vβ17. It forms a binding site for the second binding site of the bispecific antibody. In some embodiments, the second binding site of the bispecific antibody The main target is the antigen of the second target. In some embodiments, the second target of the bispecific antibody is the antigen of the second target. The binding domain 2 binds to the epitope of the second target. In some embodiments, two Heavily specific antibodies: VH CDR1, VH CDR2, VH CDR3, VL CDR1, V L CDR2 and VL CDR3 form binding sites for the second target antigen. In some embodiments, the bispecific antibodies VH CDR1, VH CDR2, and VH C DR3, VL CDR1, VL CDR2, and VL CDR3 are the epithet of the second target. It forms a binding site for the pepper. In some embodiments, the second pepper of the bispecific antibody The target is located on the surface of the second cell.

[0047] In some embodiments, the first binding domain of the bispecific antibody is (i) Sequence ID No. 6 VH CDR1 has the amino acid sequence of 4, and VH has the amino acid sequence of SEQ ID NO: 65. VH containing CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 66, and (i i) VL CDR1 having the amino acid sequence of SEQ ID NO: 67, amino acid sequence of SEQ ID NO: 68 VL CDR2 has the amino acid sequence of SEQ ID NO: 69 and VL CDR3 has the amino acid sequence of SEQ ID NO: 69. It includes VL and. In some embodiments, the bispecific antibody is the amino acid of SEQ ID NO: 83. It contains VH having an acid sequence. In some embodiments, the bispecific antibody is SEQ ID NO: 84 It contains a VL having the amino acid sequence. In some embodiments, the bispecific antibody has the sequence VH has amino acid sequence number 83, and VL has amino acid sequence number 84. Includes. In some embodiments, the bispecific antibody Vβ17 is present on the surface of T cells. In some embodiments, the first binding domain of the bispecific antibody is humanized. The second binding domain is humanized, or the first binding domain and the second Both binding domains are humanized. In some embodiments, the bispecific antibody is , containing IgG antibodies. In some embodiments, the bispecific antibodies are IgG1, IgG2 It contains an IgG3 or IgG4 antibody. In some embodiments, the first bispecific antibody The binding domain binds to the Vβ17 antigen. In some embodiments, a bispecific antibody The first binding domain binds to the Vβ17 epitope. In some embodiments, two Heavily specific antibodies: VH CDR1, VH CDR2, VH CDR3, VL CDR1, V L CDR2 and VL CDR3 form the binding sites for the Vβ17 antigen. In some embodiments, the bispecific antibodies VH CDR1, VH CDR2, and VH CD R3, VL CDR1, VL CDR2, and VL CDR3 are epitopes of Vβ17. It forms a binding site for the second binding site of the bispecific antibody. In some embodiments, the second binding site of the bispecific antibody The main target is the antigen of the second target. In some embodiments, the second target of the bispecific antibody is the antigen of the second target. The binding domain 2 binds to the epitope of the second target. In some embodiments, two Heavily specific antibodies: VH CDR1, VH CDR2, VH CDR3, VL CDR1, V L CDR2 and VL CDR3 form binding sites for the second target antigen. In some embodiments, the bispecific antibodies VH CDR1, VH CDR2, and VH C DR3, VL CDR1, VL CDR2, and VL CDR3 are the epithet of the second target. It forms a binding site for the pepper. In some embodiments, the second pepper of the bispecific antibody The target is located on the surface of the second cell.

[0048] In some embodiments, the first binding domain of the bispecific antibody is (i) Sequence ID No. 7 VH CDR1 has an amino acid sequence of 0, and VH has an amino acid sequence of SEQ ID NO: 49. VH containing CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 71, and (i i) VL CDR1 having the amino acid sequence of SEQ ID NO: 61, amino acid sequence of SEQ ID NO: 72 VL CDR2 has the amino acid sequence of SEQ ID NO: 73 and VL CDR3 has the amino acid sequence of SEQ ID NO: 73. It includes VL and. In some embodiments, the bispecific antibody is the amino acid of SEQ ID NO: 85. It contains VH having an acid sequence. In some embodiments, the bispecific antibody is SEQ ID NO: 86 It contains a VL having the amino acid sequence. In some embodiments, the bispecific antibody has the sequence VH has amino acid sequence number 85, and VL has amino acid sequence number 86. Includes. In some embodiments, the bispecific antibody Vβ17 is present on the surface of T cells. In some embodiments, the first binding domain of the bispecific antibody is humanized. The second binding domain is humanized, or the first binding domain and the second Both binding domains are humanized. In some embodiments, the bispecific antibody is , containing IgG antibodies. In some embodiments, the bispecific antibodies are IgG1, IgG2 It contains an IgG3 or IgG4 antibody. In some embodiments, the first bispecific antibody The binding domain binds to the Vβ17 antigen. In some embodiments, a bispecific antibody The first binding domain binds to the Vβ17 epitope. In some embodiments, two Heavily specific antibodies: VH CDR1, VH CDR2, VH CDR3, VL CDR1, V L CDR2 and VL CDR3 form the binding sites for the Vβ17 antigen. In some embodiments, the bispecific antibodies VH CDR1, VH CDR2, and VH CD R3, VL CDR1, VL CDR2, and VL CDR3 are epitopes of Vβ17. It forms a binding site for the second binding site of the bispecific antibody. In some embodiments, the second binding site of the bispecific antibody The main target is the antigen of the second target. In some embodiments, the second target of the bispecific antibody is the antigen of the second target. The binding domain 2 binds to the epitope of the second target. In some embodiments, two Heavily specific antibodies: VH CDR1, VH CDR2, VH CDR3, VL CDR1, V L CDR2 and VL CDR3 form binding sites for the second target antigen. In some embodiments, the bispecific antibodies VH CDR1, VH CDR2, and VH C DR3, VL CDR1, VL CDR2, and VL CDR3 are the epithet of the second target. It forms a binding site for the pepper. In some embodiments, the second pepper of the bispecific antibody The target is located on the surface of the second cell.

[0049] In some embodiments, the first binding domain of the bispecific antibody is (i) Sequence ID No. 4 VH CDR1 has an amino acid sequence of 8, and VH has an amino acid sequence of SEQ ID NO: 74. VH containing CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 75, and (i i) VL CDR1 having the amino acid sequence of SEQ ID NO: 56, and the amino acid sequence of SEQ ID NO: 57 VL CDR2 has the amino acid sequence of SEQ ID NO: 76 and VL CDR3 has the amino acid sequence of SEQ ID NO: 76. It includes VL. In some embodiments, the bispecific antibody is the amino acid of SEQ ID NO: 87. It contains VH having an acid sequence. In some embodiments, the bispecific antibody is SEQ ID NO: 88 It contains a VL having the amino acid sequence. In some embodiments, the bispecific antibody has the sequence VH having amino acid sequence number 87 and VL having amino acid sequence number 88 Includes. In some embodiments, the first binding domain of the bispecific antibody is (i) sequence number VH CDR1 having the amino acid sequence of No. 1, VH having the amino acid sequence of SEQ ID NO: 2 VH containing VH CDR3 having the amino acid sequence of CDR2 and SEQ ID NO: 3, and (ii ) VL CDR1 having the amino acid sequence of SEQ ID NO: 664, and the amino acid sequence of SEQ ID NO: 5 V contains VL CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 6. L and, in some embodiments, the bispecific antibody has the amino acid combination of SEQ ID NO: 21. It includes VH having a column. In some embodiments, the bispecific antibody is SEQ ID NO: 677 It contains VL having an amino acid sequence. In some embodiments, the bispecific antibody is sequence number VH having the amino acid sequence of number 21 and VL having the amino acid sequence of sequence number 677 Includes. In some embodiments, the bispecific antibody Vβ17 is present on the surface of T cells. In some embodiments, the first binding domain of the bispecific antibody is humanized. The second binding domain is humanized, or the first binding domain and the second Both binding domains are humanized. In some embodiments, the bispecific antibody is , containing IgG antibodies. In some embodiments, the bispecific antibodies are IgG1, IgG2 It contains an IgG3 or IgG4 antibody. In some embodiments, the first bispecific antibody The binding domain binds to the Vβ17 antigen. In some embodiments, a bispecific antibody The first binding domain binds to the Vβ17 epitope. In some embodiments, two Heavily specific antibodies: VH CDR1, VH CDR2, VH CDR3, VL CDR1, V L CDR2 and VL CDR3 form the binding sites for the Vβ17 antigen. In some embodiments, the bispecific antibodies VH CDR1, VH CDR2, and VH CD R3, VL CDR1, VL CDR2, and VL CDR3 are epitopes of Vβ17. It forms a binding site for the second binding site of the bispecific antibody. In some embodiments, the second binding site of the bispecific antibody The main target is the antigen of the second target. In some embodiments, the second target of the bispecific antibody is the antigen of the second target. The binding domain 2 binds to the epitope of the second target. In some embodiments, two Heavily specific antibodies: VH CDR1, VH CDR2, VH CDR3, VL CDR1, V L CDR2 and VL CDR3 form binding sites for the second target antigen. In some embodiments, the bispecific antibodies VH CDR1, VH CDR2, and VH C DR3, VL CDR1, VL CDR2, and VL CDR3 are the epithet of the second target. It forms a binding site for the pepper. In some embodiments, the second pepper of the bispecific antibody The target is located on the surface of the second cell.

[0050] In some embodiments, the first binding domain of the bispecific antibody is (i) Sequence ID No. 9 VH CDR1 has a 79-amino acid sequence, and V has the amino acid sequence of SEQ ID NO: 980. VH containing H CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 981 (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 994, and SEQ ID NO: 995 VL CDR2 having a amino acid sequence, and VL having the amino acid sequence of SEQ ID NO: 996 VL containing CDR3, and in some embodiments, the bispecific antibody is SEQ ID NO: It contains VH having a sequence of 1000 amino acids. In some embodiments, a bispecific antibody It contains a VL having the amino acid sequence of SEQ ID NO: 1001. In some embodiments, two The hemispecific antibody has the amino acid sequence of SEQ ID NO: 1000 (VH) and SEQ ID NO: 1001 ( It includes VL having an amino acid sequence. In some embodiments, the bispecific antibody Vβ1 7 is present on the surface of T cells. In some embodiments, the first bond of the bispecific antibody Either the binding domain is humanized, or the second binding domain is humanized, Both the first and second binding domains are humanized. In the application form, the bispecific antibody includes an IgG antibody. In some embodiments, bispecific Sex antibodies include IgG1, IgG2, IgG3, or IgG4 antibodies. Several implementations In this state, the first binding domain of the bispecific antibody binds to the Vβ17 antigen. In this embodiment, the first binding domain of the bispecific antibody binds to the Vβ17 epitope. In some embodiments, the bispecific antibodies VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are antigens of Vβ17. It forms a binding site for the bispecific antibody VH CDR1. , VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CD R3 forms a binding site for the Vβ17 epitope. In some embodiments, The second binding domain of a bispecific antibody binds to the antigen of a second target. Several implementations Morphologically, the second binding domain of a bispecific antibody binds to the epitope of the second target. In some embodiments, the bispecific antibodies VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are the second target antigens. It forms a binding site for the bispecific antibody VH CDR. In some embodiments, the bispecific antibody VH CDR 1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL C DR3 forms a binding site to the epitope of a second target. In some embodiments, Therefore, the second target of the bispecific antibody is located on the surface of a second cell.

[0051] In some embodiments, the first binding domain of the bispecific antibody is (i) Sequence ID No. 1 VH CDR1 has the amino acid sequence 011, and has the amino acid sequence of SEQ ID NO: 1012. Includes VH CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 1013. VH and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 1026, SEQ ID NO: 1 VL CDR2 having amino acid sequence 027, and the amino acid sequence of SEQ ID NO: 1028 VL containing VL CDR3, and in some embodiments, a bispecific antibody It contains VH having the amino acid sequence of SEQ ID NO: 1032. In some embodiments, two The heavily specific antibody contains VL having the amino acid sequence of SEQ ID NO: 1033. Several implementations Morphologically, the bispecific antibody has VH, which has the amino acid sequence of SEQ ID NO: 1032, and sequence number It includes VL having amino acid sequence 1033. In some embodiments, it has bispecificity. The antibody Vβ17 is present on the surface of T cells. In some embodiments, bispecific antibodies Either the first binding domain of the body is humanized, or the second binding domain is humanized. Either the dolphin, or both the first and second binding domains are humanized. In some embodiments, the bispecific antibody includes an IgG antibody. Bispecific antibodies include IgG1, IgG2, IgG3, or IgG4 antibodies. In one embodiment, the first binding domain of the bispecific antibody binds to the Vβ17 antigen. In some embodiments, the first binding domain of the bispecific antibody is the Vβ17 epithet It binds to the p. In some embodiments, the bispecific antibodies VH CDR1 and VH CD R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are Vβ It forms binding sites for 17 antigens. In some embodiments, the bispecific antibody V H CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 forms a binding site for the Vβ17 epitope. In this application, the second binding domain of the bispecific antibody binds to the antigen of the second target. In some embodiments, the second binding domain of the bispecific antibody is the epitome of the second target. It binds to the p. In some embodiments, the bispecific antibodies VH CDR1 and VH CD R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are second It forms a binding site for the target antigen. In some embodiments, the bispecific antibody VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, And VL CDR3 forms a binding site to the epitope of the second target. In this embodiment, the second target of the bispecific antibody is located on the surface of a second cell.

[0052] In some embodiments, the first binding domain of the bispecific antibody is (i) Sequence ID No. 1 VH CDR1 has the amino acid sequence 043, and has the amino acid sequence of SEQ ID NO: 1044. Includes VH CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 1045. VH and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 1058, SEQ ID NO: 1 VL CDR2 having the amino acid sequence 059, and the amino acid sequence of SEQ ID NO: 1060 VL containing VL CDR3, and in some embodiments, a bispecific antibody It contains VH having the amino acid sequence of SEQ ID NO: 1064. In some embodiments, two The heavily specific antibody contains VL having the amino acid sequence of SEQ ID NO: 1065. Several implementations Morphologically, the bispecific antibody has VH, which has the amino acid sequence of SEQ ID NO: 1064, and sequence number It includes VL having amino acid sequence 1065. In some embodiments, it has bispecificity. The antibody Vβ17 is present on the surface of T cells. In some embodiments, bispecific antibodies Either the first binding domain of the body is humanized, or the second binding domain is humanized. Either the dolphin, or both the first and second binding domains are humanized. In some embodiments, the bispecific antibody includes an IgG antibody. Bispecific antibodies include IgG1, IgG2, IgG3, or IgG4 antibodies. In one embodiment, the first binding domain of the bispecific antibody binds to the Vβ17 antigen. In some embodiments, the first binding domain of the bispecific antibody is the Vβ17 epithet It binds to the p. In some embodiments, the bispecific antibodies VH CDR1 and VH CD R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are Vβ It forms binding sites for 17 antigens. In some embodiments, the bispecific antibody V H CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 forms a binding site for the Vβ17 epitope. In this application, the second binding domain of the bispecific antibody binds to the antigen of the second target. In some embodiments, the second binding domain of the bispecific antibody is the epitome of the second target. It binds to the p. In some embodiments, the bispecific antibodies VH CDR1 and VH CD R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are second It forms a binding site for the target antigen. In some embodiments, the bispecific antibody VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, And VL CDR3 forms a binding site to the epitope of the second target. In this embodiment, the second target of the bispecific antibody is located on the surface of a second cell.

[0053] In some embodiments, the first binding domain of the bispecific antibody is (i) Sequence ID No. 1 VH CDR1 has the amino acid sequence 075, and has the amino acid sequence of SEQ ID NO: 1076. Includes VH CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 1077. VH and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 1090, SEQ ID NO: 1 VL CDR2 having the amino acid sequence 091, and the amino acid sequence of SEQ ID NO: 1092 VL containing VL CDR3, and in some embodiments, a bispecific antibody This includes VH having the amino acid sequence of SEQ ID NO: 1096. In some embodiments, two The heavily specific antibody contains VL having the amino acid sequence of SEQ ID NO: 1097. Several implementations Morphologically, the bispecific antibody has VH, which has the amino acid sequence of SEQ ID NO: 1096, and sequence number It includes VL having amino acid sequence 1097. In some embodiments, it has bispecificity. The antibody Vβ17 is present on the surface of T cells. In some embodiments, bispecific antibodies Either the first binding domain of the body is humanized, or the second binding domain is humanized. Either the dolphin, or both the first and second binding domains are humanized. In some embodiments, the bispecific antibody includes an IgG antibody. Bispecific antibodies include IgG1, IgG2, IgG3, or IgG4 antibodies. In one embodiment, the first binding domain of the bispecific antibody binds to the Vβ17 antigen. In some embodiments, the first binding domain of the bispecific antibody is the Vβ17 epithet It binds to the p. In some embodiments, the bispecific antibodies VH CDR1 and VH CD R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are Vβ It forms binding sites for 17 antigens. In some embodiments, the bispecific antibody V H CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 forms a binding site for the Vβ17 epitope. In this application, the second binding domain of the bispecific antibody binds to the antigen of the second target. In some embodiments, the second binding domain of the bispecific antibody is the epitome of the second target. It binds to the p. In some embodiments, the bispecific antibodies VH CDR1 and VH CD R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are second It forms a binding site for the target antigen. In some embodiments, the bispecific antibody VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, And VL CDR3 forms a binding site to the epitope of the second target. In this embodiment, the second target of the bispecific antibody is located on the surface of a second cell.

[0054] In some embodiments, the first binding domain of the bispecific antibody is (i) Sequence ID No. 1 VH CDR1 has a 107-amino acid sequence, and has the amino acid sequence of SEQ ID NO: 1108. Includes VH CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 1109. VH and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 1122, SEQ ID NO: 1 VL CDR2, which has an amino acid sequence of 123, and the amino acid sequence of SEQ ID NO: 1124 VL containing VL CDR3, and in some embodiments, a bispecific antibody This includes VH having the amino acid sequence of SEQ ID NO: 1128. In some embodiments, two The heavily specific antibody contains VL having the amino acid sequence of SEQ ID NO: 1129. Several implementations Morphologically, the bispecific antibody has VH, which has the amino acid sequence of SEQ ID NO: 1128, and sequence number It includes VL having amino acid sequence 1129. In some embodiments, it has bispecificity. The antibody Vβ17 is present on the surface of T cells. In some embodiments, bispecific antibodies Either the first binding domain of the body is humanized, or the second binding domain is humanized. Either the dolphin, or both the first and second binding domains are humanized. In some embodiments, the bispecific antibody includes an IgG antibody. Bispecific antibodies include IgG1, IgG2, IgG3, or IgG4 antibodies. In one embodiment, the first binding domain of the bispecific antibody binds to the Vβ17 antigen. In some embodiments, the first binding domain of the bispecific antibody is the Vβ17 epithet It binds to the p. In some embodiments, the bispecific antibodies VH CDR1 and VH CD R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are Vβ It forms binding sites for 17 antigens. In some embodiments, the bispecific antibody V H CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 forms a binding site for the Vβ17 epitope. In this application, the second binding domain of the bispecific antibody binds to the antigen of the second target. In some embodiments, the second binding domain of the bispecific antibody is the epitome of the second target. It binds to the p. In some embodiments, the bispecific antibodies VH CDR1 and VH CD R2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are second It forms a binding site for the target antigen. In some embodiments, the bispecific antibody VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, And VL CDR3 forms a binding site to the epitope of the second target. In this embodiment, the second target of the bispecific antibody is located on the surface of a second cell.

[0055] In some embodiments, the bispecific antibody Vβ17 is present on the surface of T cells. In some embodiments, the first binding domain of the bispecific antibody is humanized. The second binding domain is humanized, or the first binding domain and the second binding Both domains are humanized. In some embodiments, the bispecific antibody is I Contains IgG antibodies. In some embodiments, the bispecific antibodies are IgG1, IgG2, and I It contains either an IgG3 or IgG4 antibody. In some embodiments, the first antibody of the bispecific antibody The synthetic domain binds to the Vβ17 antigen. In some embodiments, the bispecific antibody The binding domain 1 binds to the Vβ17 epitope. In some embodiments, dual domains are used. Heterosexual antibodies: VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 form the binding sites for the Vβ17 antigen. In that embodiment, the bispecific antibodies VH CDR1, VH CDR2, and VH CDR3 VL CDR1, VL CDR2, and VL CDR3 are for the Vβ17 epitope. It forms a binding site. In some embodiments, the second binding domain of the bispecific antibody The antibody binds to the antigen of the second target. In some embodiments, the second bispecific antibody The binding domain binds to the epitope of the second target. In some embodiments, dual Heterosexual antibodies: VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 form binding sites for the second target antigen. In one embodiment, the bispecific antibodies VH CDR1, VH CDR2, VH CDR 3. VL CDR1, VL CDR2, and VL CDR3 are epitopes of the second target. It forms a binding site for [the target]. In some embodiments, the second target of the bispecific antibody is It is located on the surface of the second cell.

[0056] In some embodiments, the second cell is a cancer cell. The target of 2 is a tumor-specific antigen, a tumor-associated antigen, or a novel antigen.

[0057] In some embodiments, cancer can be adrenal cancer, anal cancer, appendiceal cancer, bile duct cancer, bladder cancer, bone cancer, or brain cancer. Cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer, gestational trophoblastic disease, head and neck cancer, Hodgkin's disease Lymphoma, colon cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, neurological Endocrine tumors, non-Hodgkin lymphoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, sinus cancer, skin cancer, Soft tissue sarcoma, spinal cancer, gastric cancer, testicular cancer, pharyngeal cancer, thyroid cancer, uterine cancer, endometrial cancer, vaginal cancer, and It is vulvar cancer. In some embodiments, adrenal cancer is adrenocortical carcinoma (ACC), adrenal Renal cortical carcinoma, pheochromocytoma, or neuroblastoma. In some embodiments, anal cancer is These include squamous cell carcinoma, cloacal carcinoma, adenocarcinoma, basal cell carcinoma, or melanoma. In this embodiment, appendiceal cancer is a neuroendocrine tumor (NET), mucinous adenocarcinoma, goblet cell carcinoma It is id, intestinal adenocarcinoma, or signet ring cell adenocarcinoma. In some embodiments, cholangiocarcinoma is hepatic External cholangiocarcinoma, adenocarcinoma, hilar cholangiocarcinoma, hilar region cholangiocarcinoma, distal cholangiocarcinoma, or intrahepatic cholangiocarcinoma. In some embodiments, bladder cancer is classified as transitional cell carcinoma (TCC), papillary carcinoma, or squamous carcinoma. These are tumors, squamous cell carcinomas, adenocarcinomas, small cell carcinomas, or sarcomas. In some embodiments, Bone cancer includes primary bone cancer, sarcoma, osteosarcoma, chondrosarcoma, sarcoma, fibrosarcoma, and malignant fibrous histiocytoma. These include giant cell tumors of bone, chordomas, or metastatic bone cancers. In some embodiments, brain cancer is, Astrocytoma, brainstem glioma, glioblastoma, meningioma, ependymoma, oligodendroglioma, mixed glioma, Pituitary cancer, pituitary adenoma, craniopharyngioma, germ cell tumor, pineal gland tumor, medulloblastoma, or primary C It is NS lymphoma. In some embodiments, breast cancer is mammary carcinoma, invasive breast cancer, non-invasive Breast cancer, breast sarcoma, metaplastic carcinoma, adenocystic carcinoma, phyllodes tumor, angiosarcoma, HER2-positive breast cancer, trichomoniasis It is pull-negative breast cancer, or inflammatory breast cancer. In some embodiments, cervical cancer is phlegmon It is squamous cell carcinoma or adenocarcinoma.

[0058] In some embodiments, colorectal cancer is colorectal adenocarcinoma, primary colorectal lymphoma, Gastrointestinal stromal tumors, leiomyosarcoma, carcinoid tumors, mucinous adenocarcinoma, signet ring cell adenocarcinoma, digestive It is a tubular carcinoid tumor, or melanoma. In some embodiments, esophageal cancer is an adenocarcinoma or It is a squamous cell carcinoma. In some embodiments, gallbladder cancer is an adenocarcinoma, a papillary adenocarcinoma. It is adenosquamous carcinoma, squamous cell carcinoma, small cell carcinoma, or sarcoma. Several implementation forms In terms of condition, gestational trophoblastic disease (GTD) is a type of hydatidiform mole, gestational trophoblastic neoplasm (GTN), and chorionic villus. Trichocarcinoma, placental trophoblastic tumor (PSTT), or epithelioid trophoblastic tumor (ET) T) In some embodiments, head and neck cancers include laryngeal cancer, nasopharyngeal cancer, hypopharyngeal cancer, and nasal cavity cancer. Cancer, sinus cancer, salivary gland cancer, oral cancer, oropharyngeal cancer, or tonsil cancer. In some embodiments Hodgkin lymphoma includes classical Hodgkin lymphoma, nodular sclerosis type, mixed cell type, and lymphocytes. In Hodgkin lymphoma (NLPHL), which is characterized by abundant, lymphopenic, or nodular lymphocyte predominance, Yes. In some embodiments, intestinal cancer is small intestine cancer, small intestine cancer ( Small bowel cancer, adenocarcinoma, sarcoma, gastrointestinal stromal tumor, carcinoid tumor, or lymph It is a tumor. In some embodiments, kidney cancer is renal cell carcinoma (RCC), clear cell RCC, breast cancer. Head RCC, chromophobe RCC, collecting duct RCC, unclassified RCC, transitional cell carcinoma, urothelial carcinoma, Renal pelvis carcinoma, or renal sarcoma. In some embodiments, leukemia is acute lymphoblastic leukemia. disease (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic bone Myelin leukemia (CML), hairy cell leukemia (HCL), or myelodysplastic syndrome (MDS) In some embodiments, liver cancer is hepatocellular carcinoma (HCC), lamellar HC. C, cholangiocarcinoma, angiosarcoma, or liver metastasis. In some embodiments, lung cancer is small Cellular lung cancer, small cell carcinoma, complex small cell carcinoma, non-small cell lung cancer, lung adenocarcinoma, squamous cell lung cancer Large cell anaplastic carcinoma, pulmonary nodules, metastatic lung cancer, adenosquamous carcinoma, large cell neuroendocrine carcinoma, Salivary gland type lung carcinoma, pulmonary carcinoid, mesothelioma, sarcomatoid carcinoma of the lung, or malignant granular cell lung tumor Yes. In some embodiments, melanoma is a type of melanoma that includes superficial spreading melanoma, nodular melanoma, and acral lentiginous melanoma. Type melanoma, melanoma derived from lentigo maligna, achromatic melanoma, fibroplastic melanoma, ocular melanoma, or metastatic melanoma. It is a metastatic melanoma. In some embodiments, mesothelioma is pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma. It is mesothelioma, or testicular mesothelioma. In some embodiments, multiple myeloma is active or This is a smoldering type of multiple myeloma. In some embodiments, the neuroendocrine tumor is located in the gastrointestinal tract. The tumors are neuroendocrine tumors, pancreatic neuroendocrine tumors, or pulmonary neuroendocrine tumors. Several embodiments So, non-Hodgkin lymphomas include anaplastic large cell lymphoma, lymphoblastic lymphoma, and peripheral T lymphoma. Cellular lymphoma, follicular lymphoma, cutaneous T-cell lymphoma, lymphoplasmacytic lymphoma, marginal B-cell lymphoma, MALT lymphoma, small cell lymphocytic lymphoma, Burkitt lymphoma Chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), progenitor T lymphocytes Lymphocytic leukemia / lymphoma, acute lymphoblastic leukemia (ALL), adult T-cell lymphoma / leukemia (ATLL), hairy cell leukemia, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), Primary mediastinal B-cell lymphoma, Primary central nervous system (CNS) lymphoma, Core cell lymphoma (MCL), marginal zone lymphoma, mucosal-associated lymphoid tissue (MALT) lymphoma Parkinson's disease, marginal zone B-cell lymphoma, marginal zone B-cell lymphoma of the spleen, lymphoplasmacytic lymphoma tumor, B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, natural killer lymphoma Parkin, cutaneous T-cell lymphoma, Alibert-Bazin syndrome, Sézary syndrome, primary cutaneous lymphoma Differentiated large cell lymphoma, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL) ), anaplastic large cell lymphoma (ALCL), systemic ALCL, enteropathy-type T-cell lymphoma (EA) It is TL, or hepatosplenic gamma / delta T-cell lymphoma. In some embodiments, it is oral Cancers include squamous cell carcinoma, verrucous carcinoma, minor salivary gland carcinoma, lymphoma, benign oral tumors, and eosinophilic cancers. Granuloma, fibroma, granular cell tumor, keratoacanocyte, leiomyoma, osteochondroma, lipoma, Schwann Cell tumors, neurofibromas, papillomas, condyloma acuminata, xanthomas, pyogenic granulomas, rhabdomyos Tumors, odontogenic tumors, leukoplakia, erythroplakia, squamous cell lip carcinoma, basal cell lip carcinoma, oral cancer, gingival cancer , or tongue cancer. In some embodiments, ovarian cancer is ovarian epithelial carcinoma, mucinous epithelial ovarian carcinoma. Endometrial epithelial ovarian cancer, clear cell epithelial ovarian cancer, undifferentiated epithelial ovarian cancer, low-grade ovarian tumor, Peritoneal cancer, fallopian tube cancer, germ cell tumors, teratomas, undifferentiated ovarian germ cell carcinoma, endoderm sinus tumors, intersex cord tumors Stomatous tumors, sex cord stromal tumors, ovarian stromal tumors, granulosa cell tumors, granulosa follicular tumors, cell Tri-Leydig tumor, ovarian sarcoma, ovarian carcinosarcoma, ovarian adenosarcoma, ovarian leiomyosarcoma, ovarian gland These are visceral sarcomas, Krukenberg tumors, or ovarian cysts. In some embodiments, pancreatic cancer is exocrine pancreatic carcinoma, endocrine pancreatic carcinoma, or pancreatic adenocarcinoma, islet cell tumor, or neuroendocrine tumor In some embodiments, prostate cancer is defined as prostate adenocarcinoma, prostate sarcoma, transitional cell carcinoma, It is a small cell carcinoma or neuroendocrine tumor. In some embodiments, sinus carcinoma is a squamous cell carcinoma. Cellular carcinoma, mucosal cell carcinoma, adenoid cystic cell carcinoma, acinar cell carcinoma, undifferentiated sinus carcinoma, nasal cavity carcinoma, This includes paranasal sinus cancer, maxillary sinus cancer, ethmoid sinus cancer, or nasopharyngeal cancer. In some embodiments, it is skin cancer. This includes basal cell carcinoma, squamous cell carcinoma, melanoma, Merkel cell carcinoma, Kaposi's sarcoma (KS), and solar ulcers. These are keratosis, cutaneous lymphoma, or keratosacral cell tumor. In some embodiments, soft tissue carcinoma. These include angiosarcoma, cutaneous fibrosarcoma, epithelial sarcoma, Ewing's sarcoma, fibrosarcoma, and gastrointestinal stromal tumors. (GIST), Kaposi's sarcoma, leiomyosarcoma, liposarcoma, dedifferentiated liposarcoma (DL), myxoid Round cell liposarcoma (MRCL), well-differentiated liposarcoma (WDL), malignant fibrous histiocytoma, These are neurofibrosarcoma, rhabdomyosarcoma (RMS), or synovial sarcoma. In some embodiments, Spinal cord cancer is a metastatic tumor of the spinal cord. In some embodiments, gastric cancer is gastric adenocarcinoma, gastric phosphorus Parkinson's disease, gastrointestinal stromal tumor, carcinoid tumor, gastric carcinoid tumor, type I ECL cell carcinoma These are carcinoids, type II ECL cell carcinoids, or type III ECL cell carcinoids. In some embodiments, testicular cancer is classified as seminoma, non-seminoma, embryonic carcinoma, or yolk sac carcinoma. , choriocarcinoma, teratoma, gonadal stromal tumor, Leydig cell tumor, or Sertoli cell tumor In some embodiments, pharyngeal cancer is squamous cell carcinoma, adenocarcinoma, sarcoma, laryngeal cancer, pharyngeal cancer. Head cancer, nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, laryngeal squamous cell carcinoma, laryngeal adenocarcinoma, phosphorus These include paematous carcinoma, spindle cell carcinoma, verrucous carcinoma, undifferentiated carcinoma, or lymph node carcinoma. Several implementations Morphologically, thyroid cancer includes papillary carcinoma, follicular carcinoma, Haasle cell carcinoma, medullary thyroid carcinoma, Or it is an undifferentiated carcinoma. In some embodiments, uterine cancer is endometrial cancer, endometrial adenocarcinoma. Uterine carcinoma, endometrial carcinoma, serous adenocarcinoma, adenosquamous carcinoma, uterine carcinosarcoma, uterine sarcoma, uterine leioblastoma It is a sarcoma, endometrial stromal sarcoma, or undifferentiated sarcoma. In some embodiments, vaginal cancer is Squamous cell carcinoma, adenocarcinoma, melanoma, or sarcoma. In some embodiments, the vulva The cancer is either squamous cell carcinoma or adenocarcinoma.

[0059] In some embodiments, the second target is angiopoietin, BCMA, CD19, C D20, CD22, CD25(IL2-R), CD30, CD33, CD37, CD38 , CD52, CD56, CD123(IL-3R), cMET, DLL / Notch, E GFR, EpCAM, FGF, FGF-R, GD2, HER2, Mesothelin, Nectin 4, PDGFRα, RANKL, SLAMF7, TROP2, VEGF, VEGF-R, CEA, immature laminin receptor, TAG-72, HPV E6, HPV E7, BING -4, Calcium-dependent chlorine channel 2, Cyclin-B1, 9D7, EpCAM, Ep hA3, Her2 / neu, telomerase, mesothelin, SAP-1, surviving, B AGE family antigen, CAGE family antigen, GAGE ​​family antigen, MAGE family Family antigen, SAGE family antigen, XAGE family antigen, NY-ESO-1 / LAGE-1, PRAME, SSX-2, Melan-A, MART-1, Gp100, pmel17, tyrosinase, TRP-1, TRP-2, P. polypeptide, MC1R, Prostate-specific antigen, β-catenin, BRCA1, BRCA2, CDK4, CML66, F Ibronectin, MART-2, p53, Ras, TGF-βRII, or MUC1 ru.

[0060] In some embodiments, the second target of the bispecific antibody is CD123. In that embodiment, the second binding domain of the bispecific antibody is (i) the amide of SEQ ID NO: 34 VH CDR1 has an amino acid sequence, and VH CDR2 has the amino acid sequence of SEQ ID NO 35. , and VH containing VH CDR3 having the amino acid sequence of SEQ ID NO: 36, and (ii) sequence VL CDR1 has amino acid sequence number 37, and has amino acid sequence number 38. VL containing VL CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 39 , including.

[0061] In some embodiments, the second target of the bispecific antibody is BCMA. In this embodiment, the second binding domain of the bispecific antibody is (i) the amino acid of SEQ ID NO: 89 VH CDR1 has an acid sequence, VH CDR2 has the amino acid sequence of SEQ ID NO: 90, and VH containing VH CDR3 having the amino acid sequence of sequence number 91, and (ii) sequence number VL CDR1 has the amino acid sequence of sequence number 93, and V has the amino acid sequence of sequence number 94. VL containing L CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 94, Includes.

[0062] In some embodiments, the second cell is a B cell. The targets of 2 are CD1a, CD1b, CD1c, CD1d, CD2, CD5, CD6, CD 9, CD11a, CD11b, CD11c, CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD29, CD30, CD31, CD32a, CD32b, CD35, CD37, CD38, CD3 9, CD40, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49b, CD49c, CD49d, CD50, CD 52, CD53, CD54, CD55, CD58, CD60a, CD62L, CD63, CD68, CD69, CD70, CD72, CD73, CD74, CD75, CD75S , CD77, CD79a, CD79b, CD80, CD81, CD82, CD83, CD 84, CD85E, CD85I, CD85J, CD86, CD92, CD95, CD97 , CD98, CD99, CD100, CD102, CD108, CD119, CD120 a, CD120b, CD121b, CD122, CD124, CD125, CD126, CD130, CD132, CD137, CD138, CD139, CD147, CD14 8, CD150, CD152, CD162, CD164, CD166, CD167a, C D170, CD171, CD175, CD175s, CD180, CD184, CD18 5, CD192, CD196, CD197, CD200, CD205, CD201a, C Dw210b, CD212, CD213a1, CD213a2, CD215, CD217 , CD218a, CD218b, CD220, CD221, CD222, CD224, C D225, CD226, CD227, CD229, CD230, CD232, CD252 , CD252, CD254, CD255, CD256, CD257, CD258, CD2 59, CD260, CD261, CD262, CD263, CD264, CD267, C D268, CD269, CD270, CD272, CD274, CD275, CD277 , CD279, CD283, CD289, CD290, CD295, CD298, CD3 00, CD300c, CD305, CD306, CD307a, CD307b, CD30 7c, CD307d, CD307e, CD314, CD215, CD316, CD317 , CD319, CD321, CD327, CD328, CD329, CD338, CD3 51, CD352, CD353, CD354, CD355, CD356, CD357, C These are D358, CD360, CD361, CD362, or CD363.

[0063] In some embodiments, a bispecific antibody targets Vβ17 on the surface of T cells, and a second antibody targets Vβ17 on the surface of T cells. When it binds to a second target on the surface of the cell, the second cell dies.

[0064] In some embodiments, the bispecific antibody has an EC of less than approximately 500 pM. 50 So, the invitation In Toro, second cells induce T cell-dependent cytotoxicity. In some embodiments, Bispecific antibodies have an EC of less than approximately 300 pM. 50 Then, in vitro, the T of the second cell It induces cell-dependent cytotoxicity. In some embodiments, the bispecific antibody is approximately 160 EC below pM 50 Then, in vitro, the second cell induces T cell-dependent cytotoxicity. ru.

[0065] In some embodiments, EC 50 This involves expressing αβ T effector cells and a second target. The effector cells are evaluated in a mixture with target cells. In some embodiments, effector cells and target cells are evaluated. The ratio of cells is approximately 0.01:1 to approximately 10:1. In some embodiments, effectors The ratio of cells to target cells is approximately 0.1:1 to approximately 5:1. In some embodiments, The ratio of feta cells to target cells is approximately 1:1.

[0066] In some embodiments, the bispecific antibody is polyvalent. In some embodiments, Bispecific antibodies can bind to at least three antigens. Several embodiments Therefore, a bispecific antibody can bind to at least five antigens.

[0067] In one embodiment, a bispecific antibody is provided herein, wherein the bispecific antibody is a T-type A first means capable of binding Vβ17 on the surface of a cell, and a second target other than Vβ17 Includes a second means capable of joining targets. In some embodiments, dual specificity The antibody's second target is located on the surface of a second cell.

[0068] In one embodiment, any one antibody from the embodiments described above, or any one of the embodiments described above Nucleic acids encoding two bispecific antibodies are provided herein. Also provided herein are nucleic acids comprising A vector is also provided herein. In one embodiment, a host cell containing a vector is also provided herein. A kit is also provided, which includes the above vector and the packaging for it. In some embodiments, packaging includes compartments for holding vectors. Includes.

[0069] In one embodiment, one antibody from any of the embodiments described above, or any of the embodiments described above A pharmaceutical composition comprising a bispecific antibody and a pharmaceutically acceptable carrier is provided herein. Furthermore, a method for producing a pharmaceutical composition is provided, wherein the antibody is pharmaceutically acceptable. The process includes a step of combining it with a carrier to obtain a pharmaceutical composition.

[0070] In another embodiment, a method for directing Vβ17-expressing T cells to a second target is described herein. Provided, the above method involves contacting T cells with a bispecific antibody of any of the embodiments described above. This includes the step of contacting. In some embodiments, the contact step involves T cells as a second target. To direct.

[0071] In one embodiment, the growth or proliferation of target cells that express a second target on their cell surface is inhibited. A method is provided herein, and the above method involves dually stimulating target cells in any one of the embodiments described above. The process includes contacting the target cells with a specific antibody. In some embodiments, the target cells are brought into contact with the pharmaceutical composition. The process involves inhibiting the growth or proliferation of target cells. In some embodiments, the target cells are inhibited The step of contacting the body or a bispecific antibody inhibits the growth or proliferation of target cells.

[0072] In some embodiments, target cells undergo Vβ17 while in contact with a bispecific antibody. In the presence of T cells that express this trait.

[0073] In one embodiment, a method for eliminating target cells that express a second target in a subject is described. Provided in the details, the above method provides an effective amount of any one of the above embodiments of bispecific antibody The process includes administering the drug to a body. In some embodiments of this method, the subject has cancer. In some embodiments of this method, the subject has leukemia. In several embodiments, the subject has lymphoma.

[0074] In one embodiment, all or part of the target cells expressing the second target in the subject are extracted. A method is provided for treating the disease that is caused, wherein the method involves an effective amount of the above embodiment The procedure includes administering either one bispecific antibody to a target. Several implementations of this method In this state, the disease is cancer. In some embodiments of this method, the disease is leukemia. It is a disease. In some embodiments of this method, the disease is lymphoma.

[0075] In some embodiments of this method, the subject is the subject that requires the method. In some embodiments of this method, the subject is a human.

[0076] In one embodiment, a method for activating T cells expressing Vβ17 is provided herein, and the above The method involves contacting T cells with one of the bispecific antibodies described in the above embodiments. Includes. In some embodiments of this method, the contact step expresses Vβ17. Compared to control T cells, increased expression of CD69, CD25, and / or granzyme B was observed. To drip. In one embodiment, the control T cell is an equivalent T cell expressing Vβ17. In this study, equivalent T cells (e.g., control T cells) are not brought into contact with the bispecific antibody.

[0077] In another embodiment, a process for producing antibodies that bind to two or more target molecules is provided herein. This process yields a binding domain that can bind to Vβ17 on T cells. The process of performing a function and a binding domain that can bind to a second target on a second cell The process of performing the function of obtaining Vβ17 (e.g., Vβ17 antigen) on T cells, and A step of performing the function of providing an antibody that can bind to a second target on two cells, This includes a bond that can be bound to a second target in some embodiments of this process. The process of performing the function to obtain the synthetic domain is repeated n times, and Vβ17 on T cells, and n The process involves performing the function of providing a binding domain that can bind to individual target molecules. The process further includes steps in which n is at least 2. In some embodiments of this process, The second target is located on the surface of the second cell. In some embodiments of this process, The second cell is a cancer cell. In some embodiments, the second target is a tumor-specific antigen. , tumor-associated antigen, or novel antigen. In some embodiments of this process, the second part The cells are B cells. In some embodiments of this process, the second target is CD12 3. In some embodiments of this process, the second target is BCMA. An exemplary second target is provided herein, and as an embodiment of this process, As shown in the figure. In some embodiments of this process, it can bind to Vβ17. The binding domain binds to Vβ17. In some embodiments of this process, Vβ1 The binding domain that can bind to 7 binds to the Vβ17 epitope. In some embodiments of the , the binding domain that can bind to a second target is the second It binds to the target antigen. In some embodiments of this process, it binds to a second target. The binding domain, which can bind, binds to the epitope of the second target.

[0078] In another embodiment, a bispecific antibody is provided herein, wherein the bispecific antibody is T A first means capable of binding Vβ17 on the surface of a cell, and a second means capable of binding Vβ17 on the surface of a cell The system includes a second means capable of binding two targets. In some embodiments, the second means is also included. These cells are cancer cells. In some embodiments, the second target is a tumor-specific antigen, tumor It is a ulcer-associated antigen or a novel antigen. In some embodiments of the bispecific antibody, the second cell This is a B cell. In some embodiments of the bispecific antibody, the second target is CD12 3. In some embodiments of the bispecific antibody, the second target is BCMA. In some embodiments of the bispecific antibody, the second target is DLL3. In some embodiments of the antibody, the second target is PSMA. In one embodiment, the second target is KLK2. Other exemplary second targets are as described above. This is provided in the details and is intended as an embodiment of this process.

[0079] In some embodiments, the first means of a bispecific antibody is to convert Vβ17 to the Vβ17 antigen. It can bind. In some embodiments, the first means of the bispecific antibody is Vβ 17 can bind to the Vβ17 epitope. In some embodiments, bispecific The first means of sex antibodies can bind the second target to the antigen of the second target. In that embodiment, the first means of the bispecific antibody targets the second target and the epitome of the second target. It can bind to p. In some embodiments, the second means of the bispecific antibody is The second target can be bound to the antigen of the second target. In some embodiments, a dual A second method for specific antibodies allows the second target to bind to the epitope of the second target. ru.

[0080] Furthermore, kits containing the bispecific antibody or its antigen-binding fragment disclosed herein We also provide packages for that purpose. [Brief explanation of the drawing]

[0081] The above-mentioned summary of the invention, and the following detailed description of specific embodiments of this application, are provided with reference to the accompanying drawings. Reading them together will lead to a deeper understanding. However, this application is as shown in the drawings. It should be understood that this is not limited to the embodiment itself. [Figure 1] This figure shows how the binding of an anti-Vβ17 / antitumor antigen bispecific antibody recruits T cells to cancer cells, inducing cancer cell death. [Figure 2A] This figure shows that Vβ17+CD8+ T cells are present in healthy subjects and can be increased in vitro by culturing them with M1 peptide. This figure shows a FACS histogram of gated peripheral blood mononuclear cells (PBMCs) for CD8+ T cells expressing Vβ17 (Vβ17+) on the surface of healthy subject cells. [Figure 2B]This figure shows that Vβ17+CD8+ T cells are present in healthy subjects and can be increased in vitro by culturing them with M1 peptide. It also shows the presence of various donor HLA subtypes, as well as the percentage of Vβ17+CD8+ T cells observed on day 0 and after 14 days of in vitro expansion with M1 peptide (day 14). [Figure 3] This figure shows that Vβ17+CD8+ T cells possess characteristics of killer cytotoxic cells. The bar graph shows the expression of CD107a, CD69, granzyme B (Gzb), and interferon-γ (IFNγ) in gated PBMCs on day 0 (without M1) and on day 14 (+M1) stimulated with M1 peptide, for CD8+ T cells expressing Vβ17 (Vβ17+) on the cell surface. [Figure 4] This figure shows the binding of VB11 [anti-Vβ17 / anti-CD123] bispecific antibody and VB13 [Vβ17 null control bispecific] antibody to CD8+ T cells. The data are presented from CD8+ T cells isolated from PBMCs from three different donors (D203517, HPU09381, and HPU08694). The table below each graph shows the EC50 values ​​in nM for binding. [Figure 5] This figure shows the binding of a bispecific antibody (VB11) to Vβ17 and CD123, and a Vβ17 null control bispecific antibody (VB13), to AML cancer cell lines. The data presented show the binding of the bispecific antibodies to the Kasumi3 AML cell line. The table below the graph shows the EC50 values ​​in nM for binding. [Figure 6]This figure shows the redirection of Vβ17+ T cells by a bispecific antibody that efficiently induces the death of AML cancer cells. The data in the left graph shows the death of Kasumi3 cancer cells with an effector-to-target (E:T) ratio of 0.5:1 and the adjustment of the bispecific antibody dosage. The data in the center graph shows the death of Kasumi3 cancer cells with an E:T ratio of 1:1 and the adjustment of the bispecific antibody dosage. The data in the right graph shows the death of Kasumi3 cancer cells with an E:T ratio of 5:1 and the adjustment of the bispecific antibody dosage. The table below the graphs shows the EC50 values ​​calculated from the above graphs given in pM. [Figure 7A] This figure shows the specific binding of anti-Vβ17 / anti-CD123 bispecific antibody (VB11) and Vβ17 null bispecific antibody (VB13) to CD8+ T cells isolated from PBMCs. This figure also shows FACS histograms of gated PBMCs for CD8+ T cells expressing Vβ17 (Vβ17+) on the cell surface, from healthy subjects (left graph, Vβ17 not removed) and from PBMCs from which Vβ17+ T cells were removed using negative selection (right graph, Vβ17 removed). [Figure 7B] This figure shows the specific binding of anti-Vβ17 / anti-CD123 bispecific antibody (VB11) and Vβ17 null bispecific antibody (VB13) to CD8+ T cells isolated from PBMCs. The figure 7A shows the specific binding of anti-Vβ17 / anti-CD123 bispecific antibody (VB11) and Vβ17 null bispecific antibody (VB13) to CD8+ T cells. The dose-response of the bispecific antibodies is shown in the figure. The table below the graph shows the EC50 values ​​for binding calculated from the above graph given in nM. [Figure 8]This figure shows the specific recruitment of Vβ17 T cells by a Vβ17 bispecific antibody to kill Kasumi3 cancer cells. The left figure shows the death of the Kasumi3 AML cell line when effector cells were isolated from PBMCs containing CD8+ T cells expressing Vβ17 (Vβ17+) on the cell surface (untreated CD8 T cells). The inset shows that 10.1% of the effector cell population consisted of Vβ17+CD8 T cells. The right figure shows the death of the Kasumi3 AML cell line when effector CD8+ T cells were isolated from PBMCs, but Vβ17+ T cells were removed by negative selection. The inset shows that a minority population (0.086%) of Vβ17+CD8+ T cells were present in the effector cell population. [Figure 9A] This figure shows that there is no pan activation of T cells when using a Vβ17 bispecific antibody. The FACS plots are of Vβ17+ and Vβ17-gated CD8+ T cells. Activation of T cells with the Vβ17 bispecific antibody resulted in higher levels of CD69 upregulation in Vβ17+ cells (62.5%) compared to Vβ17- CD8+ T cells (1.80%). [Figure 9B] This figure shows that there is no pan activation of T cells when using a Vβ17 bispecific antibody. This figure shows a bar graph of CD69 upregulation on Vβ17+ and Vβ17-gated CD8+ T cells when activated with a Vβ17 bispecific antibody. [Figure 10] This figure shows that Vβ17+ T cells derived from HLA A2-negative donors are also effector killer cells, and that prior stimulation of Vβ17+ cells is not necessary. Efficient cytotoxicity mediated by a Vβ17 bispecific antibody against Kasumi3 cancer cells was demonstrated from PBMCs containing Vβ17+ T cells derived from an HLA A2-negative donor (HPU 09381). [Figure 11]This figure shows that the Vβ17 antibody (Vb17_202B4D1-Fab-RF,BCMB519-scFv(B17B622.001)) binds to T cells (left panel) and mediates T cell cytotoxicity against BCMA-expressing H929 cells in vitro (right panel). EC50 values ​​were calculated as described in the methods. Representative data presented herein are from a single experiment. [Figure 12] This figure shows that the Vβ17 antibody (Vb17_210E10A1-Fab-RF,BCMB519-scFv(B17B624.001)) binds to T cells (left panel) and mediates T cell cytotoxicity against BCMA-expressing H929 cells in vitro (right panel). EC50 values ​​were calculated as described in the methods. Representative data presented herein are from a single experiment. [Figure 13] This figure shows that the control antibody (B21M-Fab-RF x BCMB519-LH-scFv(B17B612.001)) does not bind to T cells (left panel) and does not mediate T cell cytotoxicity against BCMA-expressing H929 cells in vitro (right panel). Representative data presented herein are from a single experiment. [Figure 14] This figure shows that the Vα10.2 antibody (α10.2-TRVAB1-Fab-RF x BCMB519-scFv(B17B621.001)) activates T cells (right panel) and mediates T cell cytotoxicity against BCMA-expressing H929 cells in vitro (left panel). EC50 values ​​were calculated as described in the methods. Representative data presented herein are from a single experiment. [Figure 15] This figure shows that the Vα10.2 antibody (α10.2-TRVAB2-Fab-RF x BCMB519-scFv(B17B627.001)) activates T cells (right panel) and mediates T cell cytotoxicity against BCMA-expressing H929 cells in vitro (left panel). EC50 values ​​were calculated as described in the methods. Representative data presented herein are from a single experiment. [Figure 16A]This figure shows the evaluation of cell lysis mediated by various concentrations of anti-DLL3x Vβ17 antibody under different E:T ratios for PAN-T versus tumor and Vβ17 versus tumor, compared to HCC1833 cells alone. This figure shows cell lysis mediated by bispecific anti-DLL3x Vβ17 antibody at different concentrations with an E:T ratio of 5:1 for PAN-T versus tumor and 0.25:1 for Vβ17 versus tumor. [Figure 16B] This figure shows the evaluation of cell lysis mediated by various concentrations of anti-DLL3x Vβ17 antibody under different E:T ratios for PAN-T versus tumor and Vβ17 versus tumor, compared to HCC1833 cells alone. The figure also shows cell lysis mediated by bispecific anti-DLL3x Vβ17 antibody at different concentrations with an E:T ratio of 10:1 for PAN-T versus tumor and 0.5:1 for Vβ17 versus tumor. Impedance was recorded every 15 minutes for 120 hours, and the percentage cell lysis rate for HCC1833 tumor cells alone was calculated using RTCA software. [Figure 17A] This figure shows the evaluation of cell lysis mediated by various concentrations of anti-DLL3x Vβ17 antibody under different E:T ratios for PAN-T versus tumor and Vβ17 versus tumor, compared to G361 cells alone. It also shows cell lysis mediated by various concentrations of bispecific anti-DLL3x Vβ17 antibody in G361 cells, at a ratio of 5:1 for PAN-T versus tumor and 0.25:1 for Vβ17 versus tumor. [Figure 17B] This figure shows the evaluation of cell lysis mediated by various concentrations of anti-DLL3x Vβ17 antibody under different E:T ratios for PAN-T versus tumor and Vβ17 versus tumor, compared to G361 cells alone. This figure shows cell lysis mediated by various concentrations of bispecific DLL3x Vβ17 antibody in G361 cells, at 10:1 for PAN-T versus tumor and 0.5:1 for Vβ17 versus tumor. [Figure 18A]This figure shows the cytotoxicity mediated by the bispecific anti-DLL3 x Vβ17 antibody. It also shows the cytotoxicity mediated by 90 nM of the bispecific anti-DLL3 x Vβ17 antibody against DLL3-expressing target cells at effector-to-target ratios (E:T) of 0.5:1, 0.25:1, and 0.125:1, respectively. [Figure 18B] This figure shows the cytotoxicity mediated by the bispecific anti-DLL3 x Vβ17 antibody. It also shows the cytotoxicity mediated by 30 nM of the bispecific anti-DLL3 x Vβ17 antibody against DLL3-expressing target cells at effector-to-target ratios (E:T) of 0.5:1, 0.25:1, and 0.125:1, respectively. [Figure 18C] This figure shows the cytotoxicity mediated by the bispecific anti-DLL3 x Vβ17 antibody. It also shows the cytotoxicity mediated by 10 nM of the bispecific anti-DLL3 x Vβ17 antibody against DLL3-expressing target cells at effector-to-target ratios (E:T) of 0.5:1, 0.25:1, and 0.125:1, respectively. [Figure 19A] This figure shows the cytotoxicity mediated by a bispecific anti-DLL3xVβ17 antibody against DLL3-expressing target cells. In the presence of the anti-DLL3xVβ17 antibody, all PBMCs from two donors were cultured with DLL3+HCC1833-NLR at E:T ratios (Vβ17:target) of 1:1, 0.5:1, and 0.25:1, respectively. [Figure 19B] This figure shows the cytotoxicity mediated by a bispecific anti-DLL3xVβ17 antibody against DLL3-expressing target cells. In the presence of the anti-DLL3xVβ17 antibody, all PBMCs from two donors were cultured with G361-NLR cells at E:T ratios (Vβ17:target) of 1:1, 0.5:1, and 0.25:1, respectively. [Figure 20A]This figure shows the proliferation and frequency of Vβ17 T cells in response to different concentrations of anti-DLL3×Vβ17 antibody. This figure shows the proliferation rate (%) of Vβ17 T cells in response to different concentrations of anti-DLL3×Vβ17 antibody (DL3B588). [Figure 20B] This figure shows the proliferation and frequency of Vβ17 T cells in response to different concentrations of anti-DLL3×Vβ17 antibody. This figure shows the frequency of Vβ17 T cells in response to different concentrations of anti-DLL3×Vβ17 antibody (DL3B588). [Figure 21A] This figure shows the evaluation of cell lysis by four different bispecific anti-PSMA × Vβ17 antibodies under conditions where the PAN-T to tumor E:T ratio is 10:1 and the Vβ17 to tumor E:T ratio differs (Donor #1: 0.5:1, Donor #2: 0.3:1, Donor #3: 0.5:1). This figure shows cell lysis mediated by different concentrations of bispecific anti-PSMA × Vβ17 antibody (VB17B3). [Figure 21B] This figure shows the evaluation of cell lysis by four types of bispecific anti-PSMA × Vβ17 antibodies under conditions where the PAN-T vs. tumor E:T ratio is 10:1 and the Vβ17 vs. tumor E:T ratio differs (Donor #1: 0.5:1, Donor #2: 0.3:1, Donor #3: 0.5:1). This figure shows cell lysis mediated by different concentrations of bispecific anti-PSMA × Vβ17 antibody (VB17B4). [Figure 21C] This figure shows the evaluation of cell lysis by four types of bispecific anti-PSMA × Vβ17 antibodies under conditions where the PAN-T vs. tumor E:T ratio is 10:1 and the Vβ17 vs. tumor E:T ratio differs (Donor #1: 0.5:1, Donor #2: 0.3:1, Donor #3: 0.5:1). This figure shows cell lysis mediated by different concentrations of bispecific anti-PSMA × Vβ17 antibody (VB17B5). [Figure 21D]This figure shows the evaluation of cell lysis by four different bispecific anti-PSMA × Vβ17 antibodies under conditions where the PAN-T vs. tumor E:T ratio was 10:1 and the Vβ17 vs. tumor E:T ratio differed (Donor #1: 0.5:1, Donor #2: 0.3:1, Donor #3: 0.5:1). It also shows cell lysis mediated by different concentrations of bispecific anti-PSMA × Vβ17 antibody (VB17B6). Impedance was recorded every 15 minutes for 120 hours, and the percentage of cell lysis for C42b tumor cells only was calculated using RTCA software. [Figure 22A] This figure shows the binding of the Vβ17xPSMA antibody to Pan T cells. The figure also shows the binding quantified based on the MFI value. [Figure 22B] This figure shows the binding of the Vβ17xPSMA antibody to Pan T cells. The figure shows the binding quantified based on the binding rate (%). Both donors, NHV21-07171 and NHV-07174, showed good binding of VB17B25 (Vβ17xPSMA) to Pan T cells. Binding of the PSMB2951 (nullxPSMA) antibody was not observed in Pan T cells. [Figure 23] This figure shows the binding of Vβ17xPSMA antibody to C42B cells. Binding of VB17B25 (Vβ17xPSMA) and PSMB2951 (NullxPSMA) was observed. Binding with VB17B23 (Vβ17xNull) antibody on C4-2B cells was not observed. [Figure 24A] This figure shows cytotoxicity mediated by Vβ17 xPSMA bispecific antibodies against C4-2B cells. When whole PBMCs were used as effector cells, donor NHV21-07171 and NHV-07174 showed potent dose-dependent cytotoxicity against C4-2B cells. No cytotoxicity was observed with Null antibodies (VB17B23 and PSMB2951). [Figure 24B]This figure shows cytotoxicity mediated by Vβ17 xPSMA bispecific antibodies against C4-2B cells. When Pan T cells were used as effector cells, donor NHV21-07171, along with VB17B25, exhibited potent dose-dependent cytotoxicity against C4-2B cells. No cytotoxicity was observed with Null antibodies (VB17B23 and PSMB2951). No cytotoxicity was observed with a second donor (NHV21-07174) using the VB17B25 antibody. [Figure 24C] This figure shows the cytotoxicity mediated by a Vβ17 xPSMA bispecific antibody against C4-2B cells. When whole PBMCs were used as effector cells, donor NHV21-08653 and NHV-08227 showed cytotoxicity against C4-2B cells, but the figure shows that the maximum target cell lysis rate shown by donor NHV21-08227 was only 20%. Donor NHV21-08653 showed potent cytotoxicity. [Figure 24D] This figure shows the cytotoxicity mediated by a Vβ17 xPSMA bispecific antibody against C4-2B cells. When Pan T cells were used as effector cells, donor NHV21-08653 and NHV-08227 showed cytotoxicity against C4-2B cells, but the figure shows that the maximum target cell lysis rate shown by donor NHV21-08227 was only 20%. Donor NHV21-08653 showed potent cytotoxicity. [Figure 25] This figure shows T cell activation mediated by a Vβ17xPSMA bispecific antibody. Whole PBMCs and Pan T cells were cultured with C4-2B target cells for 72 hours in the presence of the bispecific antibody at a maximum concentration of 10 μg / mL, followed by a 3-fold dilution of 0.4 μg / mL. After 72 hours, cells were harvested, and CD3 T cells were gated for analysis of CD25 and CD71. [Figure 26A] This figure shows a bispecific antibody having one Vβ17 binding arm. The structure of the bispecific antibody with Vβ17 Fab is shown in Figure 26A. The structure of the bispecific antibody with Vβ17 Fab is shown in Figure 26B. [Figure 26B] This figure shows a bispecific antibody having one Vβ17 binding arm. The structure of the bispecific antibody with Vβ17 Fab is shown in Figure 26A. The structure of the bispecific antibody with Vβ17 Fab is shown in Figure 26B.

[0082] (Detailed description) In the "Background Technology" section, and throughout this specification, various publications, papers, and patents are cited. Or, they may be listed, and each of these references is incorporated herein by reference in its entirety. The discussion of documents, operations, materials, devices, articles, etc. included in this specification is in the context of the present invention. This is to give a hint. Such considerations are based on the fact that any or all of these things are disclosed. or to allow it to constitute part of the prior art to any of the claimed inventions. No.

[0083] Unless otherwise specified, all technical and scientific terms used herein are defined in accordance with the present invention. It has the same meaning as generally understood by those skilled in the art to which it belongs. Otherwise, Certain terms used herein have the meanings set forth herein.

[0084] When used in this specification and the appended claims, the singular forms "a", "an", and "t It is important to note that "he" can refer to multiple objects unless it is particularly clear from the context. be.

[0085] Unless otherwise specified, all numerical values, such as concentrations or concentration ranges, described herein are subject to change. In all cases, it should be understood as being modified by the term "about". Therefore, the values ​​typically include ±10% of the stated value. For example, 1 mg / mL The concentrations include 0.9 mg / mL to 1.1 mg / mL. Similarly, 1% to 10% (w / v) The concentration range includes 0.9% (w / v) to 11% (w / v). When used in this specification... The use of a numerical range means that integers within that range are used unless the context explicitly indicates otherwise. This includes all possible sub-ranges of values, including fractions, and explicitly includes all individual numbers within that range. nothing.

[0086] Unless otherwise stated, the term "at least" preceding a set of elements refers to all elements of the set. It should be understood that this refers to... A person skilled in the art would simply use the usual experimental procedure. Therefore, many equivalents are recognized for the specific embodiments of the present invention described herein, or This can be confirmed. Such equivalents are intended to be included by the present invention. ru.

[0087] When used in this specification, the terms "comprises" and "comprising" are used interchangeably. "includes", "include", "has", "having )", "contains", or "contains", or these Any other variant is intended to include the integer or group of integers mentioned, but this It does not exclude any other integers or groups of integers, and is non-exclusive or non-restrictive. It will be understood that this is intended. For example, a composition, mixture, or process comprising a series of elements. The methods, articles, or apparatus are not necessarily limited to those elements, and are expressly specified. Not specifically listed, or such compositions, mixtures, processes, methods, articles, or equipment The arrangement may include other elements that are not originally present. Furthermore, unless explicitly stated otherwise, "Or" refers to a comprehensive "or," not an exclusive "or." For example, condition A or B is such that A is true (or exists) AND B is false (or does not exist) If (not), if A is false (or does not exist) and B is true (or exists), Furthermore, if both A and B are true (or exist), then either one of them is satisfied. It can be done.

[0088] When used herein, the connecting expression "and / or" between multiple enumerated elements is used The word is understood to encompass both individual and combined options. For example. When two elements are connected by "and / or", the first option is the second element. This indicates that the first element is applicable to the second option. The second option is the second option without the first element. This indicates that the element is applicable. The third option is that the first and second elements are applicable together. It refers to being able to do something. One of these options is included in the meaning, therefore Therefore, when used in this specification, it is understood that the requirements of the term "and / or" are met. The simultaneous applicability of two or more of the options is also included in the meaning, and therefore the term "and / also" It is understood that the requirements of "ha" are met.

[0089] When used herein, the terms "consists of" or "consist of" Variations such as "st of" or "consisting of" are used in the specification and claims. When used across the entire range, it includes any enumerated integer or set of integers, but additional This indicates that the integer or set of integers will not be added to the specified method, structure, or composition. .

[0090] When used herein, the term "consists essentially of" Or "consist essentially of" or "consist essentially of" Variations such as "(essentially of)" are used throughout the specification and claims. When used, it can include any enumerated integer or group of integers, and optionally specify the method and structure. Any enumerated integer or any number that does not substantially alter the basic or novel properties of the structure or composition This indicates that it also includes integer groups. See MPEP §2111.03.

[0091] As used herein, “subject” means any animal, preferably a mammal, most preferably "Human" means human. When used herein, the term "mammal" refers to all mammals. This includes dairy animals. Examples of mammals, though not limited to these, include cattle. Horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans But, humans are even more likely to be mentioned.

[0092] As used herein, “about” refers to the dimensions or features of preferred components of the present invention. Terms such as "approximately," "generally," and "substantially" should be described in a way that is understandable to those skilled in the art. The dimensions / features are not strict boundaries or parameters, but rather functionally the same or similar. It should also be understood that this does not exclude slight differences from the minimum value. So, is such a reference, including numerical parameters, accepted in the art? Mathematical and industrial principles (e.g., rounding, measurement or other systematic errors, manufacturing tolerances, etc.) When used, it will include a variant where the least significant digit remains unchanged.

[0093] The terms "identical" or "percent "identity" refer to the combination of two or more nucleic acids or polypeptides. Column (e.g., anti-Vβ17 / anti-cancer-related antigen bispecific antibody and the polynucleotide encoding it) Otide, anti-Vβ17 / anti-CD123 bispecific antibody and the polynucleotide encoding it D, Vβ17 polypeptide and the Vβ17 polynucleotide encoding it, CD123 In relation to polypeptides and the CD123 polynucleotides that encode them, the following distribution When measured using one of the column comparison algorithms or by visual inspection, the match is Are they identical when compared and aligned to maximize the difference, or are they identical at a specific percentage? This refers to two or more sequences or partial sequences having the same amino acid residue or nucleotide. .

[0094] For sequence comparison, typically one sequence is used as a reference against which the test sequence is compared. It functions as an array. When using an array comparison algorithm, the test array and the reference array are... The data is input into the computer, and if necessary, sub-array coordinates are specified, and the array algorithm program... Gram parameters are specified. Then, the sequence comparison algorithm is specified in the program. Based on the parameters, calculate the percentage sequence identity of the test sequence to the reference sequence. .

[0095] The optimal alignment of sequences for comparison is, for example, Smith & Waterman. Local homology algorithm of Adv.Appl.Math.2:482(1981) Zum, Needleman & Wunsch, J. Mol. Biol. 48:443 (19 70) Homology alignment algorithm, Pearson & Lipman, Pr Similarity search for oc.Nat'l.Acad.Sci.USA85:2444(1988) Methods and computerized implementations of these algorithms (Wisconsin Gen etics Software Package,Genetics Computer Group, 575 Science Dr., Madison, WI: GAP , BESTFIT, FASTA, and TFASTA), or visual inspection (generally Cu rrent Protocols in Molecular Biology,FM .Ausubel et al.,eds.,Current Protocols,a joint venture between Greene Publishing Associates, Inc. and John Wiley&Sons, Inc. (See 1995 Supplement (Ausubel)) It is possible.

[0096] Examples of suitable algorithms for determining percent sequence identity and sequence similarity include Alt Schul et al.,(1990)J.Mol.Biol.215:403-41 0 and Altschul et al., (1997) Nucleic Acids R BLAST and BLAST2 are described in es.25:3389-3402, respectively. This is the .0 algorithm. The software used for BLAST analysis is provided by the National Center for Biotechnology Information. It is publicly available through the National Center for Biotechnology Information. This algorithm first matches words of the same length and position in the database array. Either they match when combined, or they satisfy a threshold score T of several positive values. By identifying short words of length W in the query sequence, high-scoring sequences can be paired. This includes identifying high-scoring sequence pairs (HSPs). T is the adjacent word score. These are called threshold words (Altschul et al., see above). A hit is a seed to start a search to find longer HSPs that contain it. It functions as follows: Then, each array can increase its cumulative alignment score as long as it can. Extend the word hit in both directions along the line.

[0097] Regarding nucleotide sequences, parameter M (reward for matching residue pairs) The core (always a value greater than 0) and parameter N (penalty for mismatched residues) The cumulative score is calculated using the score (which is always a value less than 0). Amino acid sequence For this, the cumulative score is calculated using a scoring matrix. When the score decreases by X from its maximum score, one or more negative score values When the cumulative score becomes zero or less due to the accumulation of misalignment of ng residues, or either of the following: When the end of the sequence is reached, the extension of word hits in each direction is stopped. BLAS The parameters W, T, and X of the T algorithm determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) defaults to word length (W)11, expected value (E)10, M=5, N=-4, and compare both chains. For the mino acid sequence, the BLASTP program defaults to the word length (W). 3. Use the expected value (E) 10 and the BLOSUM62 scoring matrix (H enikoff&Henikoff,Proc.Natl.Acad.Sci.USA See 89:10915 (1989).

[0098] In addition to calculating percent sequence identity, the BLAST algorithm uses two sequences Statistical analysis of similarities between columns is also performed (e.g., Karlin & Altschul, Proc. See Nat'l.Acad.Sci.USA 90:5873-5787 (1993). (I would like to be done). One measure of similarity provided by the BLAST algorithm is the minimum equivalent. This is the probability (P(N)) between two nucleotide sequences or two amino acid sequences. It provides an indicator of the probability that a match between two nucleic acids occurs by chance. For example, if a test nucleic acid and a reference nucleic acid are... The minimum sum probability in the comparison is less than approximately 0.1, more preferably less than approximately 0.01, and most preferably less than 0.01. If the value is less than approximately 0.001, it is considered similar to the reference sequence.

[0099] Further indicators that two nucleic acid sequences or polypeptides are substantially identical are described below. As shown, the polypeptide encoded by the first nucleic acid is encoded by the second nucleic acid It is immunologically reactive with the polypeptide. Therefore, polypeptide Typically, it is substantially identical to the second polypeptide, for example, the two peptides retain They differ only by spatial substitution. Another indicator that two nucleic acid sequences are substantially identical is that the two sequences are... This refers to molecules hybridizing with each other under stringent conditions.

[0100] As used herein, the term "polynucleotide" is synonymous with "nucleic acid molecule". Also called "nucleotide" or "nucleic acid," it refers to unmodified RNA or DNA or modified RNA. Any polyribonucleotide or polydeoxyribonucleonucleotide, which may be NA or DNA. This refers to creotides. "Polynucleotides" include single-stranded and double-stranded DNA, and single-stranded and DNA, single-stranded and double-stranded RNA, and single-stranded and double-stranded RNA are mixtures of single-stranded and double-stranded regions. RNA is a mixture of strand regions, single-stranded or more typically double-stranded, or single-stranded and double-stranded. Examples include hybrid molecules containing DNA and RNA, which may be a mixture of regions. This is not limited to these. In addition, "polynucleotide" is RNA or DNA, or It refers to a triple-stranded region containing both RNA and DNA. The term polynucleotide includes 1 DNA or RNA containing one or more modified bases, and for reasons of stability or other reasons. This also includes DNA or RNA with a modified skeleton. "Modified" bases are, for example, For example, tritylated bases and abnormal bases, such as inosine. Various modifications are present in DNA and It can be done with RNA. Therefore, "polynucleotides" are typically naturally occurring The chemically, enzymatically, or metabolically modified forms of recognized polynucleotides, and the It encompasses chemical forms that have the characteristics of DNA and RNA of rus and cells. "Cydos" also include relatively short nucleic acid chains (often referred to as oligonucleotides). do.

[0101] As used herein, the term “vector” means a functional vector of another nucleic acid segment. Replicons that can replicate or express a segment by being inserted And so it is.

[0102] As used herein, the term “host cell” means a cell containing the nucleic acid molecule of the present invention. It refers to any of the following: "Host cells" are, for example, primary cells, cultured cells, or cells derived from a cell line. These may be any type of cell. In one embodiment, the “host cell” is disclosed herein. These are cells transfected with nucleic acid molecules. In another embodiment, the "host cell" is These are the offspring or potential offspring of a transfected cell. The progeny of a cell are, for example, , mutations that may occur in subsequent generations or environmental influences, or nuclear changes in the host cell genome Due to the incorporation of acid molecules, the cells may or may not be identical to the parent cells.

[0103] As used herein, the term “expression” refers to the biosynthesis of a gene product. The term encompasses the transcription of genes into RNA. This term also refers to one or more RNAs. This also includes translation into polypeptides, and further includes all naturally occurring post-transcriptional and post-translational modifications. It is rare. The bispecific antibodies that are expressed are found in the cytoplasm of host cells, in cell culture growth media, etc. It can exist in the extracellular environment or be fixed to the cell membrane.

[0104] As used herein, the terms "peptide," "polypeptide," or "protein" are used in this specification. The term can refer to a molecule composed of amino acids, and by those skilled in the art, it can refer to a protein. It can be recognized as such. In this specification, conventional one-letter or three-letter codes for amino acid residues are used. The terms "peptide," "polypeptide," and "protein" may be used in any length. These terms can be used interchangeably in this specification to refer to polymers of the amino acids. The polymer may be linear or branched, and may contain modified amino acids. It may be interrupted by a non-amino acid. This term is also naturally modified or It includes amino acid polymers modified by the intervention. An example of the intervention is, for instance, Disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other This includes manipulation or modification, such as conjugation with a labeling component. Also, for example, Contains one or more amino acid analogs (including, for example, unnatural amino acids). The definition includes polypeptides, as well as other modifications known in the art.

[0105] The peptide sequences described herein are described in accordance with common practice, and the N-terminal region of the peptide is shown. The region is on the left, and the C-terminal region is on the right. The isomer forms of amino acids are known, but separately Unless explicitly stated otherwise, the L-form of amino acids is shown.

[0106] antibody Anti-Vβ17 antibody or its antigen-binding fragment, nucleic acid encoding the antibody and expression The vector, recombinant cells containing this vector, and compositions containing the above-mentioned antibodies are described herein. Provided to: In certain embodiments, an isolated anti-Vβ17 bispecific antibody or the Antigen-binding fragment, nucleic acid encoding the above antibody, and expression vector, including the vector Recombinant cells possessing the said bispecific antibody are provided, and a composition containing the said bispecific antibody is provided. Methods for producing the antibody and methods for using the antibody to treat a disease are also provided. The disclosed antibodies include high affinity binding to Vβ17 or high specificity for Vβ17. However, it has one or more desirable functional characteristics, not limited to these. In the embodiments disclosed herein, the antibodies are used alone or in combination with other therapies against When administered to elephants, it has the ability to treat or prevent disease or disorder.

[0107] Furthermore, an anti-Vβ17 bispecific antibody or its antigen-binding fragment, or an antibody encoding the above antibody nucleic acids and expression vectors, recombinant cells containing the vectors, and bispecific antibodies Compositions containing such antibodies are provided herein. Methods for producing such antibodies and for treating diseases including cancer are also provided herein. To this end, a method using bispecific antibodies is also provided. The antibodies disclosed herein are , having one or more desirable functional characteristics. In some embodiments, as specified herein The bispecific antibody provided has high affinity binding to Vβ17. Several implementations In this configuration, the bispecific antibodies provided herein have high affinity binding to a second target antigen. In some embodiments, the bispecific antibodies provided herein are used against Vβ17. It has high specificity. In some embodiments, the bispecific anti- The body has high specificity for the second target antigen. In some embodiments, as specified herein The bispecific antibodies provided have high specificity for CD123. In terms of application, the bispecific antibody provided herein has high specificity for BCMA. In some embodiments, the bispecific antibodies provided herein are used against DLL3. It has high specificity. In some embodiments, the bispecific anti- The body has high specificity for PSMA. In some embodiments, provided herein The bispecific antibody has high specificity for KLK2. In some embodiments, The bispecific antibodies provided herein, when administered alone, cure a disease or disorder. It has the ability to treat or prevent. In some embodiments, the dual specificity provided herein Sex antibodies, when administered in combination with other therapies, have the ability to treat or prevent disease or disorder. It has power. In some embodiments, the disease or disorder is cancer. The disease or disorder is leukemia or lymphoma.

[0108] Also, an anti-Vα10.2 antibody or its antigen-binding fragment, and the nucleic acid encoding the antibody. and expression vector, recombinant cells containing this vector, and composition containing the above antibody Provided herein, in certain embodiments, isolated anti-Vα10.2 bispecific Sex antibody or its antigen-binding fragment, nucleic acid encoding said antibody and expression vector, Recombinant cells containing the vector and a composition containing the bispecific antibody are provided. Methods for producing the antibody and methods for using the antibody to treat a disease are also provided. The antibodies disclosed herein have high affinity binding to Vα10.2, or to Vα10.2. One or more desirable functional characteristics, including but not limited to high specificity for It has properties. In certain embodiments, the antibodies disclosed herein are used alone or with other antibodies. When administered to a target in combination with therapy, it has the ability to treat or prevent disease or disorder. In some embodiments, the bispecific antibody provided herein is a second target antigen. It has high specificity for. In some embodiments, the dual specificity provided herein The sex antibody has high specificity for CD123. In some embodiments, as specified herein The bispecific antibodies provided have high specificity for BCMA. Several implementations In terms of form, the bispecific antibodies provided herein have high specificity for DLL3. In some embodiments, the bispecific antibodies provided herein are against PSMA. It has high specificity. In some embodiments, the bispecific antibodies provided herein It has high specificity for KLK2. In some embodiments, provided herein The bispecific antibodies, when administered alone, have the ability to treat or prevent a disease or disorder. It possesses. In some embodiments, the bispecific antibodies provided herein are used in combination with other therapies. They have the ability to treat or prevent a disease or disorder when administered in combination. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is It is leukemia or lymphoma.

[0109] As used herein, the term "antibody" is used in a broad sense, and also refers to human, humanized, and Immunoglobulin or antibody molecules, including complex and chimeric antibodies, as well as monoclonal or It contains polyclonal antibody fragments. Generally, antibodies are polyclonal antibodies against a specific antigen. It is a protein or peptide chain that exhibits binding specificity. The structure of an antibody is well known. Robulin is classified into five main classes (i.e., I) depending on the amino acid sequence of the heavy chain constant domain. It can be assigned to IgA, IgD, IgE, IgG, and IgM. IgG is an isotype of IgA1, IgA2, IgG1, IgG2, IgG3 and IgG It is further subdivided as 4. Therefore, the antibodies provided herein are 5 major It can be either a class or a corresponding lower class. In certain embodiments, The antibodies provided herein are IgG1, IgG2, IgG3, or IgG4. The antibody light chains of vertebrate species are two distinctly different based on the amino acid sequence of their constant domain. It can be assigned to one of the following types, namely kappa and lambda. Therefore Therefore, the antibodies provided herein may contain a kappa or lambda light chain constant domain. Yes, it is possible. According to certain embodiments, the antibodies disclosed herein are derived from rat or human antibodies. Includes the conventional heavy chain and / or light chain steady region.

[0110] In addition to the heavy and light chain constant domains, antibodies have a light chain variable region (VL) and a heavy chain variable region. It contains an antigen-binding region composed of (VH), and each of these regions has three domains ( That is, it contains complementarity determination regions 1 (CDR1), CDR2, and CDR3). "DR" is a non-framework of immunoglobulin (Ig or antibody) VH β-sheet framework. One of the three hypervariable regions within the MUWORK domain (HCDR1, HCDR2, or H CDR3), or three non-framework regions of the antibody VL β-sheet framework This refers to one of the ultra-variable regions (LCDR1, LCDR2, or LCDR3). Therefore, CDR is a variable region sequence scattered within the framework region sequence. The region is well known to those skilled in the art, and for example, by Kabat, within the antibody variable (V) domain. It is defined as the region with the highest variability (Kabat et al., J.Bio). l.Chem.252:6609-6616(1977), Kabat,Adv.Pro t.Chem.32:1-75(1978). The CDR region sequence is also conserved β- Since it is not part of the sheet framework, it is a residue that can adapt to various higher-order structures. It is structurally defined by Chothia (Chothia and L esk, J.Mol.Biol.196:901-917(1987)). Both terms are , which is well recognized in the relevant technical field. The CDR region sequence is also AbM, Con Defined by tact and IMGT. Exemplary CDR region sequences are as shown herein. For example, as illustrated in the sequence listing and the table provided in the following examples, a standard antibody variable. The location of CDRs within the region is determined by comparing numerous structures (Al-Lazik ani et al., J. Mol. Biol. 273:927-948 (1997), Morea et al., Methods 20:267-279(2000)). super The number of residues in the variable region varies between antibodies, therefore additional residues are needed at the standard positions. Conventionally, a standard variable region numbering scheme (Al-Lazikani et al.) The residue numbers in the above (1997)) are followed by a, b, c, etc., to assign them. Such nomenclature is well known to those skilled in the art.

[0111] In this specification, the light chain variable region CDR1 domain is referred to as LCDR1 or VL CDR1. It is interchangeably referred to as the CDR2 domain of the light chain variable region. In this specification, the CDR2 domain is referred to as LCDR2 Alternatively, it is interchangeably referred to as VL CDR2. The light chain variable region CDR3 domain is described herein. In this context, it is interchangeably referred to as LCDR3 or VL CDR3. Heavy chain variable region CDR1 domain In this specification, "in" is interchangeably referred to as HCDR1 or VH CDR1. The variable region CDR2 domain is, in this specification, compatible with HCDR2 or VH CDR2. It is referred to as the heavy chain variable region CDR1 domain. In this specification, the heavy chain variable region CDR1 domain is referred to as HCDR3 or VH It is said to be compatible with CDR3.

[0112] As used herein, the terms VH or VL, etc., “super variable region” means super variable region in the arrangement. This refers to the region of the antibody variable region that is variable and / or forms a structurally defined loop. Generally, antibodies have six hypervariable regions, namely VH(HCDR1, HCDR2, HC Includes three DR3s and three VLs (LCDR1, LCDR2, LCDR3). The depiction of the hypervariable region is used and is included herein. The "Kabat" CDR is , based on sequence variability, and the most commonly used (e.g., Kabat et al., Sequences of Proteins of Immunolo gical Interest,5th Ed.Public Health Serv ice,National Institutes of Health,Bethes See da, MD. (1991). "Chothia" is used instead. This indicates the location of the loop (for example, Chothia and Lesk, J.Mol.Bi). See ol.196:901-917(1987). Use Kabat numbering rules. The end of the Chothia CDR-HCDR1 loop when it is numbered using is the loop's It changes from H32 to H34 depending on the length (this is because the Kabat numbering scheme is H3 This is to place the insertions in 5A and H35B, and if neither 35A nor 35B exists, If the loop ends at 32 and only 35A exists, then the loop ends at 33, and 35A and 35 If both B and B are present, the loop ends at 34). The "AbM" hypervariable region is Kaba This represents a compromise between the CDR and the Chothia structural loop, Oxford Mole Used by cular AbM antibody modeling software (e.g., Ma rtin,in Antibody Engineering,Vol.2,Chapt. See er 3, Springer Verlag). "Contact" is super OK. The range of variation is based on the analysis of available composite crystal structures.

[0113] Recently, the universal numbering system, ImMunoGeneTics (IMGT) Inf ormation System (registered trademark) (Lafranc et al., Dev Comp.Immunol.27(1):55-77(2003)) was developed and widely It is used. IMGT is an immunoglobulin (IG) and T cell receptor. (T cell receptor, TR), and major histocompatibility complex (major) of humans and other vertebrates. Histocompatibility Complex (MHC) is a specialized integrated information system. Furthermore, CDRs are referred to in terms of both the amino acid sequence and the position within the light or heavy chain. The "position" of the CDR within the structure of the immunoglobulin variable domain is conserved across species. Because it exists in a structure called a loop, the variable domain sequence is aligned according to its structural features. By using a numbering system, CDRs and framework residues can be easily identified. This information is obtained from CDR residues from one species of immunoglobulin, typically from human antibodies. It can be used to port and replace within the acceptor framework of Honeg. Ger and Pluckthun, J. Mol. Biol. 309:657-670 (2001) has led to the development of a further numbering system (AHon). For example, K The correspondence between numbering systems, including the abat numbering system and the IMGT-specific numbering system, is handled by our company. This is well known to (e.g., Kabat, above; Chothia and Lesk, above; Ma (See rtin, above; Lefranc et al., above). The example system described combines Kabat and Chothia.

[0114] [Table 1]

[0115] The hypervariable region may include the following "extended hypervariable region": 24-36 within the VL These are 24-34 (LCDR1), 46-56 or 50-56 (LCDR2), and 89-9 7 or 89-96 (LCDR3), and 26-35 or 26-35A (HCD) within VH. R1), 50-65 or 49-65 (HCDR2), and 93-102, 94-102, Or 95-102 (HCDR3). Reflecting each of the above numbering schemes included in the sequence listing. A CDR sequence is provided herein.

[0116] The term "constant region" or "constant domain" refers to the direct involvement of antibody binding to antigen. However, the light and heavy chains exhibit various effector functions, such as interactions with Fc receptors. This refers to the ruboxy terminus. This term is an immunoglobulin, a variable region containing an antigen-binding site. Immunoglobulin molecules have a more conserved amino acid sequence compared to other parts of brin. This refers to a portion of the chain. The steady-state region consists of the CH1, CH2, and CH3 regions of the heavy chain, and the CL region of the light chain. It may contain the region.

[0117] The term "framework" or "FR" residue refers to a variable region residue adjacent to the CDR. Yes, FR residues are used in, for example, chimeric antibodies, humanized antibodies, human antibodies, domain antibodies, and diamines. It is present in the body, linear antibodies, and bispecific antibodies. FR residues are hypervariable region residues or These are variable domain residues other than CDR residues.

[0118] As used herein, the term "isolated antibody" refers to an antibody having different antigen specificity. This refers to an antibody that substantially does not contain other antibodies (for example, an isolated antibody that specifically binds to Vβ17). The antibodies included substantially no antibodies that do not bind to Vβ17, and the second target (e.g., CD1) 23. Isolated antimicrobial agents that specifically bind to BCMA, DLL3, PSMA, or KLK2. The body targets a second target (e.g., CD123, BCMA, DLL3, PSMA, or KLK2) (Substantially contains no antibodies that do not bind to ) Furthermore, the isolated antibodies are other cellular material and / or substantially free of chemical substances.

[0119] As used herein, the term "monoclonal antibody" refers to a substantially homogeneous antibody. This refers to antibodies obtained from a population; in other words, the individual antibodies that make up the population exist in trace amounts. They are identical except for the spontaneously occurring mutations obtained. The monoclonal antibodies disclosed herein are Ibridomas, phage display technology, single lymphocyte gene cloning technology, and These can be produced by recombinant DNA methods. For example, monoclonal antibodies can be produced by tiger. Obtained from transgenic non-human animals, such as transgenic mice or rats. Can be generated by hybridomas including B cells, and human heavy chain transgenes and light chain transgenes. It has a genome that includes offspring.

[0120] As used herein, the term “antigen-binding fragment” means, for example, “diabo Di, Fab, Fab', F(ab')2, Fv fragment, disulfide stabilized Fv Fragment (disulfide stabilized Fv, dsFv), (dsFv)2, bispecific d sFv(dsFv-dsFv'), disulfide-stabilized diamond body (ds diamond body) ), single-chain antibody molecule (scFv), single-domain antibody (sdAb) )ScFv dimer (bivalent diabody), antibody portion containing one or more CDRs Multispecific antibodies formed from these components, camelized single-domain antibodies, nanobodies, domain antibodies Body, bivalent domain antibody, or any other antibody that binds to an antigen but does not contain a complete antibody structure. This refers to antibody fragments, such as fragments. Antigen-binding fragments are parental antibodies or parental antibodies. The body fragment can bind to the same antigen to which it binds. According to certain embodiments, The antigen-binding fragment consists of the light chain variable region, the light chain constant region, and the heavy chain Fd fragment. Includes. According to other specific embodiments, the antigen-binding fragment is Fab and F(ab'). include.

[0121] As used herein, the term "single-chain antibody" refers to an antibody with approximately 15 to 20 amino acids. In this field, including heavy chain variable regions and light chain variable regions linked by short peptides This refers to conventionally known single-chain antibodies. When used herein, the term "single-domain antibody" is used in a manner that is not applicable. The term includes the heavy chain variable region and the heavy chain steady region, or includes only the heavy chain variable region, in this field. In this context, it refers to conventionally known single-domain antibodies.

[0122] As used herein, the term "human antibody" refers to an antibody produced by a human being. or produced by humans using any known technology in the art. This refers to an antibody that has the amino acid sequence corresponding to the antibody being targeted. This definition of human antibody is based on the internet. A complete or full-length antibody, a fragment thereof, and / or at least one human weight The antibody contains chains and / or light chain polypeptides.

[0123] As used herein, the term "humanized antibody" means an antibody whose antigen-binding properties are preserved. However, the sequence phase of human antibodies is modified so that the antigenicity of the antigen in the human body is reduced. This refers to non-human antibodies that increase the number of antibodies of the same sex.

[0124] As used herein, the term "chimeric antibody" refers to an amino acid of an immunoglobulin molecule. This refers to antibodies whose acid sequences originate from two or more species. The variable regions of both the light and heavy chains are In many cases, a single species of mammal possessing the desired specificity, affinity, and capabilities (for example, This corresponds to the variable region of antibodies derived from mice, rats, rabbits, etc., but the constant region is To avoid triggering an immune response in the species, another species of mammal (e.g., humans) is used. It corresponds to the sequence of the resulting antibody.

[0125] The term "specificity" refers to the antigen-binding protein (such as an antibody) that binds to a specific epitope of an antigen. This refers to the selective recognition of an antibody. Natural antibodies, for example, are monospecific. The term "multispecificity" refers to the phenomenon where an antigen-binding protein (such as an antibody) binds to two or more antigens. This indicates that it has binding sites, and that at least two of them bind to different antigens. When used, "bispecificity" means that the antigen-binding protein has two different antigen-binding specificities. This indicates that it possesses something.

[0126] As used herein, the term "multispecific antibody" refers to a multispecific antibody that can detect multiple immunoglobulins. This refers to an antibody containing a variable domain sequence, specifically the first of several immunoglobulin variable domain sequences. It has binding specificity to the first epitope and can bind to the second immunoglobulin among several. The variant domain sequence has binding specificity to the second epitope. In one embodiment, The first and second epitopes do not overlap or substantially overlap. In one embodiment, The first and second epitopes are on different antigens, for example, different proteins (or polymers) It is located on different subunits of the protein. In one embodiment, the multispecific antibody is located on the third subunit. , comprising a fourth or fifth immunoglobulin variable domain. In one embodiment, multispecific anti The antibody molecule is a bispecific antibody molecule, a triplicate antibody molecule, or a quadruplicate antibody molecule.

[0127] As used herein, the term "bispecific antibody" refers to an antibody that has two or fewer epitopes or This refers to a multispecific antibody that binds to two or fewer antigens. A bispecific antibody is a primary epitometa A first immunoglobulin having binding specificity to a p (e.g., an epitope on the Vβ17 antigen) A brin variable domain sequence and a second immune sequence having binding specificity to a second epitope. Characterized by globulin variable domain sequences. In one embodiment, first and second Epitopes are found on different antigens, for example, on different proteins (or different polymer proteins). (subunit) is located on the first epitope. In one embodiment, the bispecific antibody is located on the first epitope. A heavy chain variable domain sequence and a light chain variable domain sequence having binding specificity to the target, and a second E Heavy chain variable domain sequence and light chain variable domain sequence having binding specificity to pitope Includes. In one embodiment, the bispecific antibody has binding specificity to the first epitope. A half-antibody or fragment thereof possesses a half-antibody having binding specificity to a second epitope. The antibody comprises an antibody or a fragment thereof. In one embodiment, the bispecific antibody is a first epi scFv or a fragment thereof having binding specificity to a tope, and a second epitope It comprises an scFv or fragment thereof having binding specificity to a certain embodiment. The first epitope is located at Vβ17, and the second epitope is located at CD123. In this embodiment, the first epitope is located at Vβ17, and the second epitope is located at PD-1 , PD-L1, CTLA-4, EGFR, HER-2, CD19, CD20, CD3, and It is located at and / or other tumor-associated immunosuppressive factors or surface antigens. In one embodiment, The first epitope is located at Vβ17, and the second epitope is located at BCMA. Morphologically, the first epitope is located at Vβ17, and the second epitope is located at DLL3. In one embodiment, the first epitope is located at Vβ17, and the second epitope is at PS It is located at MA. In one embodiment, the first epitope is located at Vβ17, and the second epitope is located at MA. Taupe is located in KLK2.

[0128] As used herein, the term "valence" refers to the value of an antigen-binding protein (such as an antibody). This means the presence of a specific number of binding sites. For example, natural antibodies or full-length antibodies have two It has a binding site and is divalent. Therefore, "trivalent," "tetravalent," "pentavalent," and "hexavalent" The term refers to two binding sites in an antigen-binding protein (such as an antibody). This shows the presence of 3 binding sites, 4 binding sites, 5 binding sites, and 6 binding sites. vinegar.

[0129] As used herein, the term “half-antibody” refers to an antibody associated with one immunoglobulin light chain. It refers to a single immunoglobulin heavy chain. Those skilled in the art will know that a semi-antibody surrounds this fragment. It may include, for example, an antigen-binding domain consisting of a single variable domain originating from the camelid family. It will be easy to understand that it is also possible to have a main.

[0130] As used herein, the term "Vβ17" refers to the immunotherapy against cytotoxic T cells. This refers to the T cell receptor expressed in response to a response. Vβ17-expressing CD8+ T cells are generally, Vβ17-expressing CD is generated in response to exposure to influenza A virus in the target population. 8+ T cells trigger a large recall in response to influenza exposure in the target population. The term "Vβ17" refers to cells (including T cells) that are naturally expressed or On cells transfected with the gene or cDNA encoding that polypeptide This includes any Vβ17 variant, isoform, and species homolog that may be expressed. Unless otherwise specified, Vβ17 is preferably human Vβ17. Exemplary human Vβ17 The amino acid sequence is provided by GenBank accession number AAB49730.1. It will be done.

[0131] The term "CD123" refers to a soluble cytokine that is important in the immune system. This refers to a molecule found on cells that helps transmit the signal of interleukin-3. D123 can also be called the "interleukin-3 receptor." The receptor is a type I cytoka It belongs to the ion receptor family and has a common beta subunit (beta c or CD131) It is a heterodimer with a paired, unique alpha chain. The CD123 receptor is pluripotent. It can be found on progenitor cells, induces tyrosine phosphorylation within cells, and promotes proliferation within hematopoietic cell lines. It can promote differentiation. CD123 is also used in acute myeloid leukemia (AML) subtypes. It can be expressed in cells. Unless otherwise specified, the term "CD123" refers to cells (T cells). (including) naturally expressed by, or genes encoding its polypeptide or Any CD123 variant that can be expressed on cells transfected with cDNA It includes isoforms and species homologs, preferably "CD123" is human CD12 The answer is 3. The human CD123 amino acid sequence is GenBank accession number AY78. Provided by 9109.1.

[0132] As used herein, the term "BCMA" refers to differentiated plasma cells. BCMA, CD2, are members of the tumor necrosis receptor superfamily that are expressed in a controlled manner. Human B 69, also known as TNFRSF17 (UniProt Q02223) Regarding cell maturation antigens. An example human BCMA nucleotide sequence is from GenBank. Provided by session number BC058291. The human genome contains the BCMA gene. There are four main haplotypes, and in this disclosure, the term “BCMA” refers to all four. This means encompassing (Kawasaki et al., Genes Immun .2:276-9,2001). According to UniProt, extracellular domains of human BCMA The compound consists of amino acids 1 to 54 (or 5 to 51). When used in this specification, "BC The term "antibody against MA, i.e., anti-BCMA antibody" refers to an antibody that specifically binds to BCMA. Regarding antibodies.

[0133] As used herein, the term "DLL3" refers to an inhibitory Notch pathway ligand. It refers to a molecule found on cells that acts as a ligand. DLL3 is also known as "delta-like ligand 3". It is sometimes referred to as "DLL3". The term "DLL3" refers to cells (including tumor cells) that are affected by natural processes. It is expressed naturally, or it is transcoded by the gene or cDNA encoding its polypeptide. Any DLL3 variant, isoform, that can be expressed on infected cells. and species homologs are included. In certain embodiments, DLL3 is human DLL3. UniP According to ROT, the extracellular domain of human DLL3 consists of amino acids 27 to 492. As used herein, "antibody against DLL3," or "anti-DLL3 antibody," This term relates to antibodies that specifically bind to DLL3.

[0134] As used herein, the term "prostate-specific membrane antigen," or "PSMA," is used in this specification. The term refers to a type II membrane protein expressed on specific cells. In this specification, The term "PSMA" is used in HGNC:3788, Entrez Gene:2346, Ensembl:ENSG00000086205, OMIM:600934, and Un It contains a protein called iProtKB:Q04609. The term "PSMA" is used. , naturally expressed by cells (including prostate cells), or their polypeptides are coded Any gene or cDNA that can be expressed on cells transfected with the gene or cDNA. Includes PSMA variants, isoforms, and species homologs. In certain embodiments, PS MA is human PSMA. When used herein, "antibody against PSMA" is used. In short, the term "anti-PSMA antibody" refers to an antibody that specifically binds to PSMA.

[0135] When used herein, "KLK2" (Kallikrein-related peptidase 2) The term (also known as) refers to the grandular kallikrein protein. Refers to a member of the family. Kallikreins are clustered on chromosome 19. It is a subgroup of serine proteases that are converted into serine proteases. The members of this family are diverse. It is involved in a series of biological functions. This protein is primarily expressed in prostate tissue. It is involved in cleaving prostate-specific antigens into their enzymatically active form. HGNC:6363, Entrez Gene:3817, Ensembl:ENSG0 0000167751, OMIM:147960, and UniProtKB:P2015 Also known as 1. The term "KLK2" refers to a naturally occurring enzyme produced by cells (including tumor cells). It is expressed, or transferred by the gene or cDNA encoding its polypeptide. Any KLK2 variant, isoform, and species that can be expressed on the cells are Includes homologs. In certain embodiments, KLK2 is human KLK2. When used, the term "antibody against KLK2", i.e., "anti-KLK2 antibody", relates to an antibody that specifically binds to KL K2.

[0136] As used herein, an antibody that "specifically binds to Vβ17" binds to Vβ17 at a KD of 1 × 10 -7 M or less, for example, 1 × 10 M or less, 5 × 10 -8 M or less, 1 × 10 -9 M or less, 5 × 10 -9 M or less, 5 × 10 -10 M or less, or 1 × 10 -10 M or less, and preferably binds to human Vβ1 7.

[0137] As used herein, an antibody that "specifically binds to Vα10.2" binds to Vα10.2 at a KD of 1 × 10 -7 M or less, for example, 1 × 10 -8 M or less, 5 × 10 -9 M or less, 1 × 10 -9 M or less, 5 × 10 -10 M or less, or at 1 × 10 -10 M or less, and preferably binds to human Vα10.2.

[0138] As used herein, an antibody that "specifically binds to a second target antigen" binds to the second target antigen at a KD of 1 × 10 - 7 M or less, for example, 1 × 10 -8 M or less, 5 × 10 -9 M or less, 1 × 10 -9 M or less, 5 × 10 -10 M or less, or 1 × 10 -10 M or less and refers to an antibody that binds to the second target antigen.

[0139] As used herein, an antibody that "specifically binds to CD123" binds to CD123 at 1 × 10[[ID=7I]] -7 M Preferably, 1 × 10 -8 M or less, more preferably 5×10 -9 M or less, 1×1 0 -9 M or less, 5×10 -10 M or less, or 1 × 10 -10 For KD below M, CD123 Preferably, this refers to an antibody that binds to human CD123.

[0140] When used herein, an antibody that "specifically binds to BCMA" is defined as 1 × 10⁶ antibodies. -7 More than M Below, preferably 1 × 10 -8 M or less, more preferably 5×10 -9 M or less, 1×10 -9 M or less, 5×10 -10 M or less, or 1 × 10 -10 KD below M, BCMA, for example For example, it refers to antibodies that bind to human BCMA.

[0141] When used herein, an antibody that "specifically binds to DLL3" is defined as 1 × 10⁶ antibodies. -7 More than M Below, preferably 1 × 10 -8 M or less, more preferably 5×10 -9 M or less, 1×10 -9 M or less, 5×10 -10 M or less, or 1 × 10 -10 For KDs below M, DLL3, for example For example, it refers to antibodies that bind to human DLL3.

[0142] When used herein, an antibody that "specifically binds to PSMA" is defined as 1 × 10⁶ antibodies. -7 More than M Below, preferably 1 × 10 -8 M or less, more preferably 5×10 -9 M or less, 1×10 -9 M or less, 5×10 -10 M or less, or 1 × 10 -10 KD of M or less, PSMA, for example For example, it refers to antibodies that bind to human PSMA.

[0143] When used herein, an antibody that "specifically binds to KLK2" is defined as 1 × 10⁶ antibodies. -7 More than M Below, preferably 1 × 10 -8 M or less, more preferably 5×10 -9 M or less, 1×10 -9 M or less, 5×10 -10 M or less, or 1 × 10 -10 KD below M, KLK2, for example For example, it refers to antibodies that bind to human KLK2.

[0144] When used herein, the antigen-binding domain that "specifically binds to tumor-associated antigens" or Antigen-binding fragments are less than 1 × 10⁷ M, for example, less than 1 × 10⁸ M, or 5 × 10⁹ M. Below, for KDs of 1 × 10⁹M or less, 5 × 10¹M or less, or 1 × 10¹M or less, tumors This refers to an antigen-binding domain or antigen-binding fragment that binds to the relevant antigen.

[0145] The term "KD" is derived from the ratio of Kd to Ka (i.e., Kd / Ka). This refers to the dissociation constant expressed as molar concentration (M). The KD value of the antibody is determined in consideration of this disclosure. It can be determined using methods in the technical field. For example, the KD of an antibody is determined by the surface plastic By using Zumon resonance, for example, the Biacore® system, etc. By using the biosensor system or the Octet RED96 system This can be determined by using biolayer interferometry techniques such as Cut.

[0146] The lower the KD value of an antibody, the higher its affinity for binding to the target antigen.

[0147] In a particular embodiment, the present invention comprises (a) a first heavy chain (HC1), and (b) a second heavy chain (H (c) a first light chain (LC1), and (d) a second light chain (LC2), including isolation This relates to a Vβ17 bispecific antibody or its antigen-binding fragment. HC1 is LC HC1 may be related to sequence number 1, and HC2 may be related to LC2. HC1 is related to sequence number 1, sequence Heavy chain complementarity determination region 1 (HCDR1), containing the amino acid sequences of number 2 and sequence number 3, H CDR2 and HCDR3 may be included, and LC1 may be sequence number 4, sequence number 5, and The light chain complementarity determination region 1 (LCDR1), LCDR2, which contains the amino acid sequence of sequence number 6, and may include LCDR3.

[0148] In one embodiment, an antibody that binds to Vβ17 is provided herein. In several embodiments The antibody includes a heavy chain variable region and a light chain variable region. In some embodiments, Vβ17 The antibody is not a single-domain antibody or a nanobody. In some embodiments, Vβ17 The antibody is a humanized antibody.

[0149] In certain embodiments, the VH region of any one of the antibodies described herein , VL area, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL Anti-Vβ17 antibodies comprising CDR2 and / or VL CDR3 are provided herein. In some embodiments, the VH region of any one of the antibodies described herein Anti-Vβ17 antibodies, including those described herein, are provided herein. In some embodiments, This specification provides for anti-Vβ17 antibodies containing any one of the VL regions of the antibodies described. In some embodiments, one of the antibodies described herein is used. Anti-Vβ comprising an H region and a VL region of any one of the antibodies described herein. 17 antibodies are provided herein. In some embodiments, the antibodies described herein are used. Includes any one of VH CDR1, VH CDR2, and VH CDR3, Anti-Vβ17 antibodies are provided herein. In some embodiments, as described herein One of the antibodies VL CDR1, VL CDR2, and VL CDR3 Anti-Vβ17 antibodies, including those described herein, are provided herein. In some embodiments, One of the antibodies listed is VH CDR1, VH CDR2, or VH CD R3 and one of the antibodies described herein, VL CDR1, VL CD Anti-Vβ17 antibodies comprising R2 and VL CDR3 are provided herein. The Vβ17 antibodies provided are VH CDR1, VH CDR2, VH CDR3, and VL Representative VH and CDR1, VL CDR2, and VL CDR3 amino acid sequences The VL amino acid sequences are provided in the sequence listing and in Tables 1-21.

[0150] In certain embodiments, the VH region of any one of the antibodies described herein , VL area, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL Includes a binding domain that binds to Vβ17 having CDR2 and / or VL CDR3. In some embodiments, a bispecific anti-Vβ17 antibody is provided herein. A conjugate that binds to Vβ17 having one of the VH regions among the antibodies described in the book. Several embodiments of anti-Vβ17 bispecific antibodies, including the main antibody, are provided herein. Therefore, if Vβ17 has any one of the VL regions of the antibodies described herein, This specification provides for anti-Vβ17 bispecific antibodies containing binding domains. In that embodiment, the VH region of any one of the antibodies described herein and the present invention A antibody that binds to Vβ17 having one of the VL regions of the antibodies described in the document. Several embodiments are provided herein of anti-Vβ17 bispecific antibodies containing a synthetic domain. Morphologically, one of the antibodies described is VH CDR1, VH CDR2, and Anti-Vβ17 bispecific, containing a binding domain that binds to Vβ17 having VH CDR3 Sex antibodies are provided herein. In some embodiments, the antibodies described herein A V with any one of VL CDR1, VL CDR2, and VL CDR3 A bispecific anti-Vβ17 antibody containing a binding domain that binds to β17 is provided herein. In some embodiments, one of the antibodies described herein is used. CDR1, VH CDR2, and VH CDR3, and any of the antibodies described herein or connected to Vβ17 having one VL CDR1, VL CDR2, and VL CDR3. An anti-Vβ17 bispecific antibody containing a binding domain is provided herein. The Vβ17 antibody is provided in the sequence listing, as well as in the drawings and the table in the section of these examples. The first exemplary binding domain to be bound is shown in the sequence listing, as well as in the drawings and the section table of this embodiment. To be served.

[0151] In certain embodiments, the anti-Vβ17 antibody is a bispecific antibody. In terms of form, the anti-Vβ17 bispecific antibody is a VH of the anti-CD123 antibody provided herein. area, VL area, VH CDR1, VH CDR2, VH CDR3, VL CDR1, A second coupling that binds to CD123 having VL CDR2 and / or VL CDR3. The domain further comprises. In some embodiments, the anti-Vβ17 bispecific antibody is described herein. A second binding agent that binds to CD123 having the VH region of the anti-CD123 antibody provided to [the organization] The main component is further included. In some embodiments, an anti-Vβ17 bispecific antibody is used herein. A second binding domain that binds to CD123 having the VL region of the provided anti-CD123 antibody It further includes [a specific antibody]. In some embodiments, an anti-Vβ17 bispecific antibody is provided herein. The VH region of the anti-CD123 antibody provided and the VL region of the anti-CD123 antibody provided herein. It further includes a second binding domain that binds to CD123 having a region. In terms of form, the anti-Vβ17 bispecific antibody is a VH of the anti-CD123 antibody provided herein. A second CD123 is coupled to CD123 which has CDR1, VH CDR2, and VH CDR3. It further includes a binding domain. In some embodiments, the anti-Vβ17 bispecific antibody is The anti-CD123 antibodies provided in the specification are VL CDR1, VL CDR2, and VL C It further includes a second binding domain that binds to CD123 having DR3. Several implementations In terms of form, the anti-Vβ17 bispecific antibody is a VH of the anti-CD123 antibody provided herein. CDR1, VH CDR2, and VH CDR3, and anti-CD12 provided herein CD123 containing three antibodies, VL CDR1, VL CDR2, and VL CDR3 It further includes a second binding domain. An example CD123 antibody is shown in the sequence listing, as well as An exemplary second coupling that couples with CD123 is provided in the drawings and the table in the section of this embodiment. The main information is provided in the sequence list, as well as in the drawings and the table in the section of this embodiment.

[0152] In certain embodiments, the anti-Vβ17 antibody is a bispecific antibody. Morphologically, the anti-Vβ17 bispecific antibody is the VH region of the anti-BCMA antibody provided herein. area, VL area, VH CDR1, VH CDR2, VH CDR3, VL CDR1, V A second binding domain that binds to BCMA having L CDR2 and / or VL CDR3 It further includes [a specific antibody]. In some embodiments, an anti-Vβ17 bispecific antibody is provided herein. The second binding domain of the provided anti-BCMA antibody binds to BCMA having the VH region. Furthermore, it includes. In some embodiments, anti-Vβ17 bispecific antibodies are provided herein. It further contains a second binding domain that binds to BCMA having the VL region of the anti-BCMA antibody. In some embodiments, the anti-Vβ17 bispecific antibody is an anti-B antibody provided herein. B has the VH region of a CMA antibody and the VL region of an anti-BCMA antibody provided herein. It further includes a second binding domain that binds to CMA. In some embodiments, it is anti-Vβ1 7. The bispecific antibodies are VH CDR1 and VH C, anti-BCMA antibodies provided herein. It further includes a second binding domain that binds to BCMA having DR2 and VH CDR3. In some embodiments, the anti-Vβ17 bispecific antibody is an anti-B antibody provided herein. BCMA containing CMA antibodies VL CDR1, VL CDR2, and VL CDR3 It further includes a second binding domain that binds. In some embodiments, the anti-Vβ17 dual feature The heterozygous antibodies are VH CDR1, VH CDR2, and other anti-BCMA antibodies provided herein. and VH CDR3 and the anti-BCMA antibodies VL CDR1 and VL CDR1 provided herein. A second binding domain that binds to BCMA having CDR2 and VL CDR3 is further It is included in the following. Exemplary BCMA antibodies are provided in the sequence listing, as well as in the drawings and the table in the section of these embodiments. An exemplary second binding domain that binds to BCMA is shown in the sequence listing, as well as in the drawings and this. This is provided in the table in the Examples section.

[0153] In certain embodiments, the anti-Vβ17 antibody is a bispecific antibody. Morphologically, the anti-Vβ17 bispecific antibody is the VH region of the anti-DLL3 antibody provided herein. area, VL area, VH CDR1, VH CDR2, VH CDR3, VL CDR1, V A second binding domain that binds to DLL3 having L CDR2 and / or VL CDR3 It further includes [a specific antibody]. In some embodiments, an anti-Vβ17 bispecific antibody is provided herein. The second binding domain of the provided anti-DLL3 antibody binds to DLL3 having the VH region. Furthermore, it includes. In some embodiments, anti-Vβ17 bispecific antibodies are provided herein. The anti-DLL3 antibody further comprises a second binding domain that binds to DLL3 having the VL region. In some embodiments, the anti-Vβ17 bispecific antibody is an anti-D antibody provided herein. D having the VH region of the LL3 antibody and the VL region of the anti-DLL3 antibody provided herein. It further includes a second binding domain that binds to LL3. In some embodiments, it is anti-Vβ1 7. The bispecific antibodies are VH CDR1 and VH C of the anti-DLL3 antibodies provided herein. It further includes a second binding domain that binds to DLL3 having DR2 and VH CDR3. In some embodiments, the anti-Vβ17 bispecific antibody is an anti-D antibody provided herein. DLL3 containing LL3 antibodies VL CDR1, VL CDR2, and VL CDR3 It further includes a second binding domain that binds. In some embodiments, the anti-Vβ17 dual feature The isogender antibodies are VH CDR1, VH CDR2, and other anti-DLL3 antibodies provided herein. and VH CDR3 and the anti-DLL3 antibodies VL CDR1 and VL CDR1 provided herein. A second binding domain is further added to DLL3 which has CDR2 and VL CDR3. It is included in the following. An exemplary DLL3 antibody is provided in the sequence listing, as well as in the drawings and the table in the section of this embodiment. An exemplary second binding domain that binds to DLL3 is shown in the sequence listing, as well as in the drawings and this. This is provided in the table in the Examples section.

[0154] In certain embodiments, the anti-Vβ17 antibody is a bispecific antibody. Morphologically, the anti-Vβ17 bispecific antibody is the VH region of the anti-PSMA antibody provided herein. area, VL area, VH CDR1, VH CDR2, VH CDR3, VL CDR1, V A second binding domain that binds to PSMA having L CDR2 and / or VL CDR3 It further includes [a specific antibody]. In some embodiments, an anti-Vβ17 bispecific antibody is provided herein. The second binding domain of the provided anti-PSMA antibody binds to PSMA having the VH region. Furthermore, it includes. In some embodiments, anti-Vβ17 bispecific antibodies are provided herein. The anti-PSMA antibody further comprises a second binding domain that binds to PSMA having the VL region. In some embodiments, the anti-Vβ17 bispecific antibody is an anti-P antibody provided herein. P has the VH region of an SMA antibody and the VL region of an anti-PSMA antibody provided herein. It further comprises a second binding domain that binds to the SMA. In some embodiments, it is anti-Vβ1 7. The bispecific antibodies are VH CDR1 and VH C, anti-PSMA antibodies provided herein. It further includes a second binding domain that binds to PSMA having DR2 and VH CDR3. In some embodiments, the anti-Vβ17 bispecific antibody is an anti-P antibody provided herein. PSMA containing SMA antibodies VL CDR1, VL CDR2, and VL CDR3 It further includes a second binding domain that binds. In some embodiments, the anti-Vβ17 dual feature The heterozygous antibodies are VH CDR1, VH CDR2, and other anti-PSMA antibodies provided herein. and VH CDR3 and the anti-PSMA antibodies VL CDR1 and VL CDR1 provided herein. A second binding domain that binds to PSMA having CDR2 and VL CDR3 is further It is included in the following. Exemplary PSMA antibodies are provided in the sequence listing, as well as in the drawings and the table in the section of these embodiments. An exemplary second binding domain that binds to PSMA is shown in the sequence listing, as well as in the drawings and this. This is provided in the table in the Examples section.

[0155] In certain embodiments, the anti-Vβ17 antibody is a bispecific antibody. Morphologically, the anti-Vβ17 bispecific antibody is the VH region of the anti-KLK2 antibody provided herein. area, VL area, VH CDR1, VH CDR2, VH CDR3, VL CDR1, V A second binding domain that binds to KLK2 having L CDR2 and / or VL CDR3 It further includes [a specific antibody]. In some embodiments, an anti-Vβ17 bispecific antibody is provided herein. A second binding domain that binds to KLK2 having the VH region of the provided anti-KLK2 antibody Furthermore, it includes. In some embodiments, anti-Vβ17 bispecific antibodies are provided herein. It further includes a second binding domain that binds to KLK2 having the VL region of the anti-KLK2 antibody. In some embodiments, the anti-Vβ17 bispecific antibody is the anti-K antibody provided herein. The K has a VH region of an LK2 antibody and a VL region of an anti-KLK2 antibody provided herein. It further includes a second binding domain that binds to LK2. In some embodiments, it is anti-Vβ1 7. The bispecific antibodies are VH CDR1 and VH C of the anti-KLK2 antibodies provided herein. It further includes a second binding domain that binds to KLK2 having DR2 and VH CDR3. In some embodiments, the anti-Vβ17 bispecific antibody is the anti-K antibody provided herein. KLK2 antibodies possessing VL CDR1, VL CDR2, and VL CDR3 It further includes a second binding domain that binds. In some embodiments, the anti-Vβ17 dual feature The isogender antibodies are VH CDR1, VH CDR2, and other anti-KLK2 antibodies provided herein. and VH CDR3 and the anti-KLK2 antibodies VL CDR1 and VL CDR1 provided herein. A second binding domain that binds to KLK2 having CDR2 and VL CDR3 is further It is included in the following. Exemplary KLK2 antibodies are provided in the sequence listing, as well as in the drawings and the table in the section of this embodiment. An exemplary second binding domain that binds to KLK2 is shown in the sequence listing, as well as in the drawings and this. This is provided in the table in the Examples section.

[0156] In one particular embodiment, an intact antibody, an anti-Vβ17 antibody, is provided. In the embodiment, an anti-Vβ17 antibody is provided, and further, an antigen-binding fragment of the anti-Vβ17 antibody is provided. A is provided. In some embodiments, the antigen-binding fragment of the anti-Vβ17 antibody is It is a functional fragment. In some embodiments, the antigen-binding fragment is a diamond It is the body. In some embodiments, the antigen-binding fragment is the Fab. In some embodiments, the antigen-binding fragment is Fab'. The antigen-binding fragment is F(ab')2. In some embodiments, the antigen-binding fragment is F(ab')2. The binding fragment is the Fv fragment. In some embodiments, the antigen-binding fragment The ment is a disulfide-stabilized Fv fragment (dsFv). Several implementations In this state, the antigen-binding fragment is (dsFv)2. In some embodiments, the antigen The original binding fragment has a bispecificity dsFv(dsFv-dsFv'). In this embodiment, the antigen-binding fragment is a disulfide-stabilized diabody (ds die). Abody) In some embodiments, the antigen-binding fragment is a single-chain antibody molecule ( (scFv) In some embodiments, the antigen-binding fragment is a single-domain anti It is a (sdAb) body. In some embodiments, the antigen-binding fragment is scFv2 It is a mer (divalent diabody). In some embodiments, the antigen-binding fragment is It is a multispecific antibody formed from a portion of an antibody containing one or more CDRs. In some embodiments, the antigen-binding fragment is a camelized single-domain antibody. In some embodiments, the antigen-binding fragment is a nanobody. In this state, the antigen-binding fragment is a domain antibody. In some embodiments, the antigen The binding fragment is a bivalent domain antibody. In some embodiments, the antigen-binding fragment A ligment is an antibody fragment that binds to an antigen but does not contain a complete antibody structure.

[0157] In certain embodiments, the anti-Vβ17 antibody includes a VH region and a VL region.

[0158] In some embodiments, the anti-Vβ17 antibody is a single-chain antibody. In some embodiments, anti-Vβ17 antibodies are single-domain antibodies. Antibodies are nanobodies. In certain embodiments, the anti-Vβ17 antibody is a VHH antibody. Yes. In certain embodiments, the anti-Vβ17 antibody is a llama antibody. Several embodiments In this configuration, the anti-Vβ17 bispecific antibody contains a single-chain antibody. In some embodiments, the anti-Vβ17 β17 bispecific antibodies include single-domain antibodies. In certain embodiments, anti-Vβ1 7. The bispecific antibody contains nanobodies. In certain embodiments, the anti-Vβ17 bispecific antibody The heterozygous antibodies include VHH antibodies. In certain embodiments, the anti-Vβ17 bispecific antibody is It contains a llama antibody. In some embodiments, the anti-Vβ17 antibody is not a single-chain antibody. In some embodiments, the anti-Vβ17 antibody is not a single-domain antibody. Morphologically, anti-Vβ17 antibodies are not nanobodies. In certain embodiments, anti-Vβ1 Antibody 7 is not a VHH antibody. In certain embodiments, the anti-Vβ17 antibody is a llama antibody. No. In some embodiments, the anti-Vβ17 bispecific antibody does not contain a single-chain antibody. In some embodiments, the anti-Vβ17 bispecific antibody does not contain a single-domain antibody. In certain embodiments, the anti-Vβ17 bispecific antibody does not contain nanobodies. In certain embodiments, the anti-Vβ17 bispecific antibody does not contain the VHH antibody. In this embodiment, the anti-Vβ17 bispecific antibody does not contain the llama antibody.

[0159] In some embodiments, the anti-Vβ17 antibody is a multispecific antibody. In other embodiments, In this particular embodiment, anti-Vβ17 is a bispecific antibody. , comprising an antigen-binding fragment of an anti-Vβ17 antibody provided herein. In other embodiments, The bispecific antibody is the antigen-binding fragment of the anti-Vβ17 antibody provided herein. Includes. In some embodiments, the anti-Vβ17 antibody is an agonist antibody. In one embodiment, the anti-Vβ17 antibody activates T cells. In another embodiment, the anti-Vβ17 The antibody is an antagonist antibody. In a particular embodiment, the anti-Vβ17 antibody is a T cell. The cells are deactivated. In some embodiments, the anti-Vβ17 antibody blocks T cell activation. In some embodiments, anti-Vβ17 antibodies modulate T cell activity. In this embodiment, the anti-Vβ17 antibody can either activate or deactivate T cells. No. In certain embodiments, the T cells are human T cells. In certain embodiments, the knob The Vβ17 antibody provided herein in knob-in-hole form is bispecific. Sex antibodies are provided. In some embodiments, the anti-Vβ17 antibodies provided herein are , may be included in bispecific antibodies. In some embodiments, the antibodies provided herein The Vβ17 bispecific antibody may be included in the multispecific antibody. In a particular embodiment, The bispecific antibodies provided herein bind to the first Vβ17 epitope. The first binding domain contains an anti-Vβ17 antibody provided in the book, and the second Vβ17 epitope It comprises a second binding domain containing an anti-Vβ17 antibody provided herein that binds to the second, Vβ17 epitope 1 and Vβ17 epitope 2 are not the same. Specific implementation In this context, the Vβ17 antibody or its antigen-binding fragment provided herein is Vβ1 It specifically binds to 7. In certain embodiments, the Vβ17 antibody provided herein or The antigen-binding fragment does not bind to the Vβ17 epitope.

[0160] In some embodiments, VH CDR1, VH CDR2, VH CDR3, VL The CDR1, VL CDR2, and VL CDR3 sequences follow the Kabat numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR3, VL The CDR1, VL CDR2, and VL CDR3 sequences are assigned to the Chothia numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR3, V The L CDR1, VL CDR2, and VL CDR3 sequences follow an exemplary numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR3, VL The CDR1, VL CDR2, and VL CDR3 sequences are assigned by the Contact numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR3, The VL CDR1, VL CDR2, and VL CDR3 sequences are assigned to the IMGT numbering system. In some embodiments, VH CDR1, VH CDR2, VH CDR3, V The L CDR1, VL CDR2, and VL CDR3 sequences follow the AbM numbering system. . Six CDRs (VH CDR1-3 and VL CDR1-3) of a specific antibody embodiment An exemplary set is provided herein. Other CDR sets are also intended and provided herein. This is within the scope of the antibody embodiment.

[0161] In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 has the amino acid sequence of sequence number 1, and V has the amino acid sequence of sequence number 2. VH includes H CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 3, (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, amino acid sequence of SEQ ID NO: 5 Includes VL CDR2 having the amino acid sequence of SEQ ID NO: 6 and VL CDR3 having the amino acid sequence of SEQ ID NO: 6 , including VL. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the above antibody The body has (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 97, and the amino acid sequence of SEQ ID NO: 98. VH CDR2 having an amino acid sequence, and VH CD having the amino acid sequence of SEQ ID NO 99. VH containing R3, and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 100, VL CDR2 having the amino acid sequence of SEQ ID NO: 101, and the amino acid sequence of SEQ ID NO: 102 VL includes VL CDR3 having a sequence. In another embodiment, it binds to Vβ17. An antibody is provided herein, wherein the antibody has (i) the amino acid sequence of SEQ ID NO: 103 VH CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 104, and SEQ ID NO: VH containing VH CDR3 having an amino acid sequence of 105, and (ii) SEQ ID NO: 106 VL CDR1 has the amino acid sequence of SEQ ID NO: 107, VL VL includes CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 108. Includes. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody is (i ) VH CDR1 having the amino acid sequence of SEQ ID NO: 109, and the amino acid sequence of SEQ ID NO: 110 VH CDR2 having a column, and VH CDR3 having the amino acid sequence of SEQ ID NO: 111 (ii) VH and VL CDR1 having the amino acid sequence of SEQ ID NO: 112, sequence VL CDR2 having amino acid sequence number 113, and amino acid sequence of sequence number 114 VL comprises VL CDR3 having VL. In another embodiment, an antibody that binds to Vβ17. The above antibody is provided herein, and the above antibody has (i) the amino acid sequence of SEQ ID NO: 115 VH CDR2 having the amino acid sequence of CDR1, SEQ ID NO: 116, and SEQ ID NO: 11 VH containing VH CDR3 having amino acid sequence 7, and (ii) the a of sequence number 118 VL CDR1 has a amino acid sequence, and VL CD has the amino acid sequence of SEQ ID NO: 119. VL includes VL CDR3 having the amino acid sequence of R2 and SEQ ID NO: 120. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 having the amino acid sequence of sequence number 121, and the amino acid sequence of sequence number 122 It contains VH CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 123. (ii) VH and VL CDR1 having the amino acid sequence of SEQ ID NO: 124, SEQ ID NO: VL CDR2 has an amino acid sequence of 125, and has an amino acid sequence of SEQ ID NO: 126 In another embodiment, an antibody that binds to Vβ17 is included. Provided in the specification, the above antibody is (i) VH C having the amino acid sequence of SEQ ID NO: 127 VH CDR2 having the amino acid sequence of DR1, SEQ ID NO: 128, and SEQ ID NO: 129 VH containing VH CDR3 having an amino acid sequence, and (ii) the amino acid of SEQ ID NO: 130 VL CDR1 has an acid sequence, and VL CDR2 has the amino acid sequence of SEQ ID NO: 131. VL includes VL CDR3 having the amino acid sequence of SEQ ID NO: 132. In this embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody is (i) sequence number VH CDR1 has the amino acid sequence of sequence number 133, and has the amino acid sequence of sequence number 134. VH CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 135 are included. VH and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 136, SEQ ID NO: 13 VL CDR2 has the amino acid sequence of 7, and has the amino acid sequence of SEQ ID NO: 138 VL CDR3 is included, and VL is included. In another embodiment, an antibody that binds to Vβ17 is included in this specification. Provided in the document, the above antibodies are VH CDR1 and VH CDR2, respectively, of SEQ ID NO: 25. , and VH CDR1, VH CDR2, and which have the amino acid sequence of VH CDR3. VH containing VH CDR3. In another embodiment, an antibody that binds to Vβ17 is specified herein. The antibodies provided are VL CDR1 and VL CDR2 of SEQ ID NO: 26, respectively. VL CDR1, VL CDR2, and V have the amino acid sequence of VL CDR3. The VL contains L CDR3. In another embodiment, an antibody that binds to Vβ17 is provided herein. The antibodies provided are VH CDR1, VH CDR2, and VH CDR1 of SEQ ID NO: 7, respectively. VH CDR1, VH CDR2, and VH C have the amino acid sequence H CDR3. Contains VH including DR3. In another embodiment, an antibody that binds to Vβ17 is provided herein. The antibodies mentioned above are VL CDR1, VL CDR2, and VL C, respectively, of Sequence ID No. 8. VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence of DR3. Includes VL containing. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the above The antibodies are VH CDR1, VH CDR2, and VH CDR3, respectively, as shown in SEQ ID NO: 9. VH CDR1, VH CDR2, and VH CDR3 have the following amino acid sequence Contains VH. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody is The VL CDR1, VL CDR2, and VL CDR3 of sequence number 10, respectively. VL containing VL CDR1, VL CDR2, and VL CDR3 having a mino acid sequence This includes. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the antibody is ( i) VH CDR1, VH CDR2, and VH CDR3 of Sequence ID 25, respectively. Includes VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence, VH and (ii) Sequence ID 26, VL CDR1, VL CDR2, and V VL CDR1, VL CDR2, and VL CD have the amino acid sequence L CDR3. In another embodiment, an antibody that binds to Vβ17 is provided herein. The above antibodies are (i) VH CDR1, VH CDR2, and (i) of Sequence ID No. 7. VH CDR1, VH CDR2, and VH CDR3 have the amino acid sequence of VH CDR3. VH, including CDR3, and (ii) VL CDR1 and VL C, respectively, of sequence number 8. VL CDR1, VL CDR2, which have the amino acid sequences of DR2 and VL CDR3, and VL CDR3, and VL. In another embodiment, an antibody that binds to Vβ17 is Provided in the specification, the above antibodies are (i) VH CDR1 and VH CDR1 of SEQ ID NO: 9, respectively. VH CDR1 and VH CDR3 have amino acid sequences of CDR2 and VH CDR3. 2, and VH including VH CDR3, and (ii) VL C of Sequence ID No. 10, respectively VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3, VL includes VL CDR2 and VL CDR3. In some embodiments, The antibody contains VH having the amino acid sequence of SEQ ID NO: 25. In some embodiments, the anti The body contains VL having the amino acid sequence of SEQ ID NO: 26. In some embodiments, the antibody This includes VH having the amino acid sequence of SEQ ID NO: 25 and having the amino acid sequence of SEQ ID NO: 26 VL is included. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 7. The chain is included. In some embodiments, the antibody has a light chain having the amino acid sequence of SEQ ID NO: 8. Includes. In some embodiments, the antibody has a heavy chain having the amino acid sequence of SEQ ID NO: 7 and a It includes a light chain having the amino acid sequence of column number 8. In some embodiments, the antibody has the sequence It contains a heavy chain having amino acid sequence number 9. In some embodiments, the antibody is sequence number 9. It contains a light chain having a sequence of 10 amino acids. In some embodiments, the antibody is sequence number 9 It comprises a heavy chain having the amino acid sequence of [specified sequence] and a light chain having the amino acid sequence of SEQ ID NO: 10. In some embodiments, the antibody has little identity with respect to the amino acid sequence of SEQ ID NO: 25. It also contains VH having 95% of the amino acid sequence. In some embodiments, the antibody is sequence number VL having an amino acid sequence that is at least 95% identical to the amino acid sequence of No. 26 Includes. In some embodiments, the antibody has identity with respect to the amino acid sequence of SEQ ID NO: 25. VH having at least 95% of the amino acid sequence and relative to the amino acid sequence of SEQ ID NO: 26 It includes a VL having at least 95% identity in its amino acid sequence. In some embodiments, The antibody has at least 95% amino acid sequence identity with respect to the amino acid sequence of SEQ ID NO: 7. It contains a heavy chain having a column. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 8 The corresponding light chain has at least 95% of the amino acid sequence. Several implementations In this state, the antibody has at least 95% identity with the amino acid sequence of SEQ ID NO: 7. A heavy chain having an acid sequence and having at least 95% identity with the amino acid sequence of SEQ ID NO: 8 It includes a light chain having an amino acid sequence. In some embodiments, the antibody is the A of SEQ ID NO: 9 It contains a heavy chain having an amino acid sequence with at least 95% identity to the amino acid sequence. In several embodiments, the antibody has at least the same amino acid sequence as SEQ ID NO: 10. It contains a light chain having 95% of the amino acid sequence. In some embodiments, the antibody is SEQ ID NO: A heavy chain having an amino acid sequence with at least 95% identity to the 9 amino acid sequence, and The amino acid sequence of column number 10 has at least 95% identity with the amino acid sequence of the light Includes chains.

[0162] In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 has the amino acid sequence of sequence number 1, and V has the amino acid sequence of sequence number 2. VH includes H CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 3, (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, amino acid sequence of SEQ ID NO: 5 Includes VL CDR2 having the amino acid sequence of SEQ ID NO: 6 and VL CDR3 having the amino acid sequence of SEQ ID NO: 6 , including VL. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the above antibody The body has (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 139, SEQ ID NO: 140 VH CDR2 having an amino acid sequence, and VH having the amino acid sequence of SEQ ID NO: 141 (ii) VH containing CDR3 and VL CD having the amino acid sequence of SEQ ID NO: 142 R1, VL CDR2 having the amino acid sequence of SEQ ID NO: 143, and A VL includes VL CDR3 having a mino acid sequence. In another embodiment, it is linked to Vβ17. A matching antibody is provided herein, wherein the antibody (i) has the amino acid sequence of SEQ ID NO: 145 VH CDR1 has the amino acid sequence of SEQ ID NO: 146, and VH CDR2 has the amino acid sequence of SEQ ID NO: 146, and VH containing VH CDR3 having the amino acid sequence of sequence number 147, and (ii) Sequence ID VL CDR1 has a 148-amino acid sequence, and has the amino acid sequence of SEQ ID NO: 149. VL CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 150 are included. Includes L. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody is (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 151, and the amino acid sequence of SEQ ID NO: 152 VH CDR2 has an amino acid sequence, and VH C has the amino acid sequence of SEQ ID NO 153. VH containing DR3 and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 154 VL CDR2 having the amino acid sequence of SEQ ID NO: 155, and amino acid sequence of SEQ ID NO: 156 VL contains VL CDR3 having an acid sequence. In another embodiment, it is bound to Vβ17. An antibody is provided herein, wherein the antibody has (i) the amino acid sequence of SEQ ID NO: 157 VH CDR1, VH CDR2 having the amino acid sequence of sequence number 158, and sequence number VH containing VH CDR3 having amino acid sequence number 159, and (ii) SEQ ID NO: 16 VL CDR1 has the amino acid sequence 0, and VL has the amino acid sequence of SEQ ID NO: 161. VL and VL CDR3 having the amino acid sequence of CDR2 and SEQ ID NO: 162 This includes. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the antibody is ( i) VH CDR1 having the amino acid sequence of SEQ ID NO: 163, amino acids of SEQ ID NO: 164 VH CDR2 having the sequence, and VH CDR having the amino acid sequence of SEQ ID NO: 165 (ii) VH containing 3, and VL CDR1 having the amino acid sequence of SEQ ID NO: 166, VL CDR2 having the amino acid sequence of sequence number 167, and the amino acid sequence of sequence number 168 VL includes VL CDR3 having a column. In another embodiment, an antibody that binds to Vβ17. The body is provided herein, and the above antibody is (i) V having the amino acid sequence of SEQ ID NO: 169 H CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 170, and SEQ ID NO: 1 VH containing VH CDR3 having a 71-amino acid sequence, and (ii) SEQ ID NO: 172 VL CDR1 has an amino acid sequence, and VL C has an amino acid sequence of SEQ ID NO: 173. VL contains DR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 174. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 175, amino acid sequence of SEQ ID NO: 176 VH CDR2 having the amino acid sequence of SEQ ID NO: 177, and VH CDR3 having the amino acid sequence of SEQ ID NO: 177 (ii) VH and VL CDR1 having the amino acid sequence of sequence number 178, sequence number VL CDR2 having the amino acid sequence of number 179, and the amino acid sequence of sequence number 180 The VL comprises VL containing VL CDR3. In another embodiment, the antibody that binds to Vβ17 is The antibodies provided herein are VH CDR1 and VH C, respectively, of SEQ ID NO: 19. VH CDR1 and VH CDR2 have the amino acid sequences of DR2 and VH CDR3. , and VH including VH CDR3. In another embodiment, an antibody that binds to Vβ17 is included. Provided in the specification, the antibodies mentioned above are VL CDR1 and VL CD of SEQ ID NO: 22, respectively. VL CDR1, VL CDR2, having the amino acid sequences of R2 and VL CDR3, and VL containing VL CDR3. In another embodiment, an antibody that binds to Vβ17 is present. Provided in the details, the above antibodies are (i) VH CDR1 and VH CDR1 of SEQ ID NO: 19, respectively. VH CDR1 and VH CDR3 have amino acid sequences of CDR2 and VH CDR3. 2, and VH including VH CDR3, and (ii) VL C of Sequence ID No. 22, respectively VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3, VL includes VL CDR2 and VL CDR3. In some embodiments, The antibody contains VH having the amino acid sequence of SEQ ID NO: 19. In some embodiments, the anti The body contains VL having the amino acid sequence of SEQ ID NO: 22. In some embodiments, the antibody VH has the amino acid sequence of SEQ ID NO: 19 and has the amino acid sequence of SEQ ID NO: 22 VL is included. In some embodiments, the antibody is against the amino acid sequence of SEQ ID NO: 19 It includes a VH having at least 95% identity in its amino acid sequence. In some embodiments, The antibody has at least 95% amino acid sequence identity with respect to the amino acid sequence of SEQ ID NO: 22. It includes a VL having a column. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 19 VH has an amino acid sequence that is at least 95% identical to the one in sequence number 22, and the amino acid sequence of sequence number 22. It includes a VL having an amino acid sequence that is at least 95% identical to the no-acid sequence.

[0163] In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 has the amino acid sequence of sequence number 1, and V has the amino acid sequence of sequence number 2. VH includes H CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 3, (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, amino acid sequence of SEQ ID NO: 5 Includes VL CDR2 having the amino acid sequence of SEQ ID NO: 6 and VL CDR3 having the amino acid sequence of SEQ ID NO: 6 , including VL. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the above antibody The body has (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 139, SEQ ID NO: 140 VH CDR2 having an amino acid sequence, and VH having the amino acid sequence of SEQ ID NO: 141 (ii) VH containing CDR3 and VL CD having the amino acid sequence of SEQ ID NO: 184 R1, VL CDR2 having the amino acid sequence of SEQ ID NO: 185, and A VL includes VL CDR3 having a mino acid sequence. In another embodiment, it is linked to Vβ17. A matching antibody is provided herein, wherein the antibody (i) has the amino acid sequence of SEQ ID NO: 145 VH CDR1 has the amino acid sequence of SEQ ID NO: 146, and VH CDR2 has the amino acid sequence of SEQ ID NO: 146, and VH containing VH CDR3 having the amino acid sequence of sequence number 147, and (ii) Sequence ID VL CDR1 has an amino acid sequence of 190, and has the amino acid sequence of SEQ ID NO: 191. VL CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 192 are included. Includes L. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody is (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 151, and the amino acid sequence of SEQ ID NO: 152 VH CDR2 has an amino acid sequence, and VH C has the amino acid sequence of SEQ ID NO 153. VH containing DR3 and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 196 VL CDR2 having the amino acid sequence of SEQ ID NO: 197, and amino acid sequence of SEQ ID NO: 198 VL contains VL CDR3 having an acid sequence. In another embodiment, it is bound to Vβ17. An antibody is provided herein, wherein the antibody has (i) the amino acid sequence of SEQ ID NO: 157 VH CDR1, VH CDR2 having the amino acid sequence of sequence number 158, and sequence number VH containing VH CDR3 having amino acid sequence 159, and (ii) SEQ ID NO: 20 VL CDR1 has the amino acid sequence of 2, and VL has the amino acid sequence of SEQ ID NO: 203. VL and VL CDR3 having the amino acid sequence of CDR2 and SEQ ID NO: 204 This includes. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the antibody is ( i) VH CDR1 having the amino acid sequence of SEQ ID NO: 163, amino acids of SEQ ID NO: 164 VH CDR2 having the sequence, and VH CDR having the amino acid sequence of SEQ ID NO: 165 (ii) VH containing 3, and VL CDR1 having the amino acid sequence of SEQ ID NO: 208, VL CDR2 having the amino acid sequence of sequence number 209, and the amino acid sequence of sequence number 210 VL includes VL CDR3 having a column. In another embodiment, an antibody that binds to Vβ17. The body is provided herein, and the above antibody is (i) V having the amino acid sequence of SEQ ID NO: 169 H CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 170, and SEQ ID NO: 1 VH containing VH CDR3 having a 71-amino acid sequence, and (ii) SEQ ID NO: 214 VL CDR1 has an amino acid sequence, and VL C has an amino acid sequence of SEQ ID NO: 215. VL contains DR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 216. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 175, amino acid sequence of SEQ ID NO: 176 VH CDR2 having the amino acid sequence of SEQ ID NO: 177, and VH CDR3 having the amino acid sequence of SEQ ID NO: 177 (ii) VH and VL CDR1 having the amino acid sequence of sequence number 220, sequence number VL CDR2 having the amino acid sequence of number 221, and the amino acid sequence of sequence number 222 The VL comprises VL containing VL CDR3. In another embodiment, the antibody that binds to Vβ17 is The antibodies provided herein are VH CDR1 and VH C, respectively, of SEQ ID NO: 19. VH CDR1 and VH CDR2 have the amino acid sequences of DR2 and VH CDR3. , and VH including VH CDR3. In another embodiment, an antibody that binds to Vβ17 is included. Provided in the specification, the antibodies mentioned above are VL CDR1 and VL CD, respectively, of SEQ ID NO: 23. VL CDR1, VL CDR2, having the amino acid sequences of R2 and VL CDR3, and VL containing VL CDR3. In another embodiment, an antibody that binds to Vβ17 is present. Provided in the details, the above antibodies are (i) VH CDR1 and VH CDR1 of SEQ ID NO: 19, respectively. VH CDR1 and VH CDR3 have amino acid sequences of CDR2 and VH CDR3. 2, and VH including VH CDR3, and (ii) VL C of Sequence ID No. 23, respectively VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3, VL includes VL CDR2 and VL CDR3. In some embodiments, The antibody contains VH having the amino acid sequence of SEQ ID NO: 19. In some embodiments, the anti The body contains VL having the amino acid sequence of SEQ ID NO: 23. In some embodiments, the antibody VH has the amino acid sequence of SEQ ID NO: 19 and has the amino acid sequence of SEQ ID NO: 23 VL is included. In some embodiments, the antibody is against the amino acid sequence of SEQ ID NO: 19 It includes a VH having at least 95% identity in its amino acid sequence. In some embodiments, The antibody has at least 95% amino acid sequence identity with respect to the amino acid sequence of SEQ ID NO: 23. It includes a VL having a column. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 19 VH has an amino acid sequence that is at least 95% identical to the one in sequence number 23, and the amino acid sequence of sequence number 23. It includes a VL having an amino acid sequence that is at least 95% identical to the no-acid sequence.

[0164] In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 has the amino acid sequence of sequence number 1, and V has the amino acid sequence of sequence number 2. VH includes H CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 3, (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, amino acid sequence of SEQ ID NO: 5 Includes VL CDR2 having the amino acid sequence of SEQ ID NO: 6 and VL CDR3 having the amino acid sequence of SEQ ID NO: 6 , including VL. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the above antibody The body has (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 139, SEQ ID NO: 140 VH CDR2 having an amino acid sequence, and VH having the amino acid sequence of SEQ ID NO: 141 (ii) VH containing CDR3 and VL CD having the amino acid sequence of SEQ ID NO: 226 R1, VL CDR2 having the amino acid sequence of SEQ ID NO: 227, and A VL includes VL CDR3 having a mino acid sequence. In another embodiment, it is linked to Vβ17. A matching antibody is provided herein, wherein the antibody (i) has the amino acid sequence of SEQ ID NO: 145 VH CDR1 has the amino acid sequence of SEQ ID NO: 146, and VH CDR2 has the amino acid sequence of SEQ ID NO: 146, and VH containing VH CDR3 having the amino acid sequence of sequence number 147, and (ii) Sequence ID VL CDR1 has a 232-amino acid sequence, and has the amino acid sequence of SEQ ID NO: 233. VL CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 234 are included. Includes L. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the above The antibodies are (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 151, SEQ ID NO: 152 VH CDR2 having the amino acid sequence of SEQ ID NO: 153, and V (ii) VH containing H CDR3 and VL C having the amino acid sequence of SEQ ID NO: 238 VL CDR2 having the amino acid sequence of DR1, SEQ ID NO: 239, and SEQ ID NO: 240 VL includes VL CDR3 having an amino acid sequence. In another embodiment, Vβ17 The antibody to be bound is provided herein, and the antibody is (i) the amino acid sequence of SEQ ID NO: 157 VH CDR1 having the amino acid sequence of SEQ ID NO: 158, VH CDR2 having the amino acid sequence of SEQ ID NO: 158, and VH containing VH CDR3 having the amino acid sequence of sequence number 159, and (ii) sequence number VL CDR1 has the amino acid sequence of sequence number 244, and has the amino acid sequence of sequence number 245. VL CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 246 are included. Includes VL. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the antibody (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 163, and SEQ ID NO: 164 VH CDR2 having a amino acid sequence, and VH having the amino acid sequence of SEQ ID NO: 165 (ii) VH containing CDR3 and VL CDR having the amino acid sequence of SEQ ID NO: 250 1. VL CDR2 having the amino acid sequence of SEQ ID NO: 251, and the amino acid sequence of SEQ ID NO: 252 VL includes VL CDR3 having an acid sequence. In another embodiment, it is bound to Vβ17. An antibody is provided herein, wherein the antibody has (i) the amino acid sequence of SEQ ID NO: 169 VH CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 170, and sequence VH containing VH CDR3 having amino acid sequence number 171, and (ii) SEQ ID NO: 2 VL CDR1 has a 56-amino acid sequence, and V has the amino acid sequence of SEQ ID NO: 257. VL CDR3 contains L CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 258. This includes, In another embodiment, an antibody that binds to Vβ17 is provided herein, the antibody is, (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 175, and amino acid sequence of SEQ ID NO: 176 VH CDR2 having an acid sequence, and VH CD having the amino acid sequence of SEQ ID NO: 177. VH containing R3, and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 262, VL CDR2 having the amino acid sequence of SEQ ID NO: 263, and the amino acid sequence of SEQ ID NO: 264 VL includes VL CDR3 having a sequence. In another embodiment, it binds to Vβ17. Antibodies are provided herein, and the above antibodies are VH CDR1 and V, respectively, of SEQ ID NO: 19. VH CDR1, VH CDR1, VH CDR3 have amino acid sequences H CDR2 and VH CDR3. VH includes DR2 and VH CDR3. In another embodiment, an anti-Vβ17 binding The bodies provided herein are VL CDR1 and VL CDR1 of SEQ ID NO: 24, respectively. VL CDR1, VL CD, which have the amino acid sequences of CDR2 and VL CDR3, respectively. VL includes R2 and VL CDR3. In another embodiment, an antibody that binds to Vβ17. Provided herein are the antibodies of (i) SEQ ID NO: 19, respectively, VH CDR1 VH CDR1, VH CDR3, and VH CDR3 have amino acid sequences. VH and (ii) VH, including CDR2 and VH CDR3, and VH, respectively, of sequence number 24. VL CD having amino acid sequences L CDR1, VL CDR2, and VL CDR3 VL includes R1, VL CDR2, and VL CDR3. Several embodiments The antibody then contains VH having the amino acid sequence of SEQ ID NO: 19. In some embodiments, The antibody contains a VL having the amino acid sequence of SEQ ID NO: 24. In some embodiments, The antibody has VH, which has the amino acid sequence of SEQ ID NO: 19, and SEQ ID NO: 24 It includes having VL. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 19 The corresponding identity includes VH having at least 95% of the amino acid sequence. Several implementations In this state, the antibody has at least 95% identity with the amino acid sequence of SEQ ID NO: 24. It contains a VL having an amino acid sequence. In some embodiments, the antibody is the amino acid sequence of SEQ ID NO 19. VH having an amino acid sequence with at least 95% identity to the acid sequence, and SEQ ID NO: 24 It contains VL having the amino acid sequence.

[0165] In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 has the amino acid sequence of sequence number 1, and V has the amino acid sequence of sequence number 2. VH includes H CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 3, (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, amino acid sequence of SEQ ID NO: 5 Includes VL CDR2 having the amino acid sequence of SEQ ID NO: 6 and VL CDR3 having the amino acid sequence of SEQ ID NO: 6 , including VL. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the above antibody The body has (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 181, SEQ ID NO: 182 VH CDR2 having an amino acid sequence, and VH having the amino acid sequence of SEQ ID NO: 183 (ii) VH containing CDR3 and VL CD having the amino acid sequence of SEQ ID NO: 142 R1, VL CDR2 having the amino acid sequence of SEQ ID NO: 143, and A VL includes VL CDR3 having a mino acid sequence. In another embodiment, it is linked to Vβ17. A matching antibody is provided herein, wherein the antibody (i) has the amino acid sequence of SEQ ID NO: 187 VH CDR1 has the amino acid sequence of SEQ ID NO: 188, and VH CDR2 has the amino acid sequence of SEQ ID NO: 188, and VH containing VH CDR3 having the amino acid sequence of sequence number 189, and (ii) Sequence ID VL CDR1 has a 148-amino acid sequence, and has the amino acid sequence of SEQ ID NO: 149. VL CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 150 are included. Includes L. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody is (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 193, and the amino acid sequence of SEQ ID NO: 194 VH CDR2 having an anoic acid sequence, and VH C having the amino acid sequence of SEQ ID NO 195 VH containing DR3 and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 154 VL CDR2 having the amino acid sequence of SEQ ID NO: 155, and amino acid sequence of SEQ ID NO: 156 VL contains VL CDR3 having an acid sequence. In another embodiment, it is bound to Vβ17. An antibody is provided herein, wherein the antibody has (i) the amino acid sequence of SEQ ID NO: 199 VH CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 200, and sequence number VH containing VH CDR3 having amino acid sequence 201, and (ii) SEQ ID NO: 16 VL CDR1 has the amino acid sequence 0, and VL has the amino acid sequence of SEQ ID NO: 161. VL and VL CDR3 having the amino acid sequence of CDR2 and SEQ ID NO: 162 This includes. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the antibody is ( i) VH CDR1 having the amino acid sequence of SEQ ID NO: 205, amino acids of SEQ ID NO: 206 VH CDR2 having the sequence, and VH CDR having the amino acid sequence of SEQ ID NO: 207 (ii) VH containing 3, and VL CDR1 having the amino acid sequence of SEQ ID NO: 166, VL CDR2 having the amino acid sequence of sequence number 167, and the amino acid sequence of sequence number 168 VL includes VL CDR3 having a column. In another embodiment, an antibody that binds to Vβ17. The body is provided herein, and the above antibody is (i) V having the amino acid sequence of SEQ ID NO: 211 H CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 212, and SEQ ID NO: 2 VH containing VH CDR3 having a 13-amino acid sequence, and (ii) SEQ ID NO: 172 VL CDR1 has an amino acid sequence, and VL C has an amino acid sequence of SEQ ID NO: 173. VL contains DR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 174. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 217, amino acid sequence of SEQ ID NO: 218 VH CDR2 having the amino acid sequence of SEQ ID NO: 219, and VH CDR3 having the amino acid sequence of SEQ ID NO: 219 (ii) VH and VL CDR1 having the amino acid sequence of sequence number 178, sequence number VL CDR2 having the amino acid sequence of number 179, and the amino acid sequence of sequence number 180 The VL comprises VL containing VL CDR3. In another embodiment, the antibody that binds to Vβ17 is The antibodies provided herein are VH CDR1 and VH C, respectively, of SEQ ID NO: 20. VH CDR1 and VH CDR2 have the amino acid sequences of DR2 and VH CDR3. , and VH including VH CDR3. In another embodiment, an antibody that binds to Vβ17 is included. Provided in the specification, the antibodies mentioned above are VL CDR1 and VL CD of SEQ ID NO: 22, respectively. VL CDR1, VL CDR2, having the amino acid sequences of R2 and VL CDR3, and VL containing VL CDR3. In another embodiment, an antibody that binds to Vβ17 is present. Provided in the details, the above antibodies are (i) VH CDR1 and VH CDR1 of SEQ ID NO: 20, respectively. VH CDR1 and VH CDR3 have amino acid sequences of CDR2 and VH CDR3. 2, and VH including VH CDR3, and (ii) VL C of Sequence ID No. 22, respectively VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3, VL includes VL CDR2 and VL CDR3. In some embodiments, The antibody contains VH having the amino acid sequence of SEQ ID NO: 20. In some embodiments, the anti The body contains VL having the amino acid sequence of SEQ ID NO: 22. In some embodiments, the antibody VH has the amino acid sequence of SEQ ID NO: 20, and VH has the amino acid sequence of SEQ ID NO: 22 VL is included. In some embodiments, the antibody is against the amino acid sequence of SEQ ID NO: 20 It includes a VH having at least 95% identity in its amino acid sequence. In some embodiments, The antibody has at least 95% amino acid sequence identity with respect to the amino acid sequence of SEQ ID NO: 22. It includes a VL having a column. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 20 VH has an amino acid sequence that is at least 95% identical to the one in sequence number 22, and the amino acid sequence of sequence number 22. It includes a VL having an amino acid sequence that is at least 95% identical to the no-acid sequence.

[0166] In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 has the amino acid sequence of sequence number 1, and V has the amino acid sequence of sequence number 2. VH includes H CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 3, (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, amino acid sequence of SEQ ID NO: 5 Includes VL CDR2 having the amino acid sequence of SEQ ID NO: 6 and VL CDR3 having the amino acid sequence of SEQ ID NO: 6 , including VL. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the above antibody The body has (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 181, SEQ ID NO: 182 VH CDR2 having an amino acid sequence, and VH having the amino acid sequence of SEQ ID NO: 183 (ii) VH containing CDR3 and VL CD having the amino acid sequence of SEQ ID NO: 184 R1, VL CDR2 having the amino acid sequence of SEQ ID NO: 185, and A VL includes VL CDR3 having a mino acid sequence. In another embodiment, it is linked to Vβ17. A matching antibody is provided herein, wherein the antibody (i) has the amino acid sequence of SEQ ID NO: 187 VH CDR1 has the amino acid sequence of SEQ ID NO: 188, and VH CDR2 has the amino acid sequence of SEQ ID NO: 188, and VH containing VH CDR3 having the amino acid sequence of sequence number 189, and (ii) Sequence ID VL CDR1 has an amino acid sequence of 190, and has the amino acid sequence of SEQ ID NO: 191. VL CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 192 are included. Includes L. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody is (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 193, and the amino acid sequence of SEQ ID NO: 194 VH CDR2 having an anoic acid sequence, and VH C having the amino acid sequence of SEQ ID NO 195 VH containing DR3 and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 196 VL CDR2 having the amino acid sequence of SEQ ID NO: 197, and amino acid sequence of SEQ ID NO: 198 VL contains VL CDR3 having an acid sequence. In another embodiment, it is bound to Vβ17. An antibody is provided herein, wherein the antibody has (i) the amino acid sequence of SEQ ID NO: 199 VH CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 200, and sequence number VH containing VH CDR3 having amino acid sequence 201, and (ii) SEQ ID NO: 20 VL CDR1 has the amino acid sequence of 2, and VL has the amino acid sequence of SEQ ID NO: 203. VL and VL CDR3 having the amino acid sequence of CDR2 and SEQ ID NO: 204 This includes. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the antibody is ( i) VH CDR1 having the amino acid sequence of SEQ ID NO: 205, amino acids of SEQ ID NO: 206 VH CDR2 having the sequence, and VH CDR having the amino acid sequence of SEQ ID NO: 207 (ii) VH containing 3, and VL CDR1 having the amino acid sequence of SEQ ID NO: 208, VL CDR2 having the amino acid sequence of sequence number 209, and the amino acid sequence of sequence number 210 VL includes VL CDR3 having a column. In another embodiment, an antibody that binds to Vβ17. The body is provided herein, and the above antibody is (i) V having the amino acid sequence of SEQ ID NO: 211 H CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 212, and SEQ ID NO: 2 VH containing VH CDR3 having 13 amino acid sequences, and (ii) SEQ ID NO: 214 VL CDR1 has an amino acid sequence, and VL C has an amino acid sequence of SEQ ID NO: 215. VL contains DR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 216. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 217, amino acid sequence of SEQ ID NO: 218 VH CDR2 having the amino acid sequence of SEQ ID NO: 219, and VH CDR3 having the amino acid sequence of SEQ ID NO: 219 (ii) VH and VL CDR1 having the amino acid sequence of sequence number 220, sequence number VL CDR2 having the amino acid sequence of number 221, and the amino acid sequence of sequence number 222 The VL comprises VL containing VL CDR3. In another embodiment, the antibody that binds to Vβ17 is The antibodies provided herein are VH CDR1 and VH C, respectively, of SEQ ID NO: 20. VH CDR1 and VH CDR2 have the amino acid sequences of DR2 and VH CDR3. , and VH including VH CDR3. In another embodiment, an antibody that binds to Vβ17 is included. Provided in the specification, the antibodies mentioned above are VL CDR1 and VL CD, respectively, of SEQ ID NO: 23. VL CDR1, VL CDR2, having the amino acid sequences of R2 and VL CDR3, and VL containing VL CDR3. In another embodiment, an antibody that binds to Vβ17 is present. Provided in the details, the above antibodies are (i) VH CDR1 and VH CDR1 of SEQ ID NO: 20, respectively. VH CDR1 and VH CDR3 have amino acid sequences of CDR2 and VH CDR3. 2, and VH including VH CDR3, and (ii) VL C of Sequence ID No. 23, respectively VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3, VL includes VL CDR2 and VL CDR3. In some embodiments, The antibody contains VH having the amino acid sequence of SEQ ID NO: 20. In some embodiments, the anti The body contains VL having the amino acid sequence of SEQ ID NO: 23. In some embodiments, the antibody VH has the amino acid sequence of SEQ ID NO: 20, and VH has the amino acid sequence of SEQ ID NO: 23 VL is included. In some embodiments, the antibody is against the amino acid sequence of SEQ ID NO: 20 It includes a VH having at least 95% identity in its amino acid sequence. In some embodiments, The antibody has at least 95% amino acid sequence identity with respect to the amino acid sequence of SEQ ID NO: 23. It includes a VL having a column. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 20 VH has an amino acid sequence that is at least 95% identical to the one in sequence number 23, and the amino acid sequence of sequence number 23. It includes a VL having an amino acid sequence that is at least 95% identical to the no-acid sequence.

[0167] In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 has the amino acid sequence of sequence number 1, and V has the amino acid sequence of sequence number 2. VH includes H CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 3, (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, amino acid sequence of SEQ ID NO: 5 Includes VL CDR2 having the amino acid sequence of SEQ ID NO: 6 and VL CDR3 having the amino acid sequence of SEQ ID NO: 6 , including VL. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the above antibody The body has (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 181, SEQ ID NO: 182 VH CDR2 having an amino acid sequence, and VH having the amino acid sequence of SEQ ID NO: 183 (ii) VH containing CDR3 and VL CD having the amino acid sequence of SEQ ID NO: 226 R1, VL CDR2 having the amino acid sequence of SEQ ID NO: 227, and A VL includes VL CDR3 having a mino acid sequence. In another embodiment, it is linked to Vβ17. A matching antibody is provided herein, wherein the antibody (i) has the amino acid sequence of SEQ ID NO: 187 VH CDR1 has the amino acid sequence of SEQ ID NO: 188, and VH CDR2 has the amino acid sequence of SEQ ID NO: 188, and VH containing VH CDR3 having the amino acid sequence of sequence number 189, and (ii) Sequence ID VL CDR1 has a 232-amino acid sequence, and has the amino acid sequence of SEQ ID NO: 233. VL CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 234 are included. Includes L. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody is (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 193, and the amino acid sequence of SEQ ID NO: 194 VH CDR2 having an anoic acid sequence, and VH C having the amino acid sequence of SEQ ID NO 195 VH containing DR3 and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 238 VL CDR2 having the amino acid sequence of SEQ ID NO: 239, and amino acid sequence of SEQ ID NO: 240 VL contains VL CDR3 having an acid sequence. In another embodiment, it is bound to Vβ17. An antibody is provided herein, wherein the antibody has (i) the amino acid sequence of SEQ ID NO: 199 VH CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 200, and sequence number VH containing VH CDR3 having amino acid sequence 201, and (ii) SEQ ID NO: 24 VL CDR1 has the amino acid sequence of 4, and VL has the amino acid sequence of SEQ ID NO: 245. VL and VL CDR3 having the amino acid sequence of CDR2 and SEQ ID NO: 246 This includes. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the antibody is ( i) VH CDR1 having the amino acid sequence of SEQ ID NO: 205, amino acids of SEQ ID NO: 206 VH CDR2 having the sequence, and VH CDR having the amino acid sequence of SEQ ID NO: 207 (ii) VH containing 3, and VL CDR1 having the amino acid sequence of SEQ ID NO: 250, VL CDR2 having the amino acid sequence of sequence number 251, and the amino acid sequence of sequence number 252 VL includes VL CDR3 having a column. In another embodiment, an antibody that binds to Vβ17. The body is provided herein, and the above antibody is (i) V having the amino acid sequence of SEQ ID NO: 211 H CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 212, and SEQ ID NO: 2 VH containing VH CDR3 having 13 amino acid sequences, and (ii) SEQ ID NO: 256 VL CDR1 has an amino acid sequence, and VL C has an amino acid sequence of SEQ ID NO: 257. VL contains DR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 258. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 217, amino acid sequence of SEQ ID NO: 218 VH CDR2 having the amino acid sequence of SEQ ID NO: 219, and VH CDR3 having the amino acid sequence of SEQ ID NO: 219 (ii) VH and VL CDR1 having the amino acid sequence of sequence number 262, sequence number VL CDR2 having the amino acid sequence of number 263, and the amino acid sequence of sequence number 264 The VL comprises VL containing VL CDR3. In another embodiment, the antibody that binds to Vβ17 is The antibodies provided herein are VH CDR1 and VH C, respectively, of SEQ ID NO: 20. VH CDR1 and VH CDR2 have the amino acid sequences of DR2 and VH CDR3. , and VH including VH CDR3. In another embodiment, an antibody that binds to Vβ17 is included. Provided in the specification, the antibodies mentioned above are VL CDR1 and VL CD of SEQ ID NO: 24, respectively. VL CDR1, VL CDR2, having the amino acid sequences of R2 and VL CDR3, and VL containing VL CDR3. In another embodiment, an antibody that binds to Vβ17 is present. Provided in the details, the above antibodies are (i) VH CDR1 and VH CDR1 of SEQ ID NO: 20, respectively. VH CDR1 and VH CDR3 have amino acid sequences of CDR2 and VH CDR3. 2, and VH including VH CDR3, and (ii) VL C of Sequence ID No. 24, respectively VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3, VL includes VL CDR2 and VL CDR3. In some embodiments, The antibody contains VH having the amino acid sequence of SEQ ID NO: 20. In some embodiments, the anti The body contains VL having the amino acid sequence of SEQ ID NO: 24. In some embodiments, the antibody This includes VH having the amino acid sequence of SEQ ID NO: 20 and having the amino acid sequence of SEQ ID NO: 24 VL is included. In some embodiments, the antibody is against the amino acid sequence of SEQ ID NO: 20 It includes a VH having at least 95% identity in its amino acid sequence. In some embodiments, The antibody has at least 95% amino acid sequence identity with respect to the amino acid sequence of SEQ ID NO: 24. It includes a VL having a column. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 20 VH has an amino acid sequence that is at least 95% identical to the one in sequence number 24, and the amino acid sequence of sequence number 24. It includes a VL having an amino acid sequence that is at least 95% identical to the no-acid sequence.

[0168] In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 has the amino acid sequence of sequence number 1, and V has the amino acid sequence of sequence number 2. VH includes H CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 3, (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, amino acid sequence of SEQ ID NO: 5 Includes VL CDR2 having the amino acid sequence of SEQ ID NO: 6 and VL CDR3 having the amino acid sequence of SEQ ID NO: 6 , including VL. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the above antibody The body has (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 223, SEQ ID NO: 224 VH CDR2 having an amino acid sequence, and VH having the amino acid sequence of SEQ ID NO: 225 (ii) VH containing CDR3 and VL CD having the amino acid sequence of SEQ ID NO: 142 R1, VL CDR2 having the amino acid sequence of SEQ ID NO: 143, and A VL includes VL CDR3 having a mino acid sequence. In another embodiment, it is linked to Vβ17. A matching antibody is provided herein, wherein the antibody (i) has the amino acid sequence of SEQ ID NO: 229 VH CDR1 has the amino acid sequence of SEQ ID NO: 230, and VH CDR2 has the amino acid sequence of SEQ ID NO: 230, and VH containing VH CDR3 having the amino acid sequence of sequence number 231, and (ii) Sequence ID VL CDR1 has a 148-amino acid sequence, and has the amino acid sequence of SEQ ID NO: 149. VL CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 150 are included. Includes L. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody is (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 235, and the amino acid sequence of SEQ ID NO: 236 VH CDR2 having an anoic acid sequence, and VH C having the amino acid sequence of SEQ ID NO 237 VH containing DR3 and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 154 VL CDR2 having the amino acid sequence of SEQ ID NO: 155, and amino acid sequence of SEQ ID NO: 156 VL contains VL CDR3 having an acid sequence. In another embodiment, it is bound to Vβ17. An antibody is provided herein, wherein the antibody has (i) the amino acid sequence of SEQ ID NO: 241 VH CDR1, VH CDR2 having the amino acid sequence of sequence number 242, and sequence number VH containing VH CDR3 having amino acid sequence 243, and (ii) SEQ ID NO: 16 VL CDR1 has the amino acid sequence 0, and VL has the amino acid sequence of SEQ ID NO: 161. VL and VL CDR3 having the amino acid sequence of CDR2 and SEQ ID NO: 162 This includes. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the antibody is ( i) VH CDR1 having the amino acid sequence of SEQ ID NO: 247, amino acid sequence of SEQ ID NO: 248 VH CDR2 having the sequence, and VH CDR having the amino acid sequence of SEQ ID NO: 249 (ii) VH containing 3, and VL CDR1 having the amino acid sequence of SEQ ID NO: 166, VL CDR2 having the amino acid sequence of sequence number 167, and the amino acid sequence of sequence number 168 VL includes VL CDR3 having a column. In another embodiment, an antibody that binds to Vβ17. The body is provided herein, and the above antibody is (i) V having the amino acid sequence of SEQ ID NO: 253 H CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 254, and SEQ ID NO: 2 VH containing VH CDR3 having a 55-amino acid sequence, and (ii) SEQ ID NO: 172 VL CDR1 has an amino acid sequence, and VL C has an amino acid sequence of SEQ ID NO: 173. VL contains DR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 174. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 259, amino acid sequence of SEQ ID NO: 260 VH CDR2 having the amino acid sequence of SEQ ID NO: 261, and VH CDR3 having the amino acid sequence of SEQ ID NO: 261 (ii) VH and VL CDR1 having the amino acid sequence of sequence number 178, sequence number VL CDR2 having the amino acid sequence of number 179, and the amino acid sequence of sequence number 180 The VL comprises VL containing VL CDR3. In another embodiment, the antibody that binds to Vβ17 is The antibodies provided herein are, respectively, VH CDR1 and VH C, of ​​SEQ ID NO: 21. VH CDR1 and VH CDR2 have the amino acid sequences of DR2 and VH CDR3. , and VH including VH CDR3. In another embodiment, an antibody that binds to Vβ17 is included. Provided in the specification, the antibodies mentioned above are VL CDR1 and VL CD of SEQ ID NO: 22, respectively. VL CDR1, VL CDR2, having the amino acid sequences of R2 and VL CDR3, and VL containing VL CDR3. In another embodiment, an antibody that binds to Vβ17 is present. Provided in the details, the above antibodies are (i) VH CDR1 and VH CDR1 of SEQ ID NO: 21, respectively. VH CDR1 and VH CDR3 have amino acid sequences of CDR2 and VH CDR3. 2, and VH including VH CDR3, and (ii) VL C of Sequence ID No. 22, respectively VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3, VL includes VL CDR2 and VL CDR3. In some embodiments, The antibody contains VH having the amino acid sequence of SEQ ID NO: 21. In some embodiments, the anti The body contains VL having the amino acid sequence of SEQ ID NO: 22. In some embodiments, the antibody VH has the amino acid sequence of SEQ ID NO: 21 and has the amino acid sequence of SEQ ID NO: 22 VL is included. In some embodiments, the antibody is against the amino acid sequence of SEQ ID NO: 21 It includes a VH having at least 95% identity in its amino acid sequence. In some embodiments, The antibody has at least 95% amino acid sequence identity with respect to the amino acid sequence of SEQ ID NO: 22. It includes a VL having a column. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 21 VH has an amino acid sequence that is at least 95% identical to the one in sequence number 22, and the amino acid sequence of sequence number 22. It includes a VL having an amino acid sequence that is at least 95% identical to the no-acid sequence.

[0169] In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 has the amino acid sequence of sequence number 1, and V has the amino acid sequence of sequence number 2. VH includes H CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 3, (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, amino acid sequence of SEQ ID NO: 5 Includes VL CDR2 having the amino acid sequence of SEQ ID NO: 6 and VL CDR3 having the amino acid sequence of SEQ ID NO: 6 , including VL. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the above antibody The body has (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 223, SEQ ID NO: 224 VH CDR2 having an amino acid sequence, and VH having the amino acid sequence of SEQ ID NO: 225 (ii) VH containing CDR3 and VL CD having the amino acid sequence of SEQ ID NO: 184 R1, VL CDR2 having the amino acid sequence of SEQ ID NO: 185, and A VL includes VL CDR3 having a mino acid sequence. In another embodiment, it is linked to Vβ17. A matching antibody is provided herein, wherein the antibody (i) has the amino acid sequence of SEQ ID NO: 229 VH CDR1 has the amino acid sequence of SEQ ID NO: 230, and VH CDR2 has the amino acid sequence of SEQ ID NO: 230, and VH containing VH CDR3 having the amino acid sequence of sequence number 231, and (ii) Sequence ID VL CDR1 has an amino acid sequence of 190, and has the amino acid sequence of SEQ ID NO: 191. VL CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 192 are included. Includes L. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody is (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 235, and the amino acid sequence of SEQ ID NO: 236 VH CDR2 having an anoic acid sequence, and VH C having the amino acid sequence of SEQ ID NO 237 VH containing DR3 and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 196 VL CDR2 having the amino acid sequence of SEQ ID NO: 197, and amino acid sequence of SEQ ID NO: 198 VL contains VL CDR3 having an acid sequence. In another embodiment, it is bound to Vβ17. An antibody is provided herein, wherein the antibody has (i) the amino acid sequence of SEQ ID NO: 241 VH CDR1, VH CDR2 having the amino acid sequence of sequence number 242, and sequence number VH containing VH CDR3 having amino acid sequence 243, and (ii) SEQ ID NO: 20 VL CDR1 has the amino acid sequence of 2, and VL has the amino acid sequence of SEQ ID NO: 203. VL and VL CDR3 having the amino acid sequence of CDR2 and SEQ ID NO: 204 This includes. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the antibody is ( i) VH CDR1 having the amino acid sequence of SEQ ID NO: 247, amino acid sequence of SEQ ID NO: 248 VH CDR2 having the sequence, and VH CDR having the amino acid sequence of SEQ ID NO: 249 (ii) VH containing 3, and VL CDR1 having the amino acid sequence of SEQ ID NO: 208, VL CDR2 having the amino acid sequence of sequence number 209, and the amino acid sequence of sequence number 210 VL includes VL CDR3 having a column. In another embodiment, an antibody that binds to Vβ17. The body is provided herein, and the above antibody is (i) V having the amino acid sequence of SEQ ID NO: 253 H CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 254, and SEQ ID NO: 2 VH containing VH CDR3 having a sequence of 55 amino acids, and (ii) SEQ ID NO: 214 VL CDR1 has an amino acid sequence, and VL C has an amino acid sequence of SEQ ID NO: 215. VL contains DR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 216. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 259, amino acid sequence of SEQ ID NO: 260 VH CDR2 having the amino acid sequence of SEQ ID NO: 261, and VH CDR3 having the amino acid sequence of SEQ ID NO: 261 (ii) VH and VL CDR1 having the amino acid sequence of sequence number 220, sequence number VL CDR2 having the amino acid sequence of number 221, and the amino acid sequence of sequence number 222 The VL comprises VL containing VL CDR3. In another embodiment, the antibody that binds to Vβ17 is The antibodies provided herein are, respectively, VH CDR1 and VH C, of ​​SEQ ID NO: 21. VH CDR1 and VH CDR2 have the amino acid sequences of DR2 and VH CDR3. , and VH including VH CDR3. In another embodiment, an antibody that binds to Vβ17 is included. Provided in the specification, the antibodies mentioned above are VL CDR1 and VL CD, respectively, of SEQ ID NO: 23. VL CDR1, VL CDR2, having the amino acid sequences of R2 and VL CDR3, and VL containing VL CDR3. In another embodiment, an antibody that binds to Vβ17 is present. Provided in the details, the above antibodies are (i) VH CDR1 and VH CDR1 of SEQ ID NO: 21, respectively. VH CDR1 and VH CDR3 have amino acid sequences of CDR2 and VH CDR3. 2, and VH including VH CDR3, and (ii) VL C of Sequence ID No. 23, respectively VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3, VL includes VL CDR2 and VL CDR3. In some embodiments, The antibody contains VH having the amino acid sequence of SEQ ID NO: 21. In some embodiments, the anti The body contains VL having the amino acid sequence of SEQ ID NO: 23. In some embodiments, the antibody This includes VH having the amino acid sequence of SEQ ID NO: 21 and having the amino acid sequence of SEQ ID NO: 23 VL is included. In some embodiments, the antibody is against the amino acid sequence of SEQ ID NO: 21 It includes a VH having at least 95% identity in its amino acid sequence. In some embodiments, The antibody has at least 95% amino acid sequence identity with respect to the amino acid sequence of SEQ ID NO: 23. It includes a VL having a column. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 21 VH has an amino acid sequence that is at least 95% identical to the one in sequence number 23, and the amino acid sequence of sequence number 23. It includes a VL having an amino acid sequence that is at least 95% identical to the no-acid sequence.

[0170] In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 has the amino acid sequence of sequence number 1, and V has the amino acid sequence of sequence number 2. VH includes H CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 3, (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, amino acid sequence of SEQ ID NO: 5 Includes VL CDR2 having the amino acid sequence of SEQ ID NO: 6 and VL CDR3 having the amino acid sequence of SEQ ID NO: 6 , including VL. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the above antibody The body has (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 223, SEQ ID NO: 224 VH CDR2 having an amino acid sequence, and VH having the amino acid sequence of SEQ ID NO: 225 (ii) VH containing CDR3 and VL CD having the amino acid sequence of SEQ ID NO: 226 R1, VL CDR2 having the amino acid sequence of SEQ ID NO: 227, and A VL includes VL CDR3 having a mino acid sequence. In another embodiment, it is linked to Vβ17. A matching antibody is provided herein, wherein the antibody (i) has the amino acid sequence of SEQ ID NO: 229 VH CDR1 has the amino acid sequence of SEQ ID NO: 230, and VH CDR2 has the amino acid sequence of SEQ ID NO: 230, and VH containing VH CDR3 having the amino acid sequence of sequence number 231, and (ii) Sequence ID VL CDR1 has a 232-amino acid sequence, and has the amino acid sequence of SEQ ID NO: 233. VL CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 234 are included. Includes L. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody is (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 235, and the amino acid sequence of SEQ ID NO: 236 VH CDR2 having an anoic acid sequence, and VH C having the amino acid sequence of SEQ ID NO 237 VH containing DR3 and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 238 VL CDR2 having the amino acid sequence of SEQ ID NO: 239, and amino acid sequence of SEQ ID NO: 240 VL contains VL CDR3 having an acid sequence. In another embodiment, it is bound to Vβ17. An antibody is provided herein, wherein the antibody has (i) the amino acid sequence of SEQ ID NO: 241 VH CDR1, VH CDR2 having the amino acid sequence of sequence number 242, and sequence number VH containing VH CDR3 having amino acid sequence 243, and (ii) SEQ ID NO: 24 VL CDR1 has the amino acid sequence of 4, and VL has the amino acid sequence of SEQ ID NO: 245. VL and VL CDR3 having the amino acid sequence of CDR2 and SEQ ID NO: 246 This includes. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the antibody is ( i) VH CDR1 having the amino acid sequence of SEQ ID NO: 247, amino acid sequence of SEQ ID NO: 248 VH CDR2 having the sequence, and VH CDR having the amino acid sequence of SEQ ID NO: 249 (ii) VH containing 3, and VL CDR1 having the amino acid sequence of SEQ ID NO: 250, VL CDR2 having the amino acid sequence of sequence number 251, and the amino acid sequence of sequence number 252 VL includes VL CDR3 having a column. In another embodiment, an antibody that binds to Vβ17. The body is provided herein, and the above antibody is (i) V having the amino acid sequence of SEQ ID NO: 253 H CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 254, and SEQ ID NO: 2 VH containing VH CDR3 having a sequence of 55 amino acids, and (ii) SEQ ID NO: 256 VL CDR1 has an amino acid sequence, and VL C has an amino acid sequence of SEQ ID NO: 257. VL contains DR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 258. In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 259, amino acid sequence of SEQ ID NO: 260 VH CDR2 having the amino acid sequence of SEQ ID NO: 261, and VH CDR3 having the amino acid sequence of SEQ ID NO: 261 (ii) VH and VL CDR1 having the amino acid sequence of sequence number 262, sequence number VL CDR2 having the amino acid sequence of number 263, and the amino acid sequence of sequence number 264 The VL comprises VL containing VL CDR3. In another embodiment, the antibody that binds to Vβ17 is The antibodies provided herein are, respectively, VH CDR1 and VH C, of ​​SEQ ID NO: 21. VH CDR1 and VH CDR2 have the amino acid sequences of DR2 and VH CDR3. , and VH including VH CDR3. In another embodiment, an antibody that binds to Vβ17 is included. Provided in the specification, the antibodies mentioned above are VL CDR1 and VL CD of SEQ ID NO: 24, respectively. VL CDR1, VL CDR2, having the amino acid sequences of R2 and VL CDR3, and VL containing VL CDR3. In another embodiment, an antibody that binds to Vβ17 is present. Provided in the details, the above antibodies are (i) VH CDR1 and VH CDR1 of SEQ ID NO: 21, respectively. VH CDR1 and VH CDR3 have amino acid sequences of CDR2 and VH CDR3. 2, and VH including VH CDR3, and (ii) VL C of Sequence ID No. 24, respectively VL CDR1 having the amino acid sequences of DR1, VL CDR2, and VL CDR3, VL includes VL CDR2 and VL CDR3. In some embodiments, The antibody contains VH having the amino acid sequence of SEQ ID NO: 21. In some embodiments, the anti The body contains VL having the amino acid sequence of SEQ ID NO: 24. In some embodiments, the antibody VH has the amino acid sequence of SEQ ID NO: 21 and has the amino acid sequence of SEQ ID NO: 24 VL is included. In some embodiments, the antibody is against the amino acid sequence of SEQ ID NO: 21 It includes a VH having at least 95% identity in its amino acid sequence. In some embodiments, The antibody has at least 95% amino acid sequence identity with respect to the amino acid sequence of SEQ ID NO: 24. It includes a VL having a column. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 21 VH has an amino acid sequence that is at least 95% identical to the one in sequence number 24, and the amino acid sequence of sequence number 24. It includes a VL having an amino acid sequence that is at least 95% identical to the no-acid sequence.

[0171] In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 has the amino acid sequence of sequence number 45, and has the amino acid sequence of sequence number 2. VH and VH CDR3, which have the amino acid sequence of VH CDR2 and SEQ ID NO: 3 (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 4, and the amino acid sequence of SEQ ID NO: 5 VL CDR2 has a column, and VL CDR3 has the amino acid sequence of SEQ ID NO: 6. This includes VL. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the above The antibodies are (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 265, and SEQ ID NO: 266 VH CDR2 having the amino acid sequence of SEQ ID NO: 267, and V (ii) VH containing H CDR3 and VL C having the amino acid sequence of SEQ ID NO: 268 VL CDR2 having the amino acid sequence of DR1, SEQ ID NO: 269, and SEQ ID NO: 270 VL includes VL CDR3 having an amino acid sequence. In another embodiment, Vβ17 The antibody to be bound is provided herein, and the antibody is (i) the amino acid sequence of SEQ ID NO: 271 VH CDR1 having the amino acid sequence of SEQ ID NO: 272, and VH containing VH CDR3 having the amino acid sequence of sequence number 273, and (ii) sequence number VL CDR1 has the amino acid sequence of number 274, and has the amino acid sequence of sequence number 275. VL CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 276 are included. Includes VL. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the antibody (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 277, and SEQ ID NO: 278 VH CDR2 having a amino acid sequence, and VH having the amino acid sequence of SEQ ID NO: 279 (ii) VH containing CDR3 and VL CDR having the amino acid sequence of SEQ ID NO: 280 1. VL CDR2 having the amino acid sequence of SEQ ID NO: 281, and the amino acid sequence of SEQ ID NO: 282 VL includes VL CDR3 having an acid sequence. In another embodiment, it is bound to Vβ17. An antibody is provided herein, wherein the antibody has (i) the amino acid sequence of SEQ ID NO: 283 VH CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 284, and sequence VH containing VH CDR3 having amino acid sequence number 285, and (ii) SEQ ID NO: 2 VL CDR1 has an 86-amino acid sequence, and V has the amino acid sequence of SEQ ID NO: 287. VL CDR3 contains L CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 288. This includes, In another embodiment, an antibody that binds to Vβ17 is provided herein, the antibody is, (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 289, and amino acid sequence of SEQ ID NO: 290 VH CDR2 having an acid sequence, and VH CD having the amino acid sequence of SEQ ID NO: 291. VH containing R3, and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 292, VL CDR2 having the amino acid sequence of SEQ ID NO: 293, and the amino acid sequence of SEQ ID NO: 294 VL includes VL CDR3 having a sequence. In another embodiment, it binds to Vβ17. An antibody is provided herein, wherein the antibody (i) has the amino acid sequence of SEQ ID NO: 295 VH CDR1, VH CDR2 having the amino acid sequence of SEQ ID NO: 296, and SEQ ID NO: VH containing VH CDR3 having a 297 amino acid sequence, and (ii) SEQ ID NO: 298 VL CDR1 has the amino acid sequence of SEQ ID NO: 299. VL includes CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 300. Includes. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the antibody is (i ) VH CDR1 having the amino acid sequence of SEQ ID NO: 301, and the amino acid sequence of SEQ ID NO: 302 VH CDR2 having a column, and VH CDR3 having the amino acid sequence of SEQ ID NO: 303 (ii) VH and VL CDR1 having the amino acid sequence of SEQ ID NO: 304, sequence VL CDR2 having amino acid sequence number 305, and amino acid sequence of SEQ ID NO: 306 VL comprises VL CDR3 having VL. In another embodiment, an antibody that binds to Vβ17. The antibodies provided herein are VH CDR1 and VH CDR1 of SEQ ID NO: 46, respectively. VH CDR1, VH CDR3, which have the amino acid sequences of CDR2 and VH CDR3. 2, and VH including VH CDR3. In another embodiment, an antibody that binds to Vβ17 Provided herein, the antibodies described above are VL CDR1 and VL C, respectively, of SEQ ID NO: 49. VL CDR1 and VL CDR2 have the amino acid sequences of DR2 and VL CDR3, respectively. , and VL containing VL CDR3. In another embodiment, an antibody that binds to Vβ17 is included. Provided in the specification, the above antibodies are (i) VH CDR1 and V, respectively, of SEQ ID NO: 46. VH CDR1 and VH CD have amino acid sequences of H CDR2 and VH CDR3, respectively. VH, including R2 and VH CDR3, and (ii) VL, each of the numbers in Sequence ID No. 49. VL CDR1 has the amino acid sequences of CDR1, VL CDR2, and VL CDR3. VL includes VL CDR2 and VL CDR3. In some embodiments, The antibody contains VH having the amino acid sequence of SEQ ID NO: 46. In some embodiments, The antibody contains VL having the amino acid sequence of SEQ ID NO: 47. In some embodiments, the anti The body has VH, which has the amino acid sequence of SEQ ID NO: 46, and SEQ ID NO: 47. It includes VL. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 11. It contains a heavy chain. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 12 It contains a light chain. In some embodiments, the antibody has the amino acid sequence of SEQ ID NO: 11. It comprises a chain and a light chain having the amino acid sequence of SEQ ID NO: 12. In some embodiments, it is an anti The body has at least 95% identity with the amino acid sequence of SEQ ID NO: 46. It contains VH. In some embodiments, the antibody is matched to the amino acid sequence of SEQ ID NO: 47 The identity includes a VL having at least 95% of the amino acid sequence. Several embodiments Therefore, the antibody has at least 95% identity with the amino acid sequence of SEQ ID NO: 46. VH with an acid sequence has at least 95% identity with the amino acid sequence of SEQ ID NO: 47. It includes VL having the amino acid sequence of SEQ ID NO: 11. In some embodiments, the antibody is SEQ ID NO: 11 It contains a heavy chain having an amino acid sequence that is at least 95% identical to the amino acid sequence of the given amino acid sequence. In some embodiments, the antibody has little identity with respect to the amino acid sequence of SEQ ID NO: 12. Both contain a light chain having 95% of the amino acid sequence. In some embodiments, the antibody is sequence Heavy chain having an amino acid sequence with at least 95% identity to amino acid sequence number 11 And, the amino acid sequence of sequence number 12 has at least 95% identity with the amino acid sequence. It includes a light chain.

[0172] In another embodiment, an antibody that binds to Vβ17 is provided herein, wherein the antibody (i) VH CDR1 has the amino acid sequence of sequence number 48, and has the amino acid sequence of sequence number 49. VH CDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO: 50 are included. H and (ii) VL CDR1 having the amino acid sequence of SEQ ID NO: 51, and A of SEQ ID NO: 52 VL CDR2 has a amino acid sequence, and VL C has the amino acid sequence of SEQ ID NO: 53. The present invention includes DR3 and VL. In another embodiment, an antibody that binds to Vβ17 is provided herein. The above antibody (i) has the amino acid sequence of SEQ ID NO: 307, VH CDR1, sequence VH CDR2 having amino acid sequence number 308, and amino acid sequence of SEQ ID NO: 309 VH containing VH CDR3 having (ii) the amino acid sequence of SEQ ID NO: 310 VL CDR1, VL CDR2 having the amino acid sequence of sequence number 311, and sequence number VL includes VL CDR3 having the amino acid sequence of no. 312. In another embodiment, An antibody that binds to Vβ17 is provided herein, and the above antibody is (i) the A of SEQ ID NO: 313 VH CDR1 has a amino acid sequence, and VH CD has the amino acid sequence of SEQ ID NO: 314. VH and (i i) VL CDR1 having the amino acid sequence of SEQ ID NO: 316, amino acids of SEQ ID NO: 317 VL CDR2 having the sequence, and VL CDR having the amino acid sequence of SEQ ID NO: 318 Includes 3, and includes VL. In another embodiment, an antibody that binds to Vβ17 is provided herein. The above antibody is (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 319, SEQ ID NO: VH CDR2 has an amino acid sequence of 320, and has an amino acid sequence of SEQ ID NO: 321 (ii) VH containing VH CDR3, and V having the amino acid sequence of SEQ ID NO: 322 L CDR1, VL CDR2 having the amino acid sequence of SEQ ID NO: 323, and SEQ ID NO: 3 VL comprises VL CDR3 having a 24-amino acid sequence. In another embodiment, Vβ An antibody that binds to 17 is provided herein, wherein the antibody is (i) the amino acid of SEQ ID NO: 325 VH CDR1 has an acid sequence, and VH CDR2 has the amino acid sequence of SEQ ID NO: 326. VH and (ii) VH CDR3 having the amino acid sequence of SEQ ID NO: 327 VL CDR1 having the amino acid sequence of SEQ ID NO: 328, amino acid sequence of SEQ ID NO: 329 VL CDR2 having the amino acid sequence of SEQ ID NO: 330, and VL CDR3 having the amino acid sequence of SEQ ID NO: 330 Includes, and includes VL. In another embodiment, an antibody that binds to Vβ17 is provided herein, above The antibody in question is (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 331, SEQ ID NO: 33 VH CDR2 has the amino acid sequence of 2, and has the amino acid sequence of SEQ ID NO: 333 VH containing VH CDR3 and (ii) VL having the amino acid sequence of SEQ ID NO: 334 CDR1, VL CDR2 having the amino acid sequence of SEQ ID NO: 335, and SEQ ID NO: 336 VL includes VL CDR3 having the amino acid sequence. In another embodiment, Vβ17 An antibody that binds to (i) the amino acid combination of (i) SEQ ID NO: 337 is provided herein, and the antibody is (i) the amino acid combination of SEQ ID NO: 337 VH CDR1 having a column, VH CDR2 having the amino acid sequence of SEQ ID NO: 338, and VH and (ii) sequence containing VH CDR3 having the amino acid sequence of sequence number 339 VL CDR1 has amino acid sequence number 340, and has amino acid sequence number 341. Includes VL CDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO: 342. , including VL. In another embodiment, an antibody that binds to Vβ17 is provided herein, and the above antibody The body has (i) VH CDR1 having the amino acid sequence of SEQ ID NO: 343, SEQ ID NO: 344 VH CDR2 having an amino acid sequence, and VH having the amino acid sequence of SEQ ID NO: 345 (ii) VH containing CDR3 and VL CD having the amino acid sequence of SEQ ID NO: 346 R1, VL CDR2 having the amino acid sequence of SEQ ID NO: 347, and A VL includes VL CDR3 having a mino acid sequence. In another embodiment, it is linked to Vβ17. The antibodies that can be combined are provided herein, and each of the above antibodies is a VH CDR of SEQ ID NO: 77. 1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. VH includes H CDR2 and VH CDR3. In another embodiment, it is bound to Vβ17. Antibodies are provided herein, and each of the above antibodies is a VL CDR1 of SEQ ID NO: 78. VL CDR1, VL CDR3, which have the amino acid sequences of VL CDR2 and VL CDR3. Includes VL containing CDR2 and VL CDR3. In another embodiment, it binds to Vβ17. The antibodies provided herein are (i) of SEQ ID NO: 77, respectively, VH C VH CDR1 having the amino acid sequences of DR1, VH CDR2, and VH CDR3, VH and (ii) Sequence ID 78, including VH CDR2 and VH CDR3 Therefore, VL has the amino acid sequences of VL CDR1, VL CDR2, and ...

Claims

1. An antibody that binds to Vβ17, (1) (i) Each of the VH CDR1s having the amino acid sequence of SEQ ID NO: 21, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) each of sequence number 677 VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence VL containing VL CDR1, VL CDR2, and VL CDR3 having a mino acid sequence 、 (2) (i) Each of the VH CDR1s having the amino acid sequence of SEQ ID NO: 77, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) respectively, the a of sequence number 78 VL CDR1, VL CDR2, and VL CDR3 of VL having a mino acid sequence VL containing VL CDR1, VL CDR2, and VL CDR3 having an acid sequence, (3) (i) Each of the VH CDR1s having the amino acid sequence of SEQ ID NO: 79, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) respectively, the a of sequence number 80 VL CDR1, VL CDR2, and VL CDR3 of VL having a mino acid sequence VL containing VL CDR1, VL CDR2, and VL CDR3 having an acid sequence, (4) (i) Each of the VH CDR1s having the amino acid sequence of SEQ ID NO: 81, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) respectively, the a of sequence number 82 VL CDR1, VL CDR2, and VL CDR3 of VL having a mino acid sequence VL containing VL CDR1, VL CDR2, and VL CDR3 having an acid sequence, (5) (i) Each of the VH CDR1s having the amino acid sequence of SEQ ID NO: 83, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) respectively, the a of sequence number 84 VL CDR1, VL CDR2, and VL CDR3 of VL having a mino acid sequence VL containing VL CDR1, VL CDR2, and VL CDR3 having an acid sequence, (6) (i) Each of the VH CDR1s having the amino acid sequence of SEQ ID NO: 85, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) respectively, the a of sequence number 86 VL CDR1, VL CDR2, and VL CDR3 of VL having a mino acid sequence VL containing VL CDR1, VL CDR2, and VL CDR3 having an acid sequence, (7) (i) Each of the VH CDR1s having the amino acid sequence of SEQ ID NO: 87, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) respectively, the a of sequence number 88 VL CDR1, VL CDR2, and VL CDR3 of VL having a mino acid sequence VL containing VL CDR1, VL CDR2, and VL CDR3 having an acid sequence, (8) (i) Each of the VH CDRs having the amino acid sequence of SEQ ID NO: 1000 1. VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. H CDR2 and VH CDR3 are included in VH, and (ii) each of SEQ ID NO: 10 VL CDR1, VL CDR2, and VL CDR have the amino acid sequence 01. It contains VL CDR1, VL CDR2, and VL CDR3, which have the amino acid sequence of 3. mu VL, (9) (i) Each of the VH CDRs having the amino acid sequence of SEQ ID NO: 1032 1. VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. H CDR2 and VH CDR3 are included in VH, and (ii) each of SEQ ID NO: 10 VL CDR1, VL CDR2, and VL CDR have a 33-amino acid sequence. It contains VL CDR1, VL CDR2, and VL CDR3, which have the amino acid sequence of 3. mu VL, (10) (i) Each of the VHs having the amino acid sequence of SEQ ID NO: 1064 VH CD VH CDR1, which has the amino acid sequences R1, VH CDR2, and VH CDR3 VH including VH CDR2 and VH CDR3, and (ii) each, Sequence ID 1 VL CDR1, VL CDR2, and VL CD have the amino acid sequence 065. VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence of R3. Including VL, (11) (i) Each of the VHs having the amino acid sequence of SEQ ID NO: 1096 VH CD VH CDR1, which has the amino acid sequences R1, VH CDR2, and VH CDR3 VH including VH CDR2 and VH CDR3, and (ii) each, Sequence ID 1 VL CDR1, VL CDR2, and VL CD have the amino acid sequence 097. VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence of R3. Includes VL, or (12) (i) Each of the VHs having the amino acid sequence of SEQ ID NO: 1128 VH CD VH CDR1, which has the amino acid sequences R1, VH CDR2, and VH CDR3 VH including VH CDR2 and VH CDR3, and (ii) each, Sequence ID 1 VL CDR1, VL CDR2, and VL CD have a 129-amino acid sequence. VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence of R3. Antibodies containing VL.

2. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The amino acid sequences of R2 and VL CDR3 conform to the Kabat numbering system, according to claim 1. The antibody described.

3. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD Claims that the amino acid sequences of R2 and VL CDR3 conform to the Chothia numbering system. The antibody described in 1.

4. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The amino acid sequences of R2 and VL CDR3 conform to the AbM numbering system, as described in claim 1. Antibodies of [the substance].

5. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The R2 and VL CDR3 amino acid sequences conform to the Contact numbering system, claim The antibody described in 1.

6. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The amino acid sequences of R2 and VL CDR3 conform to the IMGT numbering system, as described in claim 1. The antibody listed.

7. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The amino acid sequences of R2 and VL CDR3 are as described in claim 1, according to an exemplary numbering system. The antibody listed.

8. The antibody according to any one of claims 1 to 7, wherein the antibody is a humanized antibody.

9. The antibody according to any one of claims 1 to 8, wherein the antibody is an IgG antibody.

10. Claim that the IgG antibody is an IgG1, IgG2, IgG3, or IgG4 antibody. The antibody described in section 9.

11. The antibody according to any one of claims 1 to 10, wherein the antibody comprises a kappa light chain.

12. The antibody according to any one of claims 1 to 10, wherein the antibody comprises a lambda light chain.

13. The antibody according to any one of claims 1 to 12, wherein the antibody is a monoclonal antibody. 。

14. The antibody according to any one of claims 1 to 13, wherein the antibody binds to the Vβ17 antigen.

15. The antibody according to any one of claims 1 to 13, wherein the antibody binds to the Vβ17 epitope. 。

16. The antibody according to any one of claims 1 to 15, wherein the antibody specifically binds to Vβ17. body.

17. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD Claims that R2 and VL CDR3 form binding sites for the antigen of Vβ17. An antibody as described in any one of items 1 to 16.

18. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD R2 and VL CDR3 form binding sites to the epitope of Vβ17. The antibody according to any one of claims 1 to 16.

19. The Vβ17 is present on the surface of the T cell, according to any one of claims 1 to 18. antibody.

20. The antibody according to any one of claims 1 to 19, wherein the antibody is polyvalent.

21. The antibody according to claim 20, wherein the antibody is capable of binding to at least three antigens. 。

22. The antibody according to claim 20, wherein the antibody is capable of binding to at least four antigens. 。

23. The antibody according to claim 20, wherein the antibody is capable of binding to at least five antigens. 。

24. The antibody according to any one of claims 1 to 23, wherein the antibody is a multispecific antibody.

25. A multispecific Vβ17 antibody, (a) A first binding domain that binds to Vβ17, wherein the first binding domain is A first binding domain comprising the Vβ17 antibody according to any one of claims 1 to 23, (b) A multiple feature comprising a second binding domain that binds to a second target other than Vβ17. Isomeric Vβ17 antibody.

26. The multispecific Vβ17 antibody according to claim 25, wherein the antibody is a bispecific antibody.

27. The multispecific Vβ17 antibody according to claim 25, wherein the antibody is a triplicate antibody.

28. The multispecific Vβ17 antibody according to claim 25, wherein the antibody is a quadruplespecific antibody.

29. Claims 25-28, wherein the second binding domain binds to the antigen of the second target. A multispecific Vβ17 antibody as described in item one.

30. Claims 25-2, wherein the second binding domain binds to the epitope of the second target. A multispecific Vβ17 antibody as described in any one of item 8.

31. Claims 25-30, wherein the second binding domain specifically binds to the second target. A multispecific Vβ17 antibody as described in any one of the items.

32. The VH CDR1, VH CDR2, VH CDR3, V of the second binding domain L CDR1, VL CDR2, and VL CDR3 are effective against the antigen of the second target. A multispecific Vβ17 antibody according to any one of claims 25 to 31, which forms a binding site. 。

33. The VH CDR1, VH CDR2, VH CDR3, V of the second binding domain L CDR1, VL CDR2, and VL CDR3 are epitopes of the second target. A multispecific Vβ1 according to any one of claims 25 to 31, which forms a binding site for the opposite. 7 antibodies.

34. The second target is present on the surface of the target cell, according to any one of claims 25 to 33. The multispecific Vβ17 antibody described above.

35. Claims 25-34, wherein the second binding domain that binds to the second target is polyvalent. A multispecific Vβ17 antibody as described in any one of the items.

36. Claim 3, wherein the second binding domain can bind to at least three antigens. The multispecific Vβ17 antibody described in 5.

37. Claim 3, wherein the second binding domain can bind to at least four antigens. The multispecific Vβ17 antibody described in 5.

38. Claim 3, wherein the second binding domain can bind to at least five antigens. The multispecific Vβ17 antibody described in 5.

39. The multiplexing according to any one of claims 25 to 38, wherein the second target is CD123. Specific Vβ17 antibody.

40. The second coupling arm coupled to CD123 is (i) each of the meshes of sequence number 40. The amino acids of VH CDR1, VH CDR2, and VH CDR3, which have an anoic acid sequence. VH having an acid sequence, comprising VH CDR1, VH CDR2, and VH CDR3, (ii) VL CDR1 and VL, each having the amino acid sequence of SEQ ID NO: 41 VL CDR1, VL CDR3, which have the amino acid sequences of CDR2 and VL CDR3. 2, and VL containing VL CDR3, and the multispecific Vβ17 according to claim 39 antibody.

41. A multispecific antibody that binds to Vβ17, (a) A first binding domain that binds to Vβ17, wherein the first binding domain is (1) (i) Each of the VH CDR1 having the amino acid sequence of SEQ ID NO: 25 VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) respectively, Sequence ID No. 26 VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence VL containing VL CDR1, VL CDR2, and VL CDR3 having a mino acid sequence 、 (2) (i) Each of the VH CDR1s having the amino acid sequence of SEQ ID NO: 7, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) each of the amicin of Sequence ID No.

8. The amino acids of VL CDR1, VL CDR2, and VL CDR3 of VL having an anoic acid sequence. VL containing VL CDR1, VL CDR2, and VL CDR3 having an acid sequence, (3) (i) Each of the VH CDR1s having the amino acid sequence of SEQ ID NO: 9, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) respectively, the a of sequence number 10 VL CDR1, VL CDR2, and VL CDR3 of VL having a mino acid sequence VL containing VL CDR1, VL CDR2, and VL CDR3 having an acid sequence, (4) (i) Each of the VH CDR1s having the amino acid sequence of SEQ ID NO: 19 VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) respectively, SEQ ID NO: 22 VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence VL containing VL CDR1, VL CDR2, and VL CDR3 having a mino acid sequence 、 (5) (i) Each of the VH CDR1s having the amino acid sequence of SEQ ID NO: 19 VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) respectively, Sequence ID 23 VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence VL containing VL CDR1, VL CDR2, and VL CDR3 having a mino acid sequence 、 (6) (i) Each of the VH CDR1 having the amino acid sequence of SEQ ID NO: 19 VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) respectively, Sequence ID 24 VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence VL containing VL CDR1, VL CDR2, and VL CDR3 having a mino acid sequence 、 (7) (i) Each of the VH CDR1 having the amino acid sequence of SEQ ID NO: 20 VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) respectively, SEQ ID NO: 22 VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence VL containing VL CDR1, VL CDR2, and VL CDR3 having a mino acid sequence 、 (8) (i) Each of the VH CDR1 having the amino acid sequence of SEQ ID NO: 20 VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) respectively, Sequence ID 23 VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence VL containing VL CDR1, VL CDR2, and VL CDR3 having a mino acid sequence 、 (9) (i) Each of the VH CDR1 having the amino acid sequence of SEQ ID NO: 20 VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) respectively, Sequence ID 24 VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence VL containing VL CDR1, VL CDR2, and VL CDR3 having a mino acid sequence 、 (10) (i) Each of the VH CDRs having the amino acid sequence of SEQ ID NO: 21 1. VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. H CDR2 and VH CDR3 are included in VH, and (ii) SEQ ID NO: 22 VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence V containing VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence L, (11) (i) Each of the VH CDRs having the amino acid sequence of SEQ ID NO: 21 1. VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. H CDR2 and VH CDR3 are included in VH, and (ii) each is sequence number 23 VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence V containing VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence L, (12) (i) Each of the VH CDRs having the amino acid sequence of SEQ ID NO: 21 1. VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. H CDR2 and VH CDR3 are included in VH, and (ii) each is Sequence ID 24 VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence V containing VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence L, or (13) (i) VH CDR of each having the amino acid sequence of SEQ ID NO: 46 1. VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. H CDR2 and VH CDR3 are included in VH, and (ii) each is sequence number 49 VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence V containing VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence The first binding domain containing L, (b) A second target which binds to a second target which is BCMA, DLL3, PSMA, or KLK2. A multispecific Vβ17 antibody containing a binding domain.

42. The VH CDR1, VH CDR2, VH CDR3, VL of the first coupling arm The amino acid sequences of CDR1, VL CDR2, and VL CDR3 are assigned to the Kabat numbering system. A multispecific Vβ17 antibody according to claim 41, in accordance with the TEM.

43. The VH CDR1, VH CDR2, VH CDR3, VL of the first coupling arm The amino acid sequences of CDR1, VL CDR2, and VL CDR3 are Chothia numbered. A multispecific Vβ17 antibody according to claim 41, which follows the system.

44. The VH CDR1, VH CDR2, VH CDR3, VL of the first coupling arm The amino acid sequences of CDR1, VL CDR2, and VL CDR3 are assigned to the AbM numbering system. A multispecific Vβ17 antibody according to claim 41, in accordance with the present invention.

45. The VH CDR1, VH CDR2, VH CDR3, VL of the first coupling arm The amino acid sequences of CDR1, VL CDR2, and VL CDR3 are assigned Contact numbers. A multispecific Vβ17 antibody according to claim 41, which follows the system.

46. The VH CDR1, VH CDR2, VH CDR3, VL of the first coupling arm The amino acid sequences of CDR1, VL CDR2, and VL CDR3 are assigned to the IMGT numbering system. A multispecific Vβ17 antibody according to claim 41, conforming to the requirements.

47. The VH CDR1, VH CDR2, VH CDR3, VL of the first coupling arm The amino acid sequences of CDR1, VL CDR2, and VL CDR3 are exemplary numbering systems. A multispecific Vβ17 antibody according to claim 41, conforming to the requirements.

48. The second target is BCMA, as per any of claims 25-38 or 41-47. A multispecific Vβ17 antibody as described in item 1.

49. The second binding arm that binds to BCMA is (i) each of the amino acids of Sequence ID No.

95. Amino acids of VH CDR1, VH CDR2, and VH CDR3 of VH having an acid sequence VH having the sequence VH CDR1, VH CDR2, and VH CDR3, and ( ii) VL CDR1 and VL C, respectively, which have the amino acid sequence of SEQ ID NO:

96. VL CDR1 and VL CDR2 have the amino acid sequences of DR2 and VL CDR3, respectively. The multispecific Vβ17 antibody according to claim 48, comprising VL containing VL CDR3. 。

50. The second target is DLL3, according to any one of claims 25 to 38 or 41 to 47. A multispecific Vβ17 antibody as described in item 1.

51. The second connecting arm that connects to DLL3 is (i) each of the meshes of sequence number 694. The amino acids of VH CDR1, VH CDR2, and VH CDR3, which have an anoic acid sequence. VH having an acid sequence, comprising VH CDR1, VH CDR2, and VH CDR3, (ii) VL CDR1 and VL, each having the amino acid sequence of SEQ ID NO: 695 VL CDR1, VL CD The multispecific Vβ1 according to claim 50, comprising R2 and VL containing VL CDR3. 7 antibodies.

52. The second target is PSMA, as per any of claims 25-38 or 41-47. A multispecific Vβ17 antibody as described in item 1.

53. The second coupling arm that is coupled to the PSMA, (1) (i) Each of the VH CDR1 having the amino acid sequence of SEQ ID NO: 730 VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) respectively, Sequence ID 731 VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence V containing VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence L, (2) (i) Each of the VH CDR1 having the amino acid sequence of SEQ ID NO: 732 VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) each, Sequence ID 733 VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence V containing VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence L, (3) (i) Each of the VH CDR1 having the amino acid sequence of SEQ ID NO: 734 VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) each, Sequence ID 735 VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence V containing VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence L, (4) (i) Each of the VH CDR1 having the amino acid sequence of SEQ ID NO: 736 VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) each, Sequence ID 737 VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence V containing VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence L, or (5) (i) Each of the VH CDR1 having the amino acid sequence of SEQ ID NO: 899 VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) each, Sequence ID 900 VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence V containing VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence A multispecific Vβ17 antibody according to claim 52, comprising L.

54. The second target is KLK2, as per any of claims 25 to 38 or 41 to 47. A multispecific Vβ17 antibody as described in item 1.

55. The second coupling arm that is coupled to KLK2 is (i) each of the meshes of sequence number 887. The amino acids of VH CDR1, VH CDR2, and VH CDR3, which have an anoic acid sequence. VH having an acid sequence, comprising VH CDR1, VH CDR2, and VH CDR3, (ii) VL CDR1 and VL CDR1, each having the amino acid sequence of SEQ ID NO:

888. VL CDR1, VL CD The multispecific Vβ1 according to claim 54, comprising R2 and VL containing VL CDR3. 7 antibodies.

56. The VH CDR1, VH CDR2, VH CDR3, VL of the second coupling arm The amino acid sequences of CDR1, VL CDR2, and VL CDR3 are assigned to the Kabat numbering system. Multiple specificity according to any one of claims 40, 49, 51, 53, or 55, in accordance with the TEM sexual Vβ17 antibody.

57. The VH CDR1, VH CDR2, VH CDR3, VL of the second coupling arm The amino acid sequences of CDR1, VL CDR2, and VL CDR3 are Chothia numbered. Multiplexing according to any one of claims 40, 49, 51, 53, or 55, in accordance with the system. Specific Vβ17 antibody.

58. The VH CDR1, VH CDR2, VH CDR3, VL of the second coupling arm The amino acid sequences of CDR1, VL CDR2, and VL CDR3 are assigned to the AbM numbering system. Multiple specificity V according to any one of claims 40, 49, 51, 53, or 55. β17 antibody.

59. The VH CDR1, VH CDR2, VH CDR3, VL of the second coupling arm The amino acid sequences of CDR1, VL CDR2, and VL CDR3 are assigned Contact numbers. Multiplexing according to any one of claims 40, 49, 51, 53, or 55, in accordance with the system. Specific Vβ17 antibody.

60. The VH CDR1, VH CDR2, VH CDR3, VL of the second coupling arm The amino acid sequences of CDR1, VL CDR2, and VL CDR3 are assigned to the IMGT numbering system. Multiple specificity according to any one of claims 40, 49, 51, 53, or 55, in accordance with M. Vβ17 antibody.

61. The VH CDR1, VH CDR2, VH CDR3, VL of the second coupling arm The amino acid sequences of CDR1, VL CDR2, and VL CDR3 are exemplary numbering systems. Multiple specificity according to any one of claims 40, 49, 51, 53, or 55, in accordance with M. Vβ17 antibody.

62. A multispecific Vβ17 antibody capable of binding to Vβ17 on the surface of T cells. The invention includes a first means and a second means capable of binding to a second target other than Vβ17. Hmm, a multispecific Vβ17 antibody.

63. The multispecific Vβ according to claim 62, wherein the second target is located on the surface of the target cell. 17 antibodies.

64. A nucleic acid encoding an antibody according to any one of claims 1 to 63.

65. A vector comprising the nucleic acid described in claim 64.

66. A host cell comprising the vector according to claim 65.

67. A kit comprising the vector according to claim 66 and a package therefor.

68. A kit comprising an antibody according to any one of claims 1 to 63 and a package thereof.

69. A method comprising an antibody according to any one of claims 1 to 63 and a pharmaceutically acceptable carrier, Pharmaceutical composition.

70. A method for producing the pharmaceutical composition described in claim 69, wherein the antibody is pharmaceutically acceptable A method comprising the step of obtaining the pharmaceutical composition by combining it with a carrier.

71. A method for activating T cells expressing Vβ17, wherein the T cells are defined in claims 1 to 63. A method comprising the step of contacting the antibody described in any one of the paragraphs.

72. The aforementioned contact step results in CD69 and CD2 compared to control T cells expressing Vβ17.

5. The method according to claim 71, which results in an increase in granzyme B expression.

73. A process for producing antibodies that bind to two or more target molecules, the process However, in order to perform the function of obtaining the first binding domain that binds to Vβ17 present on T cells The process involves obtaining a second binding domain that binds to a second target on the surface of the target cell. The process involves adding Vβ17 present on T cells and binding to a second target on the surface of target cells. A process that includes steps for performing the function of providing a matching antibody.

74. To perform the function of obtaining a second binding domain that binds to a second target on the surface of the target cell. The above process is repeated n times, binding to Vβ17 and n target molecules present on the T cell. It further includes n steps to perform the function of providing a first binding domain, where n is small The process according to claim 73, wherein both are 2.

75. A method for directing T cells expressing Vβ17 to target cells, according to claims 25 to 63. The process includes the step of contacting the target cells with the multispecific Vβ17 antibody described in any one of the items. Furthermore, the second target is present on the surface of the target cell, and the contact step is the T A method for directing cells towards the aforementioned target cells.

76. A method for inhibiting the growth or proliferation of target cells, wherein the method is as described in any one of claims 25 to 63. The multispecific Vβ17 antibody described above is used when the second target is present on the surface of the target cell. The process includes a step of bringing the target cells into contact with the Vβ17-expressing cells. In the presence of T cells, the contact step inhibits the growth or proliferation of the target cells. The method of bringing about something.

77. A method for eliminating target cells in a subject, the method described in any one of claims 25 to 63. The multispecific Vβ17 antibody described herein is used when the second target exists on the surface of the target cell. The step includes bringing the target cells into contact, wherein the contact step expresses Vβ17. A method in which the contact step results in the elimination of the target cells, in the presence of T cells.

78. A method for treating a disease in a subject, wherein an effective amount is any one of claims 25 to 63. The process includes administering the multispecific Vβ17 antibody described above to the subject, wherein the disease is characterized by The second target located on the surface of the target cell is pulled in whole or in part by the target cell. The way to be woken up.

79. The method according to claim 77 or 78, wherein the subject is a human being.

80. The subject is the subject that requires the method, any one of claims 77 to 79. Methods used.

81. Claim 2, wherein the second target is located on the surface of a target cell, and the target cell is a cancer cell. A multispecific Vβ17 antibody according to any one of claims 5 to 63, or any of claims 75 to 80 The method described in any one of the items.

82. (i) The cancer cells are adrenal cancer, anal cancer, appendiceal cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, Cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer, gestational trophoblastic cancer, head and neck cancer, Hodgkin lymphoma, intestinal cancer Cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, neuroendocrine tumors, Non-Hodgkin lymphoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, sinus cancer, skin cancer, soft tissue sarcoma Cells from spinal cancer, gastric cancer, testicular cancer, pharyngeal cancer, thyroid cancer, uterine cancer, endometrial cancer, vaginal cancer, or vulvar cancer. And, (ii) The second target is angiopoietin, BCMA, CD19, CD20, CD 22, CD25 (IL2-R), CD30, CD33, CD37, CD38, CD52, CD56, CD123 (IL-3R), cMET, DLL / Notch, EGFR, Ep CAM, FGF, FGF-R, GD2, HER2, Mesothelin, Nectin-4, PAP, PDGFRα, PSA, PSA3, PSMA, RANKL, SLAMF7, STEAP1 , TARP, TROP2, VEGF, or VEGF-R, and / or (iii) The second target is CEA, immature laminin receptor, TAG-72, HPV E6, HPV E7, BING-4, Calcium-dependent chlorine channel 2, Cyclin- B1, 9D7, EpCAM, EphA3, Her2 / neu, telomerase, mesothelin SAP-1, surviving, BAGE family antigen, CAGE family antigen, GA GE family antigens, MAGE family antigens, SAGE family antigens, XAGE family antigens Millie antigen, NY-ESO-1 / LAGE-1, PRAME, SSX-2, Melan- A, MART-1, Gp100, pmel17, tyrosinase, TRP-1, TRP-2 P. polypeptide, MC1R, prostate-specific antigen, β-catenin, or BRCA1 A multispecific Vβ17 antibody or method according to claim 81.

83. The multispecific Vβ17 antibody according to claim 81, wherein the second target is CD123. That is a method.

84. The multispecific Vβ17 antibody according to claim 81, wherein the second target is BCMA or method.

85. The multispecific Vβ17 antibody according to claim 81, wherein the second target is DLL3. method.

86. The multispecific Vβ17 antibody according to claim 81, wherein the second target is PSMA. method.

87. The multispecific Vβ17 antibody according to claim 81, wherein the second target is KLK2. method.

88. (i) The adrenal cancer is an adrenocortical carcinoma (ACC), adrenocortical carcinoma, pheochromocytoma, or It is a neuroblastoma. (ii) The anal cancer is squamous cell carcinoma, cloacal carcinoma, adenocarcinoma, basal cell carcinoma, Or it is melanoma. (iii) The appendiceal cancer is a neuroendocrine tumor (NET), mucinous adenocarcinoma, goblet cell carcinoma It is either an id, intestinal adenocarcinoma, or signet ring cell adenocarcinoma. (iv) The cholangiocarcinoma is extrahepatic cholangiocarcinoma, adenocarcinoma, hilar cholangiocarcinoma, hilar region cholangiocarcinoma, distal cholangiocarcinoma, It is bile duct cancer, or intrahepatic bile duct cancer. (v) The bladder cancer is classified as transitional cell carcinoma (TCC), papillary carcinoma, squamous carcinoma, or squamous cell carcinoma. It is a carcinoma, adenocarcinoma, small cell carcinoma, or sarcoma. (vi) The bone cancer is primary bone cancer, sarcoma, osteosarcoma, chondrosarcoma, sarcoma, fibrosarcoma, malignant bone cancer It is a vascular histiocytoma, giant cell tumor of bone, chordoma, or metastatic bone cancer. (vii) The aforementioned brain cancers include astrocytoma, brainstem glioma, glioblastoma, meningioma, ependymoma, and Dendrogliomas, mixed gliomas, pituitary cancer, pituitary adenomas, craniopharyngiomas, germ cell tumors, pineal gland tumors It is a ulcer, medulloblastoma, or primary CNS lymphoma. (viii) The breast cancer is breast carcinoma, invasive breast cancer, non-invasive breast cancer, breast sarcoma, metaplastic carcinoma. , adenomatous carcinoma, phyllodes tumor, angiosarcoma, HER2-positive breast cancer, triple-negative breast cancer, or It is inflammatory breast cancer. (ix) The cervical cancer is squamous cell carcinoma or adenocarcinoma. (x) The aforementioned colorectal cancer is colorectal adenocarcinoma, primary colorectal lymphoma, or gastrointestinal stromal tumor. , leiomyosarcoma, carcinoid tumor, mucinous adenocarcinoma, signet ring cell adenocarcinoma, gastrointestinal carcinoid It is a tumor, or melanoma. (xi) The esophageal cancer is an adenocarcinoma or a squamous cell carcinoma. (xi) The gallbladder cancer is an adenocarcinoma, papillary adenocarcinoma, adenosquamous carcinoma, or squamous cell carcinoma. It is a small cell carcinoma or sarcoma. (xiiii) The aforementioned gestational trophoblastic disease (GTD) is a hydatidiform mole, gestational trophoblastic neoplasm (G TN), choriocarcinoma, placental trophoblastic tumor (PSTT), or epithelioid trophoblastic tumor It is an ETT tumor. (xiv) The head and neck cancer is laryngeal cancer, nasopharyngeal cancer, hypopharyngeal cancer, nasal cavity cancer, sinus cancer, salivary gland cancer. Cancer, oral cancer, oropharyngeal cancer, or tonsil cancer. (xv) The Hodgkin lymphoma is classical Hodgkin lymphoma, nodular sclerosis type, mixed cell type , lymphocyte-rich type, lymphocyte-depleted type, or nodular lymphocyte-predominant type Hodgkin lymphoma ( NLPHL) (xvi) The intestinal cancer is small intestine cancer, small bowel cancer NCE), adenocarcinoma, sarcoma, gastrointestinal stromal tumor, carcinoid tumor, or lymphoma, (xvii) The aforementioned kidney cancer is classified as renal cell carcinoma (RCC), clear cell RCC, papillary RCC, or chromocytic. Genetic RCC, collecting duct RCC, unclassified RCC, transitional cell carcinoma, urothelial carcinoma, renal pelvis carcinoma, or It is renal sarcoma. (xviiii) The leukemia is acute lymphoblastic leukemia (ALL), acute myeloid leukemia ( AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), hairy leukemia It is either leukemia (HCL) or myelodysplastic syndrome (MDS). (xix) the liver cancer is hepatocellular carcinoma (HCC), fibrolamellar HCC, cholangiocellular carcinoma, Angiosarcoma, or liver metastasis. (xx) The aforementioned lung cancer is small cell lung cancer, small cell carcinoma, combined small cell carcinoma, non-small cell lung cancer, lung Adenocarcinoma, squamous cell lung cancer, large cell anaplastic carcinoma, lung nodule, metastatic lung cancer, adenosquamous carcinoma Large cell neuroendocrine carcinoma, salivary gland type lung carcinoma, pulmonary carcinoid, mesothelioma, sarcomatoid carcinoma of the lung, Or it is a malignant granule cell lung tumor. (xxi) The melanoma is a superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, or malignant Melanoma originating from lentigo, achromatic melanoma, fibroplastic melanoma, ocular melanoma, or metastatic melanoma That is, (xxii) The mesothelioma is pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, or testicular mesothelioma. It is a tumor. (xxiii) The above multiple myeloma is active or smoldering multiple myeloma. (xxiv) The neuroendocrine tumor is a gastrointestinal neuroendocrine tumor, a pancreatic neuroendocrine tumor, or It is a pulmonary neuroendocrine tumor. (xxv) The aforementioned non-Hodgkin lymphoma is anaplastic large cell lymphoma, lymphoblastic lymphoma Peripheral T-cell lymphoma, follicular lymphoma, cutaneous T-cell lymphoma, lymphoplasmacytic lymphoma Parkinson's disease, marginal zone B-cell lymphoma, MALT lymphoma, small cell lymphocytic lymphoma, Burkitt's disease Trimphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), progenitor T lymphoblastic leukemia / lymphoma, acute lymphoblastic leukemia (ALL), adult T-cell lymphoma Tumor / leukemia (ATLL), hairy cell leukemia, B-cell lymphoma, diffuse large B cell lymphoma DLBCL (Deep-Liver B-Cell Lymphoma), Primary Mediastinal B-Cell Lymphoma, Primary Central Nervous System (CNS) Lymphoma Lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, mucosa-associated lymphoid tissue (MA) LT) Lymphoma, Nodular marginal zone B-cell lymphoma, Splenic marginal zone B-cell lymphoma, Lymphoid plasma cell Bocyte lymphoma, B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, natural killer T-cell lymphoma, cutaneous T-cell lymphoma, Alibert-Bazin syndrome, Sézary syndrome, Cutaneous anaplastic large cell lymphoma, peripheral T cell lymphoma, angioimmunoblastic T cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), systemic ALCL, enteropathy-type T cell lymphoma It is either EATL (Eastern Adenoma) or hepatosplenic gamma / delta T-cell lymphoma. (xxvi) The oral cancer is squamous cell carcinoma, verrucous carcinoma, minor salivary gland carcinoma, lymphoma, Benign oral tumors, eosinophilic granulomas, fibromas, granular cell tumors, keratosacral cell tumors, leiomyomas, and bone marrow tumors. Osteoma, lipoma, Schwann cell tumor, neurofibroma, papilloma, genital warts, xanthomas , suppurative granuloma, rhabdomyomas, odontogenic tumors, leukoplakia, erythroplakia, squamous cell lip carcinoma, basal cell carcinoma It is labial cancer, oral cancer, gingival cancer, or tongue cancer. (xxvii) The ovarian cancer is ovarian epithelial carcinoma, mucinous epithelial ovarian carcinoma, endometrial epithelial ovarian carcinoma, Clear cell epithelial ovarian carcinoma, undifferentiated epithelial ovarian carcinoma, low-grade ovarian tumor, primary peritoneal cancer, fallopian tube cancer, embryo Cellular tumors, teratomas, undifferentiated ovarian germ cell carcinomas, endodermal sinus tumors, sex cord-stromal tumors, sex cord-gonadal stromas Tumors, ovarian stromal tumors, granulosa cell tumors, granulosa follicular tumors, Sertley-Leydig tumors Ovarian sarcoma, ovarian carcinosarcoma, ovarian adenosarcoma, ovarian leiomyosarcoma, ovarian fibrosarcoma, Krukenberg It is a tumor or an ovarian cyst. (xxviiii) The pancreatic cancer is an exocrine adenocarcinoma of the pancreas, an endocrine adenocarcinoma of the pancreas, or an adenocarcinoma of the pancreas, an islet cell carcinoma. It is a cystic tumor or a neuroendocrine tumor. (xxx) The aforementioned prostate cancers include prostate adenocarcinoma, prostate sarcoma, transitional cell carcinoma, and small cell carcinoma. , or neuroendocrine tumor, (xxx) The aforementioned sinus carcinoma is a squamous cell carcinoma, a mucosal cell carcinoma, adenoid cystic cell carcinoma, acinar cell carcinoma Cellular carcinoma, sinonasal undifferentiated carcinoma, nasal cavity cancer, paranasal sinus cancer, maxillary sinus cancer, ethmoid sinus cancer, or nasopharyngeal cancer That is, (xxxi) The aforementioned skin cancer is basal cell carcinoma, squamous cell carcinoma, melanoma, Merkel cell carcinoma, Kaposi's sarcoma (KS), actinic keratosis, cutaneous lymphoma, or keratocanthoma. (xxxii) The soft tissue cancers mentioned above include angiosarcoma, dermatofibrosarcoma, epithelial sarcoma, and Ewing's sarcoma. Sarcoma, fibrosarcoma, gastrointestinal stromal tumor (GIST), Kaposi's sarcoma, leiomyosarcoma, liposarcoma, Differentiated liposarcoma (DL), myxoid / round cell liposarcoma (MRCL), well-differentiated liposarcoma ( WDL), malignant fibrous histiocytoma, neurofibrosarcoma, rhabdomyosarcoma (RMS), or synovial sarcoma It is a tumor. (xxxiii) The aforementioned spinal cord cancer is a metastatic tumor of the spinal cord. (xxxiv) The aforementioned gastric cancer is gastric adenocarcinoma, gastric lymphoma, gastrointestinal stromal tumor, carcinoid tumor. Surgery, gastric carcinoid tumor, type I ECL cell carcinoid, type II ECL cell carcinoid , or type III ECL cell carcinoid, (xxxv) The aforementioned testicular cancer is seminoma, non-seminoma, embryonic carcinoma, yolk sac carcinoma, chorionic carcinoma It is a carcinoma, teratoma, gonadal stromal tumor, Leydig cell tumor, or Sertoli cell tumor. 、 (xxxiv) The aforementioned pharyngeal cancer is squamous cell carcinoma, adenocarcinoma, sarcoma, laryngeal cancer, pharyngeal cancer, nasal cancer Pharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, laryngeal squamous cell carcinoma, laryngeal adenocarcinoma, lymphoepithelioma , spindle cell carcinoma, verrucous carcinoma, undifferentiated carcinoma, or lymph node carcinoma, (xxxv) The aforementioned thyroid cancer is papillary carcinoma, follicular carcinoma, Haasle cell carcinoma, thyroid marrow carcinoma. It is a type of carcinoma, or an undifferentiated carcinoma. (xxxvi) The uterine cancer is endometrial cancer, endometrial adenocarcinoma, endometrioid carcinoma, serous Adenocarcinoma, adenosquamous carcinoma, uterine carcinosarcoma, uterine sarcoma, uterine leiomyosarcoma, endometrial stromal sarcoma, Or it is an undifferentiated sarcoma. (xxxvii) If the vaginal cancer is squamous cell carcinoma, adenocarcinoma, melanoma, or sarcoma or (xxxviiii) Claim 82, wherein the vulvar cancer is squamous cell carcinoma or adenocarcinoma. The multispecific Vβ17 antibody or method described above.

89. Claim 2, wherein the second target is located on the surface of a target cell, and the target cell is a B cell. A multispecific Vβ17 antibody according to any one of claims 5 to 63, or any of claims 75 to 80 The method described in any one of the items.

90. The second target is CD1a, CD1b, CD1c, CD1d, CD2, CD5, CD 6, CD9, CD11a, CD11b, CD11c, CD17, CD18, CD19, C D20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, C D29, CD30, CD31, CD32a, CD32b, CD35, CD37, CD38 , CD39, CD40, CD45, CD45RA, CD45RB, CD45RC, CD4 5RO, CD46, CD47, CD48, CD49b, CD49c, CD49d, CD5 0, CD52, CD53, CD54, CD55, CD58, CD60a, CD62L, C D63, CD68, CD69, CD70, CD72, CD73, CD74, CD75, C D75S, CD77, CD79a, CD79b, CD80, CD81, CD82, CD8 3, CD84, CD85E, CD85I, CD85J, CD86, CD92, CD95, CD97, CD98, CD99, CD100, CD102, CD108, CD119, C D120a, CD120b, CD121b, CD122, CD124, CD125, CD 126, CD130, CD132, CD137, CD138, CD139, CD147, CD148, CD150, CD152, CD162, CD164, CD166, CD16 7a, CD170, CD171, CD175, CD175s, CD180, CD184, CD185, CD192, CD196, CD197, CD200, CD205, CD20 1a, CDw210b, CD212, CD213a1, CD213a2, CD 215, CD217, CD218a, CD218b, CD220, CD221, CD222, CD 224, CD225, CD226, CD227, CD229, CD230, CD232, CD252, CD252, CD254, CD255, CD256, CD257 CD25 8, CD259, CD260, CD261, CD262, CD263, CD264, CD 267-270, CD272, CD274, CD275, CD277, CD279, CD 283, CD289, CD290, CD295, CD298, CD300, CD300c , CD305, CD306, CD307a, CD307b, CD307c, CD307d , CD307e, CD314, CD215, CD316, CD317, CD319, CD 321, CD327, CD328, CD329, CD338, CD351, CD352, CD353, CD354, CD355, CD356, CD357, CD358, CD36 Multiple specificity V according to claim 89, which is 0, CD361, CD362, or CD363. β17 antibody or method.

91. The multispecific Vβ17 antibody according to claim 89, wherein the second target is BCMA or method.

92. An antibody that binds to Vα10.2, (1) (i) Each of the VH CDR1 having the amino acid sequence of SEQ ID NO: 568 VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) each, Sequence ID 569 VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence V containing VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence L, or (2) (i) Each of the VH CDR1 having the amino acid sequence of SEQ ID NO: 570 VH CDR1, VH CDR1, VH CDR3, which have the amino acid sequences of VH CDR2 and VH CDR3. CDR2, and VH including CDR3, and (ii) each, Sequence ID 571 VL CDR1, VL CDR2, and VL CDR3 have the amino acid sequence V containing VL CDR1, VL CDR2, and VL CDR3, which have an amino acid sequence Antibodies containing L.

93. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD Claim 92, wherein the R2 and VL CDR3 amino acid sequences conform to the Kabat numbering system. The antibody described above.

94. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD Claims that the amino acid sequences of R2 and VL CDR3 conform to the Chothia numbering system. The antibody described in 92.

95. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The amino acid sequences of R2 and VL CDR3 conform to the AbM numbering system, as described in claim 92. The antibody listed.

96. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The R2 and VL CDR3 amino acid sequences conform to the Contact numbering system, claim The antibody described in 92.

97. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD Claim 92, wherein the R2 and VL CDR3 amino acid sequences conform to the IMGT numbering system. The antibody described.

98. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD The R2 and VL CDR3 amino acid sequences are according to claim 92, in accordance with an exemplary numbering system. The antibody described.

99. The aforementioned antibody (i) Humanized antibodies, (ii) Optionally, an IgG1, IgG2, IgG3, or IgG4 antibody It is an IgG antibody. (iii) containing kappa light chain or lambda light chain and / or (iv) The antibody according to any one of claims 92 to 98, which is a monoclonal antibody.

100. The antibody binds to the Vα10.2 antigen, as described in any one of claims 92 to 99. antibody.

101. The antibody binds to the Vα10.2 epitope, as described in any one of claims 92 to 100. The antibody listed.

102. The antibody specifically binds to Vα10.2, according to any one of claims 92 to 101. The antibody described.

103. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD R2 and VL CDR3 form binding sites for the antigen of Vα10.

2. An antibody as described in any one of the requests 92 to 102.

104. Said VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CD R2 and VL CDR3 form binding sites to the epitope of Vα10.

2. an antibody according to any one of claims 92 to 103.

105. The Vα10.2 is present on the surface of the T cell, any one of claims 92 to 104 The antibody described above.

106. The antibody according to any one of claims 92 to 105, wherein the antibody is polyvalent.

107. The antibody according to any one of claims 92 to 106, wherein the antibody is a multispecific antibody. 。

108. The antibody according to any one of claims 92 to 107, wherein the antibody is a bispecific antibody.

109. Claim 10, wherein the antibody further binds to a second target, and the second target is BCMA. The antibody described in 7 or 108.

Images